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Abstract 
ABSTRACT 
Many patients suffering from Chronic Heart Failure (CHF), -exhibit sustained high 
levels of circulating catecholamines, through over-activation of the sympathetic system 
(Anker et al., 1997a). Many of these same CHF patients also experience a marked loss 
of their muscle bulk, which reduces their ability to move well and exercise, thereby 
decreasing their quality of life. As of yet there is no explanation for this phenomenon. 
This thesis tested the hypothesis that exposure to excess catecholamines causes 
significant myocyte death in both the heart and skeletal muscles. Whether this could 
lead to wasting of the skeletal muscles and how precisely the heart adapts to 
catecholamine-induced damage was determined. 
Male Wistar rats were injected with 20 mmol of isoprenaline, adrenaline, or 
noradrenaline kg" and killed at various time points over 28 days. Apoptotic and 
necrotic myocyte death and myocyte regeneration were detected 
immunohistochemically and morphologically, and quantified using image analysis. 
After characterising the acute myotoxic effects of a single injection of each 
catecholamine, the myotoxic and hypertrophic effects of chronic administrations of 
isoprenaline or adrenaline (20 mmol kg"'d"') were also investigated. 
A single injection of each catecholamine induced significant (P<0.05) myocyte necrosis 
and apoptosis in both the heart and slow-twitch soleus muscle, but not the fast-twitch 
muscles. Through its satellite cell system, the soleus muscle completely restored its total 
number of fibres by 28 days. The heart compensated for catecholamine-induced 
myocyte death and Joss through secondary myocyte hypcrtrophy and hyperplasia. The 
latter was produced by the activation and differentiation of cardiac stem-progenitor 
cells. The continuous infusion of the same dose of isoprcnaline over 28 days caused 
significant myocyte death, hypertrophy and fibrosis in the heart. Both fast and slow 
skeletal muscles in these same rats significantly increased in weight (P<0.05) and this 
was explained by increased fibre cross-sectional areas. Chronic catecholamine exposure 
still caused significant fibre death: their replacement met by a continual need for cycles 
of regeneration, in the soleus muscle. The current work describes the injurious effects of 
excess catecholamines on the heart and soleus muscle. Both striated muscles repair the 
loss of myocytes, in order to restore functional capacity. However, when the high levels 
of catecholamines are sustained, muscle wasting may result due to a compromised 
regenerative capacity. 
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Introduction 
1.0 INTRODUCTION 
1.1 Heart Failure and Adrenergic Activity 
Heart failure (1117) is a major public health problem in western society. A staggering 
2.7 million people are estimated to be living with coronary heart disease in the UK - 
a number that is rising year on year. This year almost one in eight people - or 12% - 
have been diagnosed with a disease of the heart or circulatory system. In 1989 this 
was just 7%. Despite 30 years in decline, the UK death rate from heart failure is still 
one of the highest in Western Europe - only Finland and Ireland have slightly 
higher rates. A working man is more than twice as likely to die from heart disease in 
the UK than in Italy. The UK death rate is also higher than most other developed 
countries, including the USA, Australia and Japan (British Heart Foundation 
Statistics, 2004). 
Heart failure is a complex clinical syndrome that can result from any structural or 
functional cardiac disorder that impairs the ability of the ventricle to fill with, or 
eject blood. Coronary artery disease is the underlying cause of HF in approximately 
two-thirds of patients with left ventricular systolic dysfunction (Hunt et al., 2001). 
The remainder have non-ischemic causes of systolic dysfunction and may have an 
identifiable cause e. g. hypertension, valvular disease, myocardial toxins, or 
myocarditis or may have no discernible cause, e. g. idiopathic dilated 
cardiomyopathy (116fit et al., 2001). 
Left ventricular (LV) dysfunction begins with some injury to the myocardium and is 
usually a progressive process, even in the absence of a new identifiable insult to the 
myocardium. The principal manifestation of such progression is a process known as 
remodelling, which occurs in association with homeostatic attempts to decrease wall 
stress through increases in wall thickness. This ultimately results in a change in the 
geometry of the left ventricle such that the chamber dilates, hypertrophies, and 
becomes more spherical. The process of cardiac remodelling generally precedes the 
development of symptoms, occasionally by months or even years. The process of 
I 
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remodelling continues after the appearance of symptoms and may contribute 
importantly to worsening of symptoms despite treatment. 
It has been established that many patients suffering from Chronic Heart Failure 
(CHF) exhibit sustained high levels of circulating catecholamines through over 
activation of the sympathetic system (Anker et al., 1997a). Subsequently, this plays 
an important role in the progression of heart failure, with the severity of the disease 
increasing in proportion with the level of catecholamines (Francis ct al., 1990; 
Packer, 1992), or vice versa. 
Regulation by the sympathetic nervous system constitutes an important modulator 
of cardiac function. More specifically, the catecholamines, adrenaline and 
noradrenaline, perform hormonal and transmitter functions to regulate and control 
cardiac performance and metabolism, and re-direct systemic blood flow, substrate 
mobilisation and utilisation. All regions of the heart are innervated by sympathetic 
nerves to varying degrees. The density of P-adrenoceptors (AR) in a single 
myocardial cell is much higher than that of cc, -receptors, and the effects of 
catecholamines during normal functioning of the heart are mediated mainly by 
AR stimulation (Hiraoka, 2002). 
The fl, -AR constitutes approximately 80% of the cardiac fl-AR complement 
(Freedman and Lefkowitz, 2004). Like the fl2-AR (with 54% overall homology), the 
81-AR is a seven-membrane-spanning receptor, with three extracellular polypeptide 
sequences ("loops") connecting the transmembrane helices. With their intracellular 
domains, the fl-ARs couple to the stimulatory heterotrimeric GTP-binding protein 
(Gs). Activation of the fli-AR requires a specific receptor conformation; one that is 
stabilized by the agonist and the binding of certain immunoglobulin Gs (IgGs) to the 
second extracellular loop (Jahns et al., 2004). The seven-membrane-spanning 01-AR 
is stimulated by the physiological agonists, catecholamines. The receptor site is 
highly stereo-specific, the best fit among catecholamines being isoprenaline (ISO), a 
synthetic catecholamine, rather than adrenaline (Ad) and noradrenaline (NAd). 
2 
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More specifically, in the case of 91 receptors, the order of agonist activity is ISO > 
Ad = NAd, whereas for #2 receptors the order is ISO > Ad > NAd (Opie, 200 1). 
The stimulated fl, -AR then activates the heterotrimeric G,, which dissociates into its 
G, and Gi substituents. The G, activates both adenyl cyclase (AC), which catalyses 
cyclic adenosine monophosphate (cAMP) formation, and the L-type calcium 
channel, which then permits calcium ions (Ca 2) to enter the cardiomyocyte through 
the sarcolemma of the T tubule. These C2+ ions release more Ca2+ from the 
sarcoplasmic reticulum (SR) to increase cytosolic Ca 2+ and to activate troponin C. 
On a slower time scale, this Ca2+ can also promote cardiomyocyte apoptosis by 
activating Ca2+/calmodulin kinase 11 (Katz, 2001). The cAMP produced by AC 
activates Protein Kinase A (PKA), which subsequently phosphorylates numerous 
substrates important to sarcoplasmic Ca2+ regulation: the L-type Ca 2+ channel, the 
ryanodine receptor (RyR) and phospholamban (PLB). Taken as a whole, there is 
greater and more rapid rise of intracellular free Ca 2+ concentration, increased 
calcium-troponin C interaction with de-inhibition of tropomyosin effect of actin- 
myosin interaction, and increased rate and number of cross bridges interacting with 
increased myosin ATPase activity (Opie, 2001). Activation of G. can also increase 
L-type Ca2+ channel currents directly. The increase in cytosolic Ca2+ concentration 
during a contraction is immediately followed by Ca 2+ removal, resulting in de- 
activation of the contractile machinery and muscle relaxation. Cytosolic Ca 2+ is 
pumped back into the SR by SR Ca 2+*ATPase (SERCA2). These sequences of 
events are illustrated in Figure I. I. The net effect of this activity in the short term is 
to augment sarcoplasmic Ca2+ and contractility, but in the long term this activity 
engenders cardiomyocyte toxicity (Freedman and Lefkowitz, 2004). 
Overall, the major effects of catecholarnines on cardiac function mainly exerted 
through the 91 receptor sub-type (Cui et al., 1996) are an increase in heart rate 
(chronotrophic effect) and force of contraction (inotropic), caused by enhanced 
myosin ATPase activity and increased activation of troponin C. There is also an 
increased rate of relaxation and acceleration of impulse conduction (dromotropbic 
3 
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effect) through the AV node. The increased rate of' relaxation is mediated by tile 
phosphorylation of' P1,13 which controls the rate of' rc-uptakc of* Ca into the SR 
through SFRCA2 (()plc, 2001 ). 
Figure 1.1 Sigiial systems involved in the effects of fl-adrenergic stimula(ion 
(Opic, 2001). 
'I'lic O-AR sys(cm plays a major rolc ill licart Callurc xvith studics shoxvIng altcrallOlls 
01' (11C Cal-diac 0-i-cccptor systcm in failing licarts (Lolisc et al., 2003). Fngdhardt ct 
al. ( 1996) rcportcd a rccluction of' the [31 subtype and it's nIRNA by ilp to 50'%, 
which was con-clatcd to scvcrity of' the discasc, whilc the 02-i-cccl)(ol- Icvc1s 
rcmaincd uncliangcd. It is not c1car why down-rcgulation ill licart I'ailurc is spccilic 
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for the fl, subtype. The remaining P-receptors are desensitised and are uncoupled 
from Gs, via increased activity of the receptor kinases (Ungerer et al., 2003). Heart 
failure-induced elevated catecholamine levels are most likely the cause of all these 
alterations that functionally limit the contractile reserve. Even though these changes 
have been confirmed repeatedly, their interpretation is uncertain. They can be 
interpreted either as beneficial mechanisms that protect the heart from the 
detrimental effects of chronic fl-AR stimulation, including arrhythmias, 
hypertrophy, and apoptosis, even though they deprive the heart from the benefits of 
short-term P-adrenergic responsiveness. Alternatively, they may lead to further 
deterioration of the failing heart, since they hinder the heart to meet its demands. 
Clinically, the use of fl-receptor antagonists in heart failure, pioneered in the 1970s 
(Waagstein et al., 1975), is now standard treatment. Blocking fl-receptors when 
cardiac function depends on sympatho-adrcnergic drive long appeared 
counterintuitive. Today, studies using fl-blockade show a reduction in the risk of 
death by one-third or more; a benefit greater than of any other drug used in heart 
failure (Bristow, 2000). This is mainly due to a block of the detrimental 
consequences of sustained fll-receptor stimulation, i. e. arrhythmia, apoptosis, 
necrosis, hypertrophy (Lohse et al., 2003). Also, #-blockade may cause re- 
sensitisation of the cardiac fl-receptor system through upregulation of fl-receptor 
levels and normalisation of elevated receptor kinase activity and Gi levels (Lowes et 
T 
al., 2002). 
1.2 Catecholamine Cardiotoxicity 
For many years it has been established that excess catecholamines are cardio-toxic, 
directly damaging the heart (Rona et al., 1959; Todd ct al., 1980; Benjamin et al., 
1989; Teerlink et al., 1994; Heap ct al., 1996; Shizukuda et al., 1998; Xi ct al., 2000; 
Goldspink et al., 2004). In the early study conducted by Rona et al. (1959) it was 
reported that isoprenaline was capable of producing both gross and microscopic 
myocardial necrosis (most frequently found in the apex) to otherwise normal rats. 
Accordingly, the amount of necrosis depended on the dose of isoprenaline 
5 
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administered (Rona et al., 1959). Benjamin et al. (1989) also found that a single 
subcutaneous injection of isoprenaline to rats resulted in the appearance of necrotic 
myocytes. This damage was largely confined to the subendocardial region of the 
heart and increased from 3 to 24 hours after administration. Similarly, Xi et al. 
(2000) reported the development of lesions, characterised by degraded 
cardiornyocytes and infiltrating cells, in the subendocardiurn of hearts administered 
10 mg of isoprenaline kg". This region of injury increased in a time dependent 
manner, from 3 to 16 hours after the isoprenaline injection. Furthermore, apoptotic 
myocytes were detected 8 hours following isoprcnaline injection (Xi et al., 2000). In 
support of these findings, Shizukuda et al. (1998) reported significant apoptosis of 
cardiornyocytes in the hearts of rats 12 hours after treatment with 40OAg kg"h", 
isoprenaline and this persisted up to 7 days of treatment. More specifically, 
Communal et al. (1998) reported that noradrenaline stimulated apoptosis in adult rat 
ventricular myocytes when exposed for 24 hours in vitro. This cell death was 
mediated through the activation of the fl-adrenergic pathway and protein kinase A, 
as this effect was completely blocked by the fl-adrenergic antagonist propranolol 
(Communal et al., 1998). More recently, in vitro work has been reported describing 
the anti-apoptotic effects of Pz-AR stimulation (Kang and Izumo, 2003). 
Teerlink ct al. (1994) investigated the adaptation of the heart, i. e. in terms of LV 
remodelling, to graded myocardial injury in the presence of a patent coronary 
circulation. These workers found that isoprenaline caused signiricant necrosis, 
increased LV-end diastolic pressure (LVEDP), myocardial hypertrophy, decreased 
the ratio of LV mass to volume, increased wall stress, vcntricular dilation and 
altered the pressure-volume relation (LV contraction and relaxation) (Teerlink et al., 
1994). Subsequently, these changes correlated with increased dose and time after 
isoprenaline shock. It was concluded that isoprenaline-induced myocardial necrosis 
resulted in enlargement of the LV cavity that is out of proportion to mass, similar to 
that observed after discrete myocardial infarction (Tcerlink et al., 1994). 
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The mechanisms and pathways by which elevated catecholarnines become cardio- 
toxic and cause progressive heart failure are controversial. Ile most popular theory 
is that alteration of the sarcolemma by catecholamine-induced cardiac injury, leads 
to myocardial calcium (Ca 2+) overload. This results in myofilament over- 
stimulation, increased contractile force and oxygen requirement, and excessive ATP 
breakdown; all contributing to cardiornyocyte injury (Rona, 1985). Supporting this 
view, Mann et al. (1992) found that catecholamine cardiotoxicity is a result of 
cAMP-mediated Ca 2+ overload. 
Defective Ca 2+ handling has been implicated in many pathological conditions. In 
Ca 2+. driven cell death, the Ca 2+ storage status of the endoplasmic reticulurn and the 
levels of cytoplasmic free Ca 2+ are proposed as the main determinants of cell fate. 
The spatial organization of Ca 2+ release channels, ryanodine receptors (RyR2 and 
RyRI in the heart and skeletal muscle, respectively), or inositol 1,4 5-trisphosphate 
receptors (IP3R) appears to be of key importance in determining cellular fate. RyRs 
are large hornotetrameric channels (molecular mass, 2.3 MDa) that mediate Ca 2+ 
release from SR in skeletal and cardiac muscle. Increased density of IP3R and RyR 
triggers cell death (Jayaraman and Marks, 1997; George et al., 2003), and the 
finding that both IP3R and RyR can directly sense cytoplasmic and luminal Ca2+ 
environments (Xu and Meissner, 1998; Koizumi et al., 1999) suggests that Ca 2+ 
itself is a key transducer in the activation of programmed cell death. Marx et al. 
(2003) have reported that in failing human hearts, there is PKA-hyper- 
phosphorylation of the RyR2 receptor, resulting in defectivc channel function and 
excitation coupling, in turn contributing to cardiac dysfunction. Furthermore, 
infusion of isoprenaline resulted in PKA phosphorylation of RyR2 in the rat, 
indicating that systemic catecholamines can activate phosphorylation of RyR2 in 
vivo, and therefore this could play a role in catecholamine cardiotoxicity (Reiken et 
al., 2003). 
Several other indirect mechanisms may contribute to the development of myocardial 
injury from catecholamines. These include mobilisation, of free fatty acids 
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(Kjekshus, 1975), increased intracellular acidity (Mosinger et al., 1997), increased 
platelet aggregation (Hoak et al., 1969), inefficient 02 utilisation (Horak and Opie, 
1983), and hindrance of coronary circulation (Handsforth, 1962). Interestingly, 
another factor which may be responsible for catecholamine-induced myocardial 
injury relates to the oxidative products of catecholamines and the subsequent 
generation of free radicals (Yunge et al., 1989; Rupp et al., 1994). These could 
damage cell membranes and other structures. Therefore, it could be that it is not 
catecholamines per se, but their oxidation products which cause cardiac injury. It is 
obvious that the development of myocardial injury from catecholamines is multi- 
factorial, but which mechanism predominates has yet to be ascertained. 
It has become apparent that many CIIF patients also experience a marked loss of 
muscle bulk. Through the loss of this metabolically important tissue, there is a 
decreased tolerance to exercise, thereby decreasing the patient's quality of life. The 
metabolic impact also potentially increases their risk of death (Ankcr et al., 1997b). 
As yet there is no explanation for this loss of muscle bulk. Chronic Heart Failure 
patients exhibit a greater proportion of type II fibres (fast), decreased oxidative 
enzymes and subsequent decreased exercise capacity and fatigue resistance (Minotti 
et al., 1991; Drexler et al., 1992). These changes are mainly due to the inactivity of 
these patients. When muscles become smaller and weaker, they become susceptible 
to injury (McArdlc et al., 2002). 
Ankcr ct al. (1997a) found that cachexia, of which muscle wasting is an important 
factor, was strongly associated with the hormonal changes that accompany CIIF. 
They (1997a) reported that CIIF patients who also exhibited signs of cachcxia had 
sustained higher than normal levels of noradrcnaline (x 3) and adrenaline (x 5), 
when compared to normal and non-cachexic CIIF patients. Furthermore, 
noradrenaline was found to correlate independently with wasting in CHF. 
Subsequently, Anker et al. (1997b) reported wasting as an independent risk factor 
for mortality in CHF. It is conceivable that sustained elevated catecholamines, 
instead of boosting cardiac performance (i. e. CO), may induce cumulative myocyte 
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damage and loss in both cardiac and skeletal muscles, leading to a generalised, 
rather than cardiac specific, myopathy (Opasich et al., 1999). 
Our laboratory and others have found a direct effect of catecholamines on skeletal 
muscle. Heap et al., (1996) found necrosis in both the subendocardial region of the 
heart and in the soleus muscle of rats administered a minimum of 5mg of 
isoprenaline kg". Data from our laboratory agree with these findings. We have 
recently shown in normal rats that acute exposure to high levels of isoprenaline 
causes myocyte death in both the heart and the skeletal muscles, via a combination 
of necrosis and apoptosis (Ng et al., 2002; Ellison et al., 2002; 2003; Goldspink et 
al., 2004). Such cell death and the ability or otherwise to regenerate them, will 
inevitably affect muscle function. 
1.3 Chronic fl-AR Stimulation 
Chronic P-AR stimulation results in cardiac hypertrophy and desensitization and/or 
downregulation of the fl-receptors (Kudej et al., 1997; Morisco et al., 2001). 
Furthermore, enhanced fl-adrenergic signalling through over-expression of upstream 
adrenergic signalling effectors, i. e. G,,, PI-AR or P2-AR, in transgenic mice results 
in either normal or increased cardiac function in young adult animals, but the 
development of cardiornyopathy with age (Vatner et al., 1999; Engelhardt et al., 
2001). This is characterized by reduced LV function (Engelhardt et al., 2001; 2002), 
LV hypertrophy and chamber dilation (Engelhardt et al., 1999; 2002), fibrosis 
(Engelhardt et al., 2001; 2002), and apoptosis (Geng et al., 1999). 
The mechanisms underlying these detrimental changes have been extensively 
investigated. Engelhardt et al. (2001) reported that abnormal Ca 2+ transients in 
cardiornyocytes were responsible for early contractile dysfunction, i. e. before the 
appearance of interstitial fibrosis and cardiomyocyte hypertrophy, and this was due 
to decreased expression of the SR protein, junctin (Engelhardt et al., 2001). Junctin 
plays an important role in sarcoplasmic calcium handling by mediating the binding 
of calsequestrin to RyR. 
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In another study Engelhardt et al. (2002) identified the importance of the cardiac 
Ne-H+ exchanger I (NHEI) in the detrimental effects of fl-adrenergic stimulation 
during the progression of heart failure. Compared with wild-type controls, 
Engelhardt et al. (2002) found a 140% and 30% increase in NHEI mRNA and 
protein levels respectively, in hearts of 5 month old #, -receptor over-expressed 
transgenic mice. Furthermore, the treatment of fli-receptor transgenic mice with 
selective NHE1 inhibitor, cariporide, completely prevented LV fibrosis, reduced 
cardiomyocyte hypertrophy by 88% and completely inhibited the impairment of LV 
systolic contraction (dp/dt,,,,,, ) and relaxation (dp/dt,,, I,, ). The mechanisms of how 
NHEI exerts its detrimental effects are currently unknown. However, it is 
postulated that an increased sodium load could be involved in inducing hypertrophy, 
with increased intracellular sodium being exchanged for Ca 2+ via the cardiac Na'- 
Ce exchanger. The resulting increase in Ca 2+ during diastole might exert several 
deleterious effects, including activation of protein kinase C and Ca 2+-dependent 
transcription factors. This concept is supported by the earlier finding of altered 
intracellular Ca 2+ handling in fli-AR transgenic mice (Engelhardt et al., 2001). More 
recently, in further support of this mechanism, Engelhardt et al. (2004) reported that 
altered calcium handling is critical for the detrimental effects of Pl-adrenergic 
signalling. This was shown by deleting the principal inhibitor of SR Ca2+ uptake, 
phospholamban (PLB) in PI-AR transgenic mice. Phospholamban knockout (PLB' 
fli-adrenergic receptor transgenic mice showed enhanced survival, less cardiac 
hypertrophy and fibrosis, and improved cardiac function. The latter was 
demonstrated by a preservation of LV systolic pressure, improved LV congestion 
(normalized LVEDP), LV contractility (dp/dt,,,,, ) and diastolic function (dp/dt,,, in). 
Engelhardt ct al. (2004) also showed a faster decay of intracellular Ca 2+ transients in 
fll-adrenergic receptor PLBT transgenic mice, when compared to 01-AR transgenic 
mice or wild-type controls. Subsequently, diastolic Ca 2+ levels and Ca2+ load were 
significantly decreased in fli-AR PLB/' transgenic mice. These findings are 
supported by Iwanaga et al. (2004) who found that the inhibition of PLB in rats after 
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myocardial infarction with gene therapy prevented the progression of heart failure 
by improving cardiac function and preventing fibrosis (lwanaga ct al., 2004). 
As with ovcr-cxprcssion of fl-receptors, it is well documented that ovcr-expression 
of G-protcin receptors results in chronically enhanced fl-AR signalling and either 
normal or increased cardiac function in young adult animals, but the development of 
cardiornyopathy with age (Iwase ct al., 1997). Furthermore, fl-AR blockade with 
propranolol prevented the development of cardiomyopathy (Asai et al., 1999). This 
was shown through the prevention of cardiac dilation and the decline in LV 
function, whilst also arresting myocyte hypertrophy, fibrosis and apoptosis. 
Consequently, premature mortality, usually seen in this transgenic animal model, 
was abolished (Asai et al., 1999). More recently, the cellular mechanisms of P-AR 
blockade were found to be related to alterations in mitogen-activated protein kinases 
(Karoor et al., 2004). Karoor and colleagues (2004) found that in G,,, over- 
expressed mice, there were significant increases in phospho-kinase levels of p38 
MAP kinase, p70S6K 9 ERK, Akt and JNK up to 15-20 months. However, following 
treatment with propranolol for 5 weeks there was a reversal in the levels and 
activities of these phospho-kinases, which are involved in the growth and death of 
cardiomyocytes (Karoor et al., 2004). Furthermore, Gaussin et al. (2003) found a 
role for uncoupling protein 2 (UCP2), a protein involved in the control of 
mitochondrial membrane potential, and four-and-a-half LIM domain protein-1 
(FHLI) for causing cardiornyopathy in mice over expressing G.,,,. However, fl-AR 
blockade treatment reversed the cardiomyopathy and suppressed the increased 
expression of UCP2 and FHLl (Gaussin et al., 2003). 
Caution should be exercised when interpreting these findings as signalling 
mechanisms caused by agonist stimulation and those by receptor over-expression 
might not be identical. 
Increases in catecholamine stimulation have been implicated as a causative factor in 
the development of cardiornyopathy (Dash et al., 2001). Using over-expression of 
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PLB transgenic mice Dash et al. (2001) reported that, as expected, there was 
initially a mild depression of ventricular contractility. Basal PLB phosphorylation 
was found to be substantially higher in transgenic mice, to relieve the inhibitory 
effects of PLB on SR function. The phosphorylation of PLB is mediated 
predominantly by fl-adrenergic drive and when the transgenic mice were treated 
with propanolol it resulted in a significant depression in contraction rate and a 
prolonging of the relaxation phase, whereas no changes in contractile parameters 
were found in wild-type littermates. Subsequently, there were reductions in cardiac 
noradrenaline, adrenaline and dopamine levels in the transgenic mice. Plasma 
noradrenaline levels however were elevated, reflecting a compensatory increased 
adrenergic drive in order to relieve the inhibitory effects of PLB (Dash et al., 2001). 
With aging, these over-expressing PLB mice developed cardiornyopathy exhibited 
by deterioration in LV function, dilated LV chambers as well as extensive 
interstitial fibrosis and myocyte hypertrophy. Aged transgenic mice also displayed a 
desensitised adenylyl cyclase response to isoprenaline, which was independent of 
any alterations in fl-receptor density. This decreased P-adrenergic response may 
have precluded adequate compensatory phosphorylation of PLB and thereby 
depressed myocardial function (Dash et al., 2001). 
These findings suggest an interaction between increased PLB expression and an 
enhanced sympathetic drive to attenuate its inhibitory effects. Over time this hyper- 
adrenergic compensatory mechanism, seems to progress to a maladaptivc one 
leading to cardiomyopathy. Therefore, it was concluded that increases in 
catecholaminc stimulation, in the absence of pre-existing heart failure, could be a 
primary causative factor in the development of cardiornyopathy and early mortality 
(Dash ct al., 2001). 
In further support of chronic catecholamine exposure resulting in cardiomyopathy, 
Benjamin et al. (1989) found that daily doses of isoprenaline, administered to rats 
for 10 days induced additional myocardial necrosis, cardiac hypertrophy and 
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significant fibrosis. In support of these findings, more recently Schlaich et al. (2003) 
found that LV hypertrophy was associated with increased sympathetic activity, and 
more specifically noradrenaline release was related to the development of LV 
hypertrophy. 
It has also been reported that the reason why myocardial G.,,, over-expressed 
transgenic mice develop cardiomyopathy is because they lack the protective 
desensitisation mechanisms against catecholamines and sympathetic stimulation 
(Vatner et al., 1998). This further suggests a link between increases in 
catecholamines and the development of cardiomyopathy. 
Chronic exposure to catecholamines has also been shown to have hypertrophic 
effects on skeletal muscles. Ishii et al. (1998) reported that 5mg of isoprenaline 
kg*ld" for up to 2 weeks induced hypertrophy to the fibres of the orbicularis oculi 
and stapedius muscles and improved muscle fibre function in rats. More recently, 
Kumar et al. (2003) reported that 1.5mg of isoprenaline kg", administered orally for 
120 days resulted in an increased body weight in growing chicks. This increased 
body weight was largely due to skeletal and cardiac muscle hypertrophy. 
In support of these findings it has been shown that the chronic administration of the 
fl2-AR agonist, fenoterol, for 4 weeks reversed the wasting and restored muscle 
mass and strength in the extensor digitorum longus and soleus muscles of aged rats 
(Ryall et al., 2003). This was specific to increases in muscle fibre cross-sectional 
areas. However, the authors also reported detrimental effects of hypertrophy in the 
heart (Ryall et al., 2003). Extreme over-expression of #2-ARs in the heart (140-fold 
increase) has been shown to cause cardiac hypertrophy (Dom et al., 1999). 
Furthermore, the anabolic effects of clenbuterol, a #2 agonist, have also been 
investigated (Choo et al., 1992). However, it has been reported that high doses of 
clenbuterol can have detrimental effects on skeletal and cardiac muscle, causing 
myocyte necrosis in both muscles (Bumiston et al., 2002). 
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1.4 Cell Death: Necrosis and Apoptosis 
Numerous studies have documented that myocyte death is an important variable in 
the development of ventricular dysfunction and failure in ischemic and idiopathic 
dilated cardiomyopathy, long-term systemic hypertension, and during myocardial 
ageing in animals and humans (Anversa, 2000). On the other hand, skeletal muscle 
fibre death has been described as a pathogenetic mechanism of several 
neuromuscular disorders and muscular dystrophies (Primeau et al., 2002). 
Apoptosis and necrosis (Figure 1.2) are presently recognised as the major types of 
physiological and pathological cell death. Apoptosis is a tightly regulated cell 
deletion process that differs morphologically and biochemically from necrotic cell 
death. Through the cell death pathway of oncosis followed by necrosis, there is a 
significant initial net increase in cytoplasmic Ca2+ (either by stimulating the uptake 
of extriicellular calcium or by facilitating the release of Ca 2+ stores from the 
endoplasmic reticulum) and swelling of the cell and mitochondria (oncosis), 
followed by membrane rupture and leakage of contents to the exterior. Cells suffer 
necrotic death when exposed to extreme environmental insults. Necrosis has been 
considered generally to be a chaotic decadence process that affects the inevitable 
demise of cells otherwise not destined to die (Syntichaki and Tavernarakis, 2002). 
Necrosis can be identified morphologically and from a standard haematoxylin and 
eosin (H&E) stain, dead necrotic cells appear completely demised with disrupted 
sarcolemmal membranes and pale cytoplasmic staining. Another method for the 
detection of necrosis involves the use of the large myosin antibody (Nolan et al., 
1983; Benjamin et al., 1989; KaJstura et al., 1996; Goldspink et al., 2004). This 
antibody is considered one of the most selective markers of necrotic myocytes due 
to its permeabilisation through leaky disrupted membranes and its specific binding 
to myosin once inside. 
The onset of apoptosis is characterised by shrinkage of the cell and the nucleus as 
well as condensation of nuclear chromatin into sharply delineated masses (Saraste 
and Pulkki, 2000). Later on, the nucleus progressively condenses and breaks up (i. e. 
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karyorrhexis). The cell detaches from the surrounding tissue and its outlines become 
convoluted and form extensions. Apoptotic budding is a process whereby these 
extensions separate and the plasma membrane seals to form a separate membrane 
around the detached solid cellular material. These apoptotic bodies are crowded 
with closely packed cellular organelles and fragments of nucleus. The fine 
structures, including membranes and mitochondria, are well preserved inside the 
bodies. The apoptotic bodies are rapidly phagocytosed into neighbouring cells, 
including macrophages and parenchymal cells. Apoptotic bodies can be recognised 
inside these cells, but eventually they become degraded (Saraste and Pulkki, 2000). 
If the fragmented cell is not phagocytosed it will undergo degradation which 
resembles necrosis and has been called secondary necrosis (Kerr et aL, 1994). 
CYTOMETRY IN CELL NECROBIOLOGY 
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Figure 1.2 Cell death pathways: necrosis and apoptosis (Darzynkiewicz et 
al., 1997). 
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The first molecular evidence of apoptotic cell death/survival machinery comes in 
the form of the Bcl2 gene. Numerous death signals and death receptors (including 
Tumor Necrosis Factor) and many growth factors culminate on a pathway regulated 
by pro-apoptotic (e. g. Bax, Bad) and anti-apoptotic members of the B62 family 
(e. g. B62, BcIX) (Satler et al., 1997). Relative balances of the two classes of B62 
proteins affect interaction of adaptor proteins, such as apoptotic protease-activating 
factor I (APAF-1) and Fas-associated death domain (FADD) with caspase enzymes 
(Chou et al., 1998), which are initially inactive but become activated on interaction 
with proteins such as APAF-I. Specifically, caspases are activated during apoptosis 
in a self-amplifying cascade. Activation of the upstream caspases, such as caspases 
2,8,9 and 10, by pro-apoptotic signals leads to proteolytic activation of the 
downstream or effector caspases 3,6 and 7. Caspase activation often leads to a 
feedback loop resulting in amplification of cell death signals (Nicholson and 
Thornberry, 1997). A class of inhibitor apoptosis proteins are thought to function in 
part by inhibiting caspases (Deveraux. et al., 1997). The effector caspases finally 
cleave a set of vital proteins and thus initiate and execute the apoptotic degradation 
phase including DNA degradation and the typical morphologic features, ultimately 
resulting in cellular demise. Regulation of cell death is also mediated through 
overlapping pathways involving the tumor suppressor p53 (Clarke et al., 1993). 
"lu 
A biochemical hallmark of apoptosis is the degradation of DNA by endogenous 
DNases. These enzymes cut the intemucleosomal regions of DNA into double- 
stranded DNA fragments of 180-200 base pairs which contain blunt ends as well as 
single base 3' overhangs (Didenko and Hornsby, 1996). With the terminal 
transferase mediated DNA nick end labelling (TUNEL) assay, cells containing 
DNA strand breaks become visible in light microscopic analysis. The validity of the 
TUNEL assay as a method to detect apoptosis has however been questioned (Kanoh 
et al., 1999), as DNA damage is not a unique feature of apoptosis, but can occur in 
necrosis and during repair of reversibly damaged DNA. 
16 
Introduction 
An alternative approach to study the presence of apoptosis is to demonstrate the 
activation of downstream caspases (Boatwright and Salvesen, 2003). These can be 
detected using cleavage-site-specific antibodies that detect only the cleaved and 
active forms of caspase substrates. They can be applied to detect apoptotic cells in 
tissue sections by light microscopy. 
Several studies have provided evidence of caspase activation in cardiomyocyte 
death. Active fonns of caspases 2,3 and 7 are generated in the ischemic-reperfused 
myocardium (Holly et al., 1999). Moreover, activated form of caspase 3 has been 
shown to co-localise with the TUNEL-positive cardiomyocytes in ischemic- 
reperfused myocardium (Black et al., 1998). 
In summary, both acute and chronic exposure of catecholamines have a detrimental 
effect on the heart causing necrosis, apoptosis, hypertrophy, fibrosis and impaired 
function. Patients with CHF exhibit sustained high levels of catecholamines, due to 
over-activation of sympathetic drive. It is possible that this elevation in circulating 
catecholamines could be related to the muscle wasting seen in some of these 
patients. The effects of catecholamines on skeletal muscle are much less well 
documented. There is however evidence to suggest that they can cause cell death, as 
well as having anabolic effects of promoting muscle growth and hypertrophy. 
1.5 Skeletal Muscle Regeneration 
Under normal circumstances mammalian adult skeletal muscle is a stable tissue with 
very little turnover of its fibre number and nuclei (Decary et al., 1997). In normal rat 
muscle, it is estimated that no more than 1-2% of myonuclei are replaced every 
week (Schmalbruch and Lewis, 2000). 
It has been known for many years that skeletal muscle has a remarkable capacity for 
rapid and extensive regeneration after injuries resulting in partial or complete 
damage to muscle fibres (Bodine-Fowler, 1994). Muscle regeneration is 
characterized by two phases; a degenerative phase, followed by a regenerative 
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phase. The kinetics and amplitude of each phase varies according to the extent of 
the injury and the specific muscles injured. The process of regeneration can be 
studied in a controlled and reproducible way, using animal models of muscle injury. 
The easiest way to induce damage is through the use of myotoxins, such as 
bupivacaine (Hill et al., 2003) or notexin (Harris et al., 1975). Harris et al. (1975) 
investigated the pathological responses of rat skeletal muscle to a single injection of 
a toxin isolated from the venom of the Australian tiger snake. They found that 12- 
24hr following intramuscular injection the muscles underwent degenerative 
necrosis, accompanied by oedema and the infiltration of lymphocytes, polymorphs 
and phagocytic macrophages. Factors released by the injured muscle activated the 
inflammatory cells residing within the muscle, which in turn provided the 
chemotactic signals to circulating inflammatory cells (Tidball, 1995). Three days 
after injecting the venom, Harris et al. (1975) reported that the muscle ocdema had 
subsided and the necrotic fibres had been completely destroyed by phagocytic cells. 
Such muscle degeneration is followed by the activation of a repair process. In order 
to provide a sufficient source of new myonuclei for muscle repair, there is an 
expansion of myogenic cells (satellite cells) through cellular proliferation. 
Harris et al. (1975) found the existence of myoblasts or myogenic cells (i. e. derived 
, 4. 
from satellite cells) 3 days post-injury. After 5 days the myoblasts had differentiated 
and fused to form new myotubes. Myotubes then developed or grew into 
histochernically distinct muscle fibre types which were evident 7 days following the 
injection of the toxin. In muscle cross sections, the morphological characteristics of 
newly formed muscle fibres are small and angulated, expressing 
embryonic/developmental forms of MHC and possessing centralized nuclei 
(Williams et al., 2001). In the animal model of muscle damage using the snake 
venom, the whole regenerative process was complete, with full restoration of the 
injured muscle fibres, 21 days following injection of the venom. The regenerated 
muscle was morphologically and functionally indistinguishable from normal un- 
damaged muscle (Harris et al., 1975). This is a 'typical' example of how skeletal 
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muscles can regenerate new fibres following injury and is as much as bona fide 
embryonic myogenesis (Charge and Rudnicki, 2004). 
Essential aspects of the muscle regeneration process are revascularisation, re- 
innervation and reconstitution of the extracelluar matrix and muscle fibre basal 
lamina. Whalen et al. (1990) reported that if re-innervation of the regenerating 
muscle was allowed to occur, then there was complete restoration of muscle fibres 
in the rat soleus muscle 28 days following injection of snake venom toxin. 
However, if the muscle was denervated (and hence functionally inactive) at the time 
of toxin injection, although the early stages of regeneration took place the 
regenerating fibres failed to increase in size. Instead, they showed significant 
atrophy or less growth, relative to the size of the regenerating fibres in normally 
innervated muscles. Furthermore, adult slow myosin was the exclusive form in 
innervated regenerating fibres, but adult fast myosin was the predominant isoform in 
denervated muscle once its damaged fibres were regenerated (Whalen et al., 1990). 
Hence, the pattern of contractility affects the type of MHC expressed. Another 
critical factor that influences the rapid and complete regeneration of fibres is the 
availability of a viable population of satellite cells. 
1.6 Muscle Satellite Cells 
The remarkable ability of skeletal muscle to regenerate following injury, as well as 
adapt to physiological demands such as growth and exercise training, is largely 
attributed to a small population of dormant cells, called satellite cells. These are 
resident in adult skeletal muscle and were first described by Mauro (196 1). 
Satellite cells are small, self-renewing, undifferentiated mononuclear cells located 
between the basal lamina and plasma membrane of skeletal muscle fibres (Figure 
1.3). Therefore, they have the defining characteristic of a continuous surrounding 
basal lamina (Carlson and Faulkner, 1983). While mitotically quiescent they express 
proteins, such as c-met receptor tyrosine kinase, m-cadherin, Pax7 and myocyte 
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nuclear factor (Irintchev et al., 1994; Comelison and Wold, 1997; Seale et al., 2000; 
Garry et al., 1997). 
When activated in response to fibre damage and degeneration, the satellite cells re- 
enter the cell cycle and also express myogenic factors such as MyoD, myogenin, 
MRF-4 and myf-5 (Cusella-De Angelis et al., 1992; Grounds et al., 1992; Koishi et 
al., 1995; Comelison and Wold, 1997; Dupont-Versteegden et al., 1998). From the 
ensuing proliferation, differentiation and fusion of active satellite cells new multi- 
nucleate myofibres emerge to replace the degenerating ones. Alternatively, if a fibre 
has been damaged in part, satellite cells fuse with the ends of existing damaged 
fibres, repairing the fibre by creating continuity between the damaged ends (Figure 
1.4). Therefore, under non-nal circumstances the total number of fibres should be 
I'ully preserved. 
Figure 1.3 The location of satellite cells in the muscle fibre (Hawke and 
Garry, 2001). 
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Figure 1.4 Satellite cell response to injury (Ilawke and Garry, 2001) 
111schoIT( 1985) first f'ound that muscle regeneration is initiated by the release ot'an 
endogenous mitogen f'rorn traUrnatised, crushed adult muscle. It is now accepted that 
the activation, ensuring prolit'cration and differentiation of' satellite cells, requires 
the timcly, controlled up-regulation of' muscle transcription factors and specific 
genes. This process is mainly governed by the endocrine and paracrinc/autocri tic 
regulatory mechanisms of' various growth factors. In particular, I lepatocytc growth 
I'actor/scattcr factor (116F/SF)-, Fibroblast growth Factors (FGFs); Insulin-like 
growth factors I and 11 (IGF-I and 11), Mechano-growth Cactor (Wil; 11111 ct al., 
2003) and thcTGF-0 Camily (Charge and Rudnicki, 2004). 
I lcpatocyte growth factor/scatter factor elicits mitogenic, I11otogcl1Ic and 
niorpliogenic activities during development and tissue regeneration (/, arncgar and 
MiclialOPOLI10S, 1995). It has becil tbund that the role of' IIGF In muscle 
regeneration is most Important in the early phase of' the repair process, and it 
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appears to act directly on muscle satellite cells due to the expression of its receptor 
c-met in quiescent satellite cells (Bottaro et al., 199 1). It was reported by Tatsumi et 
al. (1998) that HGF/SF was present in crushed muscle extract and was the factor 
responsible for activating satellite cells in vitro. Furthermore, when HGF/SF was 
directly injected into the normal tibialis anterior muscle of 12 month old rats it 
stimulated satellite cell activation (Tatsumi et al., 1998). HGF has also been 
implicated as a potent chernotactic factor (Bischoff, 1997) and as an inhibitor of 
myoblast differentiation through the transcriptional inhibition of the myogenic 
regulatory factors, Myol) and myogenin (Miller et al., 2000). 
The roles of IGF-I and II in regulating growth and development of tissues have 
been recognized for many years. It has been shown that both in vitro and in vivo, 
IGF- I and IGF-II are able to alter the expression of myogenic regulatory factors and 
promote both the proliferation and differentiation/fusion of myoblasts (Allen and 
Boxhorn, 1989; Chakravarthy et al., 2000; Rabinovsky et al., 2003). Also, IGF-1 
and IGF-II levels are upregulated in skeletal muscle undergoing regeneration (Hill 
et al., 2003a, b). Subsequently, increasing the levels of IGF-I leads to increases in 
hypertrophy and muscle mass due to augmentation of muscle protein and DNA 
contents (Musaro et al., 2001). The hypertrophic effects of IGF-1 have also been 
attributed to the activation of satellite cells and their proliferation to provide more 
myonuclei (Barton-Davis et al., 1999; Hill et al., 2003a, b). 
Recently, another factor has been implicated in the activation of satellite cells and is 
known as Mechano-growth factor (MGF). It was first discovered by Goldspink et al. 
(1992), and is a splice variant derived from the IGF-1 factor, although its sequence 
is different from the systemic IGF-I produced by the liver. MGF is expressed in 
mechanically overloaded muscle and has been shown to be involved in tissue repair 
and adaptation, in particular muscle hypertrophy (Goldspink, 2001). Hill et al. 
(2003a, b) induced local muscle damage in rats with either an injection of 
bupivacaine, a local anaesthetic which induces muscle fibre necrosis, or by a 
combination of stretch and electrical stimulation. It was found that the expression of 
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MGF mRNA was maximal as early as I day following stretch and stimulation and 
peaked 4 days following bupivacaine injection. These message levels then begun to 
decrease once regeneration and fusion of myoblasts had begun. Interestingly, the 
mRNA and protein levels of M-cadherin and MyoD (i. e. markers of quiescent and 
activated satellite cells) peaked at 4-7 days following both types of injury. In 
marked contrast, the expression of mRNA for IGF-lEa peaked much later, at -12 
days after inducing the injury. IGF-lEa is an isoform of IGF-1 in muscle and is 
similar to the hepatic endocrine type of IGF-l. These data suggest an individual role 
for MGF in initiating the proliferation and differentiation of satellite cells, as it 
precedes M-cadherin and MyoD expression (Hill et al., 2003a, b). In support of 
these data, stable transfection of cells in culture with MGF was shown to stimulate 
myoblast proliferation and suppress differentiation (Yang and Goldspink, 2002). 
Satellite cell number is dependent on muscle fibre type and age. The satellite cell 
content differs between muscle fibre types. The percentage of satellite cells in rat 
adult slow soleus muscle is 2- to Mold higher (11%) than in the fast tibialis anterior 
muscle (4%) (Schmalbruch and Hellhammer, 1977). The regulatory mechanisms 
behind these differences were identified as an increased density of satellite cells in 
association with the proximity of capillaries and myonuclei; capillaries being greater 
in the slow muscle (Schmalbruch and Hellhammer, 1977). Therefore, the increased 
number of satellite cells in the soleus muscle is understandable as slow-oxidative 
muscles are characterized by their increased capillary density when compared to 
fast-glycolytic muscles. In another study, more satellite cells were also observed at 
the motor neuron junctions (Wokke et al., 1989). Renault et al. (2002) reported a 
decrease in the number of satellite cells, expressed as a proportion of myonuclei, in 
biceps brachii and masseter muscle biopsies derived from older humans. That is 
1.5% in -75 years-olds, when compared to 5% in younger adults (-23 years old). 
Therefore, the important characteristic of self-renewal by satellite cells (Schultz, 
1996) may be compromised with age. 
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It has been shown that aged muscles display a lower adaptive and regenerative 
capacity (Grounds, 1998; Blough and Lindermann, 2000) caused by a decrease in 
satellite cell numbers and proliferative cell potential with ageing (Schultz and 
Lipton, 1982). However, not all studies are in agreement (Decary et al., 1997; 
Putman et al., 2001). Whether the age-related decrease in satellite cell number 
affects the regenerative capacity of skeletal muscle has been more recently 
investigated with cells in culture. Decary et al. (1997) showed that satellite cells 
isolated from muscles of aged human subjects are still able to make about 15 
divisions, which is enough to repair muscle damage. Furthermore, Putman et al. 
(2001) reported that the satellite cells and satellite cell progeny of ageing rats are not 
compromised and possess an unaltered capacity to contribute to the adaptive 
response of 50 days of chronic low-frequency electrical stimulation. Therefore, it 
was concluded that although the number of satellite cells decreased with age, the 
proliferative potential is not greatly affected. This suggests that the ability of 
skeletal muscle fibres to adapt, or regenerate, is maintained throughout life. 
The situation would be remarkably different however if the proliferation of the 
satellite cells were to be highly solicited, as observed in muscular dystrophies 
(Decary et al., 2000). In support of this, Reimann et al. (2000) proposed that the 
failure to regeneratj fibres in dystrophic muscle was due to exhaustion of the 
proliferative potential of the satellite cell pool and the continual need for satellite 
cell proliferation and fibre repair. This 'exhaustion' of the satellite cells ability to 
proliferate results in incomplete restoration of the muscle fibre numbers and 
significant muscle atrophy and wasting. 
Sadeh et al. (1985) found that the weekly administration of bupivacaine for 6 
months resulted in marked variability in terms of fibre size and atrophy, extensive 
fibre splitting, numerous internal nuclei and many 'whorled' fibres. These findings 
suggest that chronic exposure to bupivacaine results in incomplete fibre 
regeneration after several cycles of degeneration-regeneration. 
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One mechanism which has been suggested to control this limited proliferation, or 
mitotic clock, is the shortening of the telomeric sequences. It was found that in the 
quadriceps muscles there was only a very small decrease in the length of the 
telomeric DNA with increasing age. However, a dramatic decrease in telomeric 
DNA length was observed in the muscles of children with muscular dystrophy 
(Decary et al., 2000). This progressive loss of DNA could eventually destabilise 
telomere structure, leading to chromosome modifications (Counter et al., 1992) and 
triggering the entry of cells into a senescent programme (Torella et al., 2004). 
Therefore, the more cell divisions a satellite cell undergoes (i. e. as a result of the 
continual repair of chronic muscle damage) the resulting outcome is cellular 
senescence and consequent impaired skeletal muscle regeneration. 
Until recently, the muscle satellite cell was presumed to be the sole source of 
myonuclei in muscle repair. However due to the recent findings of multipotential 
stem cells in various adult tissues, the view that tissue-specific stem cells are pre- 
determined to a specific tissue lineage has been challenged. 
Ferrari et al. (1998) transplanted genetically marked (LacZ) bone-marrow (13M) 
derived cells (BMDC) into immuno-deficient mice. It was found that these cells 
migrated into areas of irradiation-induced muscle degeneration. Here, they 
underwent myogenic differentiation and participated in the regeneration of new 
fibres (Ferrari et al., 1998). However, the contribution of BM-derived progenitors to 
muscle regeneration was minimal. Nonetheless, these cells appeared to be recruited 
as a result of the inflammatory signals originating from the degenerating tissue, as 
they accessed the damaged tissue through the circulation (Ferrari et al., 1998). 
Furthermore, it was suggested that BM cells could serve as a reservoir of 
progenitors for muscle tissue, and that under conditions of extended damage these 
progenitors might expand or maintain the pool of resident, more differentiated, 
muscle-forming precursors (Ferrari et al., 1998). With this view, the ability of the 
skeletal muscle to regenerate, even after periods of chronic degeneration- 
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regeneration when the muscle satellite cell pool has become exhausted, would never 
be compromised. 
These findings of Ferrari et al. (1998) have been more recently supported by 
LeBarge and Blau (2002). In this excellent study, it was found that green fluorescent 
protein (GFP) labelled BMI)Cs became satellite cells, occupying the muscle stem 
cell niche, when transplanted following irradiation-induced damage. Also, these 
BMDC satellite cells gave rise to new fibres, a contribution to as many as 3.5% 
muscle fibres following subsequent exercise-induced damage (LeBarge and Blau, 
2002). Furthermore, this contribution of new multinucleated fibres from BMDCs 
was much greater than that reported by Ferrari et al. (1998). Therefore, the 
frequency of conversion of BMI)Cs into the myogenic lineage could be related to 
the conditions or extent of the muscle damage. Furthermore, there may be 
differences among different skeletal muscle types and the incorporation of BMI)Cs 
(Brazelton et al., 2003). 
There is strong evidence for the presence of progenitor cells with myogenic 
potential, other than satellite cells, within skeletal muscle (Asakura et al., 2001; 
Seale et al., 2000; Jankowski et al., 2002; Blaveri et al., 1999; Gussoni et al., 1999; 
DeAngelis et al., 1999; Qu-Petersen et al., 2002; McKinney-Freeman et al., 2002; 
Torrente et al., 2001). Asakura et al. (2001) identified a novel stem cell population 
which they named side population (SP) cells within skeletal muscle. These cells 
expressed the haernatopoietic stem cell marker, Sca-1, but were negative for 
markers of satellite cells. They possessed the ability to differentiate into 
haernatopoietic cells, satellite cells and skeletal muscle following transplantation 
(Asakura et al., 2001). Therefore, SP cells may be satellite cell progenitors capable 
of direct myogenic fusion. SP cells were also present in the muscles of Pax7 null 
mice, which lack satellite cells (Seale et al., 2000). Taken together, these findings 
suggest that SP and satellite cells represent distinct cellular populations within 
skeletal muscle. 
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It has been shown that when Scal+ and CD34+muscle-derived stem cells expressing 
the LacZ gene, were injected into the arterial circulation of the hindlimb of mdx 
mice, the late passage Scal+/CD34+ cells adhered to the endothelium (Torrente et 
al., 2001). However, following muscle and blood vessel damage they were able to 
migrate from the blood vessels into host muscle tissues, and participate in the 
formation of muscle fibres. This was evidenced by the presence of -12% fl- 
galactosidase positive fibres, 48 hours after their intra-arterial injection followed by 
damage to the tibialis anterior muscle (Torrente et al., 2001). These data would 
suggest that there are bi-potential (both haemopoietic and muscle lineage) stem cells 
present within the vasculature that may be activated to enter the myogenic lineage 
when the muscle receives extensive damage. However, it should not be excluded 
that these cells, like SP cells, could also represent progenitors of satellite cells. 
Regardless of this, it was concluded that these cells may prevent irreversible 
pathological damage and thus signals governing their migration need to be 
investigated further (Torrente et al., 2001). 
To summarise, upon injury skeletal muscle possesses the ability to regenerate 
damaged fibres and this is due to its resident satellite cells. However, considerable 
evidence now exists to suggest that other 'stem' cells (e. g. SP cells) are resident in 
skeletal muscle and these potentially originate from the bloodstream. The replicative 
potential of satellite cells diminishes following repetitive recruitment of the cells 
into the cell cycle, i. e. following chronic bouts of degeneration-regeneration. 
Whether the ability of the muscle to regenerate is ever completely compromised 
could be due to the presence of SP and other cells, e. g. BMDCs, that can also give 
rise to skeletal muscle fibres. These recent advances may offer an attractive means 
of cellular therapy for muscular dystrophy. 
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1.7 Cardiac Regeneration 
Over many decades the accepted paradigm has been that the heart is a post-mitotic 
organ without any regenerative capacity. Under this opinion, cardiac homeostasis is 
stagnant, cell renewal is non-existent and the cardiomyocytes are as old as the 
individual. Now it is believed that myocyte death and regeneration are part of the 
normal homeostasis of the heart. It was previously believed that hypertrophy was 
the only form of myocyte growth in the heart. However now, in addition to myocyte 
hypertrophy, it is thought that new myocyte generation predominates over cell death 
and contributes significantly to the normal growth of the heart into adulthood 
(Nadal-Ginard et al., 2003). This is supported by the detection of myocytes 
undergoing mitosis in the hearts of normal rat (Overy and Priest, 1966), mice 
(Anversa and Kajstura, 1998) and humans (Kajstura et al., 1998). Consequently, 
DNA synthesis persists in adult cardiornyocytes (Anversa and Kajstura, 1998). 
However, these data have been questioned. 
In many species cardiac myocytes become multinucleated and exhibit polyploidy 
(Anversa and Kajstura, 1998). So, some investigators dismissed the mitoses as 
examples of multinucleation with karyokinesis but without cytokinesis. However, 
myocytes undergoinpýtrue cytokinesis have been identified (Kajstura et al., 1998; 
Beltrami et al., 2001). Also, it has been reported that there is no increase in the 
number of multinucleated myocytes after puberty in hearts of both animals and man 
(Anversa and Olivetti, 2002). Therefore, if the DNA-replicating myocytes 
underwent karyokinesis without cytokinesis, there would be an increase in the 
number of multi-nucleated myocytes with age, which is not the case 
Another cause for dispute against the existence of myocyte replication and cardiac 
regeneration is the use of Bromodeooxyuridine (BrdU) as a marker for DNA 
synthesis, cell division and replication. Its use has sparked continued criticism due 
to its incorporation into DNA during DNA repair. BrdU is therefore not considered 
a selective marker of cell replication. However, Ki-67, a nuclear antigen which is 
expressed in all stages of the cell cycle (except G,, ) and is not involved in DNA 
28 
Introduction 
repair, has also been detected in myocytes, indicating cell cycling (Beltrami et al., 
2001; Anversa et al., 2002; Quaini et al., 2002; Urbanek et al., 2003). Furthermore, 
with the increased access to highly specialised equipment, i. e. confocal microscopy, 
analysis can be carried out with greater precision and accuracy than was previously 
the case. This is undoubtedly another reason why many investigators were unable to 
reach similar conclusions regarding this area of research. 
The strongest argument in favour of new myocyte formation in the adult heart is that 
there is an increase in myocyte number between birth and young adulthood in both 
animals and humans (Anversa. and Olivetti, 2002). Furthermore, the increase in 
cardiac mass seen over this maturational time period cannot solely be accounted for 
by myocyte hypertrophy (Anversa and Olivetti, 2002). Also, the increase in 
myocyte numbers in the adult heart is an under estimation due to concurrent cell 
death seen with maturation (Anversa and Olivetti, 2002). The finding of myocyte 
cell death in the adult heart further supports the concept of cardiac regeneration, 
because if myocyte renewal did not take place then the cardiomyocytes would 
simply disappear within a few decades of life (Nadal-Ginard et al., 2003). 
It has been shown'that cell death, through both necrosis and apoptosis, occurs in the 
normal heart. Hence, subsequently the number of myocytes will decrease with age 
(Anversa et al., 1990; Kajstura et al., 1996; Anversa and Olivetti, 2002). Kajstura et 
al. (1996) found that apoptotic and necrotic myocyte death occurs in the hearts of 3, 
7,12,16 and 24 month old Fisher 344 rats. Furthermore, the incidence of cell death 
increased with age and this was associated with ventricular dysfunction and failure, 
at 16 and 24 months of age (Kajstura et al., 1996). Therefore, myocyte cell death 
constitutes an important determinant of the ageing process, participating in the 
occurrence of ventricular dysfunction and failure in the 'old' heart (Kajstura et al., 
1996). Together with the occurrence of cell death there is myocyte regeneration, 
identified by nuclear mitotic division with BrdU labelling (Anversa and Kajstura, 
1998). This process of regeneration partially counteracts the death of cells seen with 
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ageing. Hence, there is ongoing cell death and regeneration throughout the entire 
life span. 
Cell death has been shown to correlate with the size of the cell and the level of 
cellular senescence (Brenner et al., 1998). It has been shown that large myocytes are 
older, do not react to growth stimuli and are prone to activate the cell death 
pathway. In contrast, smaller cells are younger, possess the ability to undergo 
hypertrophy and are less susceptible to cell death. Also, the smaller cells have been 
formed more recently and can still undergo a limited number of divisions before 
withdrawing from the cell cycle (Nadal-Ginard et al., 2003). This concept is 
supported further by the findings that young adult rats that have been subjected to a 
myocardial infarction, possess small replicating myocytes 7 days post infarction 
(Nadal-Ginard et al., 2003). 
1.7.1 Myocyte Hyperplasia and Pathological Conditions of the Heart 
The level of cell renewal increases significantly under a variety conditions. Studies 
which have been carried out on both humans (Kajstura et al., 1998; Beltrami et al., 
2001; Urbanek et al., 2003) and animals (Anversa and Kajstura, 1998) have 
provided evidence that myocyte replication occurs under physiological and 
pathological conditions of the heart (Anversa and Nadal-Ginard, 2002). In the male 
human heart suffering from advanced chronic ischaemic cardiomyopathy, the 
measured incidence of myocyte cell death by apoptosis and necrosis (at a given time 
point) are 0.18% and 1.2%, respectively. Using these data, the diseased heart could 
not continue to function in the absence of new myocyte formation. It has been found 
that myocyte regeneration is an important contributor to the maintenance of cardiac 
mass under these physiological and pathological conditions of the heart (Nadal- 
Ginard et al., 2003). 
The magnitude of haemodynamic stress may be the main determinant of whether 
cellular hypertrophy or hyperplasia is initiated in the pathological heart (Anversa 
and Kajstura, 1998). It has been shown that a gradual or moderate increase in 
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cardiac workload ensures that myocyte hypertrophy predominates (Anversa et al., 
1978). In contrast, a severe increase in workload, whether acute or chronic in nature, 
results in myocyte DNA synthesis, mitosis and proliferation in both animals and 
humans (Kajstura et al., 1994; Anversa and Kajstura, 1998; Kajstura et al., 1998; 
Beltrami et al., 2001; Urbanek et al., 2003). 
Anversa and Kajstura (1998) have shown the presence of DNA replication and 
mitotic divisions in myocytes of the decompensated post-infarcted rat heart. 
Subsequently, it was documented that the number of nuclei per cell does not change 
in the failing heart of rats (Anversa et al., 1990), verifying that increases in the 
number of myocyte nuclei must correspond to increases in myocyte number. In an 
excellent study by Kajstura et al. (1998) it was reported that in humans 882 x 103 
and 760 x 103 myocytes were undergoing mitosis in the entire ventricular 
myocardium affected by ischaemic or idiopathic dilated cardiomyopathies, 
respectively. These figures compare with 81.2 x 103 myocytes undergoing mitosis in 
normal control hearts. More recently, Beltrarni et al. (2001) found that in infarcted 
human hearts there was an increase in Ki-67 expression in myocyte nuclei in 
regions adjacent to and distant from, the infarcted area. Also, events characteristic 
of cell division, e. g. the formation of mitotic spindles and contractile rings, 
karyokinesis and cytokinesis, were identified. This further demonstrates that there is 
myocyte proliferation in the viable myocardium after a myocardial infarction 
(Beltrami et al., 2001). It should however be noted that the replicating myocytes are 
not detectable in the infarcted area, making regeneration in this area impossible 
(Anversa et al., 2002). 
With pressure-volume overload there is also evidence of myocyte regeneration. 
Urbanek et al. (2003) reported that in human aortic stenosis there is an increase in 
cardiac mass, resulting from a combination of myocyte hypertrophy and hyperplasia 
(Urbanek et al., 2003). These findings challenge the 'heart weight theory' that 
suggests that cell replication is secondary to exhausted myocyte hypertrophy 
(Nadal-Ginard et al., 2003). Therefore, evidence does exist which suggests that the 
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heart has the capability to replicate myocytes, which contributes to the formation of 
new muscle mass. However, where do these new cycling myocytes come from? 
The cycling cells could come from 2 possible sources; i) cells which are resident 
within the heart, i. e. cardiac stem cells, or ii) systemic cells, i. e. BM-derived stem 
cells which continuously colonise the myocardiurn and contribute to myocyte 
renewal (Nadal-Ginard et al., 2003). It has previously been shown that BMDCs can 
give rise to new myocytes either when injected into, or stimulated to 'home to', the 
heart by cytokine administration following a myocardial infarction (Orlic et al., 
2001 a, b). 
In a study performed by Quaini et al. (2002) human sex-mismatched heart 
transplants were performed. When a female heart was transplanted into a male host, 
this led to the findings that host cells homed to the transplanted heart and they could 
be identified by the presence of the Y chromosome (Quaini et al., 2002). They 
showed that 9%, 10%, and 7% of myocytes, smooth muscle, and endothelial cells, 
respectively possessed the Y chromosome. Furthermore, 17%, 14%, and 16% of 
these male (Y chromosome) myocytes, smooth muscle and endothelial cells, 
respectively, were replicating as identified by labelling with Ki-67. 
The study also reported cells expressing c-kit, MDRI or Sca-I in the atria and left 
ventricle, of which 12-16% of these cells contained the Y chromosome. These 
particular markers identify stem cells, but are not exclusive to this population of 
cells. These particular cells were undifferentiated and were negative for markers of 
BMDCs, e. g. CD45. They were also negative for markers of differentiated myocytes 
(e. g. sarcomeric a-actin), endothelial cells (e. g. CD31, Factor VIII and vimentin), 
smooth muscle cells (e. g. smooth muscle cc-actin and desmin) and fibroblasts (e. g. 
vimentin) (Quaini et A, 2002). These primitive cells were also present in control 
hearts, but at lower percentages. 
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To identify the cells involved in the generation of new myocytes, the transcription 
factors MEF21) and GATA4 were recognised in Y-chromosome bearing cells, 
showing that these cells were committed to myocyte differentiation. Also, the 
intermediate filament protein, nestin, was identified indicating a more advanced 
stage of myocyte differentiation (Quaini et al., 2002). Therefore, this study showed 
that undifferentiated, primitive cells expressing surface stem cell-related antigens (c- 
kit, MDRI, Sca-1) are present in both control hearts and in female transplanted 
hearts into male recipients. Because some of these cells were Y chromosome- 
positive, they must have translocated from the host into the atria and ventricles of 
the grafted heart. Once there, they lose the marker properties of stem cells, 
proliferate, acquire their mature phenotype, and subsequently give rise to myocytes, 
coronary arterioles and capillaries (Quaini et al., 2002). 
This study does not however identify the source of these primitive cells that lead to 
the cardiac chimerism. It is possible that circulating haernatopoietic stem cells from 
the recipient could have translocated to the implanted heart. Although Quaini et al. 
(2002) found that cells expressing c-kit, MDRI or Sca-1 were negative for markers 
of bone marrow differentiation, it is still possible that stem cells were mobilised 
from the bone marrow and reached and infiltrated the transplanted heart (Quaini et 
al., 2002). 
Interestingly, the same study did identify a high number of undifferentiated, 
primitive cells in the transplanted heart that were negative for the Y chromosome. 
This suggests that groups of primitive cells may reside in the heart, and are able to 
multiply and acquire cardiac cell lineages. This is supported by the presence of 
cycling myocytes (Ki-67 positive), which were present in the female heart but were 
Y chromosome negative (Quaini et al., 2002). 
Although the study of Quaini et al. (2002) failed to identify the origin of these 
primitive cells, it is significant that it provides clear proof of new myocyte 
formation in the adult heart and that there are 'stem-like' cells which are able to 
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differentiate into the 3 types of cell (myocyte, smooth muscle and endothelial cell) 
within the heart (Nadal-Ginard et al., 2003). But can these primitive cells be termed 
'cardiac stem cells'? 
Beltrami et al. (2003) recently reported the existence of Lin- c-kitpo' cells (Lin- is a 
blood lineage marker; c-kit a stem cell marker) in the rat myocardium, with the 
properties of cardiac stem cells. These cells are negative for myocyte (oc-sarcomeric 
actin, cardiac myosin, myosin, desmin, ot-cardiac actinin and connexin 43), 
endothelial cell (Von Willebrand factor, CD31 and vimentin), smooth muscle cell 
(cc-smooth muscle actin and desmin), and fibroblast (fibronectin, procollagen I and 
vimentin) cytoplasmic proteins. 
Beltrami et al. (2003) identified one Lin7 c-kitP` cell for approximately every 104 
myocytes. Also, all of the detected c-kit" cells were negative for CD45 and the 
endothelial/haematopoietic progenitor marker CD34. The Lin' c-kitp" cells were 
found in small clusters in the interstitium between well-differentiated myocytes. In 
agreement with Quaini et al. (2002), many of these Lin' c-kip" cells expressed Ki- 
67 (indicative of a cycling cell), and the transcriptions factors GATA-4 and MEF2, 
indicative of cells at the early stages of cardiac myogenic differentiation. Also, there 
were small amounts of sarcomeric proteins in their cytoplasm. This is strong 
evidence of their cardiac myogenic potential and fate (Beltrami et al., 2003). 
This study also established a precursor-product relationship. Lin7 c-kit"" cells were 
isolated from the rat myocardium and then injected into an ischaernic heart bringing 
about the formation of new blood vessels and myocytes, with the characteristics of 
young cells, encompassing -70% of the entire ventricle just 20 days after the 
infarction (Beltrami et al., 2003). Following in vitro and in vivo testing, Beltrami et 
al. (2003) reported that the cardiac Lin' c-kitP" cells were self renewing, clonogenic 
and multi-potent, giving rise to 3 different cardiogenic cell lineages; myocytes, 
endothelial cells and smooth muscle cells. 
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Beltrami et al. (2003) found that stem cell implantation into the area bordering the 
infarct resulted in a reduced infarct size, cavity dilation and diastolic stress, while 
increasing wall thickness, ejection fraction and improving end-diastolic pressure and 
dP/dt, an indicator of contractility. Also, Beltrami et al. (2003) reported that the 
myocytes produced by the cardiac Lin' c-kitP` cells were structurally and 
functionally competent when their contractile parameters (time-to-peak shortening; 
peak shortening and velocity of shortening) were compared with the spared 
myocytes in vitro. Therefore, Lin" c-kitPO' cells are able to generate bonafide cardiac 
myocytes, which are functionally and structurally similar to the spared myocytes 
(Beltrami et al., 2003). Subsequently, the new myocardial cells improved the overall 
function of the heart due to the complete differentiation of the isolated Lin' c-Up", 
cells into myocytes. Interestingly, the injected cells were attracted to the ischaernic 
zone, as it was shown that regenerating cells (i. e. BrdU positive) were located in the 
necrotic area and not the spared, surrounding viable myocardiurn even though the 
cells were injected at the border between the ischaernic and healthy myocardiurn 
(Beltrami et al., 2003). 
This excellent study by Beltrami et al. (2003) clearly shows the presence of 
undifferentiated cells in the adult heart, which could potentially be cardiac stem 
cells. However, whether these cells reside in the heart or continuously colonise the 
heart via the circulation still remains an unanswered question. Both possibilities 
may be correct. The isolated Lin' c-kir' cells were negative for markers of bone 
marrow (CD45) and endothelial/haematopoietic progenitor marker CD34, 
suggesting that if they did reach the myocardiurn from the circulation they may have 
resided in the myocardiurn for long enough to adopt the myocardial specific 
phenotype (Beltrami et al., 2003). But perhaps the most important point is that they 
actually exist and that new myocyte formation does occur in the heart. 
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1.7.2 Cellular Therapy 
Although the full process of cellular renewal exists in the myocardium, by itself the 
heart appears to be unable to reconstitute all the lost myocardium after coronary 
artery occlusion. Therefore, a number of protocols involving cell therapies have 
been investigated in both animals and humans, in an attempt to replace lost 
myocytes with autologous or heterologous contractile cells injected into, or around, 
the necrotic infarcted area (Nadal-Ginard et al., 2003). 
Many investigations have focused on different types of cells, including embryonic 
stem cells (Behfar et al., 2002; Mummery et al., 2003), skeletal myoblasts (Tambara 
et al., 2003; Thompson et al., 2003), bone marrow and haemopoietic (Orlic et al., 
2001a, b; Yeh et al., 2003), or cardiac stem cells (Beltrami et al., 2003) in attempts 
to find the best type and source of cell to reconstitute the myocardium and improve 
function following myocardial damage. However, research into this particular area 
of cardiovascular medicine is in its early stages. Only a few clinical trials have been 
conducted thus far (Menasche et al., 2003; Perin et al., 2003; Kang et al., 2004). 
These have reported improvement in cardiac function, of which the mechanism 
remains uncertain, but it has been difficult to demonstrate long term benefit. Also, 
there are reported negative side effects (Menasche et al., 2003; Kang et al., 2004). 
These may be related to the type of cells that have been used. One problem with 
injecting skeletal myoblasts is the differentiation of these cells into myotubes and 
skeletal muscle fibres, but not cardiornyocytes. These fail to create gap junctions, 
due to lack of connexin 43, with existing cardiomyocytes and hence 
electromechanical coupling is unlikely. Furthermore, this could contribute to the 
serious adverse event of ventricular arrhythmias reported in some patients 
(Menasche et al., 2003). The use of primary fetal or neonatal cardiac myocytes, or 
cell lines derived from embryonic stem cells, proposes to be an attractive 
alternative. However, due to the difficulty in obtaining sufficient cells in order to 
make a functional difference, as well as consequent problems with 
histocompatibility and immuno-suppression, this approach has also proved to be far 
from ideal. It is important to state that this field of biomedical research is a long way 
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from identifying the most appropriate intervention to help remodel and repair, and 
hence improve the performance, of the infarcted heart. Also, in recognising the 
detrimental consequences of such cell therapy procedures. 
Some investigators have not been able to replicate other peoples' findings and 
disagree on the transdifferentiation of BMI)Cs into cardiornyocytes in the infarcted 
area, as reported specifically by Orlic et al. (2001 a, b) and others (Laflamme et al., 
2002; Deb et al., 2003), when injected into the myocardium (Murry et al., 2004; 
Balsam et al., 2004; Nygren et al., 2004). To follow haernatopoietic cell fate, Murry 
et al. (2004) used cardiomyocyte-restricted (MHC-nLAC and MHC-enhanced green 
fluorescent protein (EGFP)) and ubiquitously expressed (fl-actin-EGFP) reporter 
transgenes. They reported no transdifferentiation of these cells into cardiornyocytes 
when injected into infarcted mouse hearts. Similar results were reported by Balsam 
et al. (2004). These workers showed that haematopoietic stem cells from transgenic 
mice, and expressing GFP, did not transdifferentiate into cardiomyocytes when 
injected directly into ischaernic myocardium, as evidenced by these GFP+ cells 
failing to express cardiac-specific tissue markers. Furthermore, they found no 
evidence of myocardial regeneration from blood-borne partner-derived cells when 
using GFP+-GFP- parabiotic 2 mice 
(Balsam et al., 2004). There are certain technical 
problems within both studies which could explain why they failed to replicate 
strongly accepted scientific evidence. In particular, it is not certain that Murry et al. 
(2004) were successful in the actual injection of the BMI)Cs into the infarcted 
region of the myocardium. Furthermore, the extent of the infarct may determine 
whether regeneration takes place and Murry et al. (2004) caused considerably less 
damage than that in previous studies. The use of a parabiotic mice model in the 
Balsam et al. (2004) study is non-physiological, and bears no relevance to real life 
situations. The resolution of image analysis in both studies was poor, therefore 
detection of newly formed cardiomyocytes, previously found using high resolution 
confocal microscopy, could have been missed. Finally, and most importantly, both 
studies failed to screen for markers of myocyte proliferation (ki67 or BrdU), which 
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would undoubtedly represent regenerative processes if occurring in the 
myocardium. 
Both studies (Murry et al., 2004; Balsam et al., 2004) suggested that previous 
investigations which had reported the transdifferentiation of BMI)Cs into 
cardiornyocytes were probably not due to transdifferentiation, but as a result of cell 
fusion with existing myocytes. Using BMI)Cs which were GFP' and endogenous 
cardiornyocytes carrying the LacZ transgene, Nygren et al. (2004) recently reported 
the low frequency existence of bone-marrow derived cardiornyocytes outside the 
infarcted myocardium, which were derived exclusively through cell fusion 
following BMDC transplantation. This was evidenced by X-gal precipitate within 
the cytoplasm of the GFP+ cardiornyocytes. Furthermore, bone-marrow derived 
cardiornyocytes were typically bi-nucleated when stained with Hoechst 33342 
(Nygren et al., 2004). 
It should be noted that these above studies question the use of BMDCs to 
successfully reconstitute myocardium after an infarct. The identification and use of 
cardiac stem cells to generate new myocardium has never been disputed and their 
existence has been confirmed by three different groups (Beltrami et al., 2003; Oh et 
al., 2003; Matsuura et al., 2003). Beltrami et al. (2003) reported that the 
regenerating myocytes found in rat myocardium after transplantation of cardiac 
stem cells into the bordering regions of an infarct, was not the result of cell fusion 
between injected cells and spared myocytes. Five reasons conclusively argue against 
cell fusion in this study. First, the number of new myocytes that was generated was 
greater than the number of injected cells, which in addition also gave rise to smooth 
muscle and endothelial cells. Second, the myocardial infarct resulted in very few 
surviving, spared myocytes in this area, leaving no fusion partners. Third, no small 
myocytes (BrdU or GFP) were found in the spared myocardium, where 
differentiated fusion partners were in abundance. Fourth, the newly formed 
myocytes in this study were smaller than the fully differentiated myocytes, 
indicating their immature nature. The product of cell fusion would lead to myocytes 
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being as large as the differentiated partner. Finally, regenerating myocytes had a 2n 
DNA content and not the 4n expected for fusion products. 
Strategies to increase and improve the differentiation of cardiac stem cells into 
myocytes following injury are areas of ongoing investigation. The ultimate aim is 
the endogenous promotion of their migration and activation, as opposed to the 
injection of these cells into the myocardiurn after infarction. Interestingly, it has 
been shown that cardiac stem cells express c-met, the selective receptor of HGF, 
and that HGF promotes cardiac stem cell migration (Chimenti et al., 2002). Indeed, 
local injections of HGF and IGF- I aid the repair of infarcted hearts in mice, with the 
numbers of viable cardiac stem cells increasing in the border zone, the infarct and 
the remote surviving portion of the wall. This results in myocyte regeneration two 
weeks later, with the new myocardiurn containing parenchymal cells and coronary 
vessels consisting of resistance arterioles and capillaries (Chimenti et al., 2002). 
In summary, there is clear evidence that the heart is not a terminally differentiated 
organ and cell death and new myocyte formation is involved in the normal 
homeostasis of the heart. Furthermore, the heart has cardiac stem-progenitor cells 
supporting myocyte regeneration. The level of cell replication, renewal and 
hypertrophy increases under a variety of physiological and pathological conditions, 
thereby contributing'to the formation of new muscle mass. With ischaemic heart 
disease these processes are restricted to the remaining viable myocardium and the 
border regions around the infarct. Therefore, the concept of stem cell therapy has 
become an attractive intervention for repairing the injured myocardium. to maintain 
or improve cardiac function. However, the efficacy of such therapies still has to be 
established. 
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1.8 Cardiac vs. Skeletal Muscle 
As this thesis focuses on the cell death and regeneration in skeletal and cardiac 
muscle, the similarities and differences between these 2 muscles will now be 
discussed. Fundamentally, 3 types of muscle tissue exist: (1) skeletal (2) cardiac and 
(3) smooth muscle. 
The basic contractile cells of skeletal muscle are the muscle fibres. These are 
individually surrounded by connective tissue (endomysium) and grouped into 
bundles by perimysiurn to form a skeletal muscle (Charge and Rudnicki, 2004) 
(Figure 1.5). Muscle fibres express different characteristic protein molecules, 
principally different myosin heavy (MHC) and light chain isollorms and levels of' 
metabolic enzymes (creatine kinase; succinate dehydrogcnase). Myosin heavy 
chains are the molecules primarily responsible, together with actill, for cross bridge 
formation and the contraction of muscle fibres. MHCs are composed oftwo major 
domains. One, a rod that with another rod of MHC florms a (x-hciical coil, making 
up the principal component of thick filament. The other domain, a head that binds to 
actin, has actin-catalysed ATPase activity, and works in a ratchet fashion along the 
thin filament to bring about contraction and shortening of the muscle (1-lughcs et 
al., 1993). 
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Figure 1.5 Skeletal muscle structure (Goldspink and Cox, 1997). 
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Individual adult skeletal muscles are composed of a mixture of muscle fibres with 
different physiological properties due, in part, to the presence of different MHC 
isoforms and ATPase activities. The activity of the ATPase determines the rate of 
splitting ATP and hence velocity of shortening. Also, ATPase activity can be used 
to histochernically distinguish different fibre types. Fibre types within skeletal 
muscles range from slow-contracting/fatigue resistant types to fast 
contracting/easily-fatigued types. It is generally accepted that slow fibres have a low 
ATPase activity, while fast fibres have higher ATPase activities (Jones and Round, 
1990). The proportion of each fibre type within a muscle determines its overall 
contractile properties. For example, the soleus muscle is termed a slow-twitch 
muscle, due to its high proportion of fibres expressing the slow type I MHC 
isoform. In contrast, the fast contracting tibialis anterior muscle is composed 
predominantly of fast type Ila and Ilb MHC isoforms. Therefore, there are 3 major 
fibres types: slow (Type 1, SO) fast-oxidative (Type Ila, FOG) and fast-glycolytic 
(Type Ilb, FG). Their general characteristics, and how these compare to cardiac 
muscle cells, are outlined in Table I. I. 
Different MHC isoforms are expressed during development as muscle fibres are 
formed (via myoblast fusion), grow and then reach their adult status. Initially, an 
embryonic MHC is expressed. The expression of this isoform then declines and is 
replaced by a neonatal MHC isoform before the temporal expression of the adult 
isoforms in the fully differentiated adult muscle fibre (Schiaffino et al., 1989). 
Hughes et al. (1993) have shown that the expression of fibre-type specific isoforms, 
i. e. slow/fast is superimposed upon the expression of stage-specific isoforms (e. g. 
embryonic/neonatal). Hughes and associates (1993) reported the onset of expression 
of three slow MHC isoforms during development of humans and the rat. These 
findings were supported by the work of Narusawa et al. (1987), who found that the 
slow MHC isoform, normally expressed in the adult soleus, was expressed along 
with embryonic MHC in primary generation myotubes of limb muscles in the 16 
day old rat foetus. In this multi-gene family, the order of the gene on the 
chromosome determines their sequential expression. Tonic innervation is required 
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for slow isoform expression in skeletal muscle. Notably, the slow skeletal muscle 
isofonn is identical to the fl-cardiac MHC isoform. 
Table 1.1 Characteristics of the 3 major skeletal muscle fibre types (Type 1, 
SO; Type Ila, FOG; Type Ilb, FG) and cardiac muscle cells. 
Type I Type Ila Type Ilb Cardiac 
Molphology 
Location and 
number of nuclei 
Peripheral and multi-nucleated Central and 
single, bi- or tri- 
nucleated 
Colour Red White/Red White Red 
Fibre diameter Small Intermediate Large Very small 
Capillaries High Intermediate Low High 
Mitochondria High Intermediate Low High 
BiochemisLry 
Myoglobin High Intermediate Low High 
Myosin ATPase Low High High Low 
Glycolytic capacity Low - High High Low 
Oxidative capacity High Medium/High Low High 
Function 
Speed of 
contraction 
Slow, 
voluntary 
control 
Fast, voluntary 
control 
Fast, 
voluntary 
control 
Very slow, 
autonomic 
control 
Fatigability Low Moderate/High High Low 
Mitochondria, abundant in cardiac and slow muscle fibres, contain a number of pro- 
(cytochrome c and apoptosis-inducing factor (AIF)) and anti-apoptotic molecules 
(1362), the expression or release of which can determine cell fate. This release can 
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be triggered by a variety of external stimuli and appears to be regulated by the Bcl-2 
family of proteins associating with the inner and/or outer membranes of the 
mitochondrion. Second, mitochondria produce reactive oxygen species (ROS). 
These ROS produced in mitochondria in proportion to tissue oxygen utilization, 
have both direct effects on cell death, as well as indirect effects via the activation of 
transcription factors. These promote the selective transcription of genes which are 
implicated in regulating the formation of the permeability transition pore, and the 
subsequent release of cytochrome c and AIF. Thus, the combination of 
mitochondrial content as well as the high respiration rate could make cardiac muscle 
and slow skeletal muscle particularly susceptible to apoptosis via the mitochondrial 
pathway (Primeau et al., 2002). 
Another important feature that cardiac muscle cells and slow muscle fibres have in 
common is the presence of the PLB (Simmerman and Jones, 1998). In cardiac and 
slow skeletal muscle SR, but not in fast skeletal muscle SR, the Ca2+-ATPase 
(SERCA2) is subject to regulation by PLB, an intrinsic SR protein that is naturally 
co-expressed with SERCA2 (and not SERCAI) isoform (Simmerman and Jones, 
1998). It is widely recognised that dephospho-phospholamban inhibits Ca2+ATPase 
function through physical interaction with the enzyme, and dissociation of the two 
proteins upon phosphorylation of PLB by PKA relieves the inhibition. The 
differences between the cardiac and slow, compared with fast, muscle fibres for the 
presence of PLB could have implications for initiating cell death in these different 
muscles, considering that Ca 2+ overload is the underlying mechanism for 
catecholamine-induced cardiomyocyte death (Mann et al., 1992). 
As previously discussed it is now apparent that, like skeletal muscle, the heart is not 
a post-mitotic organ. It possesses the capacity to form new myocytes. This is 
brought about by the activation and ensuring proliferation and differentiation of the 
resident stem cells, present in both tissues. 
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As outlined above there are several similarities and differences between skeletal and 
cardiac muscle, in terms of contractile, metabolic and regenerative properties. 
Overall, the slow contracting type I skeletal muscle fibres are similar to cardiac 
muscle cells, whereas faster fibres differ. The present study questions whether the 2 
different types of muscle tissue will respond in the same way to the effects of 
catecholamines. More precisely, due to the close relationship between slow skeletal 
muscle fibres and cardiac muscle, will this mean that they will react differently 
when compared to the fast skeletal muscles? Furthermore, are the effects of 
catecholamines specific for a population of cells, i. e. differentiated cells or 
progenitor cells, if the latter then perhaps impairing the capacity of regeneration in 
each tissue? Overall, the following questions are asked: Is the cellular response to 
catecholamines the same in skeletal muscle as it is in the heart, and is the effect 
specific to mature or immature cells? 
Aims and Objectives 
1. To examine the effects of acute catecholamine exposure on skeletal muscle, 
in terms of cell death and the time course and sequence of events in the 
regeneration process, - including the involvement of satellite cells and MGF 
in this process. 
2. To investigate the effects of acute catecholarnine exposure on the heart, in 
terms of cell death and the adaptation of the heart, in terms of cellular 
renewal and hypertrophy and the functional consequences. 
3. To examine the effects of chronic catecholamine exposure on skeletal 
muscle, in terms of cell death and consequent regeneration, and the 
adaptation of skeletal muscle through fibre hypertrophy and growth. 
4. To investigate the effects of chronic catecholamine exposure on the heart, in 
terms of myocyte death, fibrosis and hypertrophy. 
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2.0 METHODS 
2.1 Fibre Death and Skeletal Muscle Regeneration 
2.1.1 Animals and husbandry 
Male, Wistar rats (264 ± 22g) derived from a conventional colony at John Moores 
University were housed under controlled conditions of 25*C, 50% relative humidity 
and a 12 hr light (6: 00 - 18: 00) and 12 hr dark cycle, with water and food 
(containing 18.5% protein) available ad libitum. All experimental procedures were 
carried out under the British Home Office Animal (Scientific Procedures) Act 1986. 
2.1.2 Experimental design 
Time course of catecholamine-induced damage 
Muscle damage was induced by a single, subcutaneous injection of isoprenaline at a 
dose of 20 mmol kg" (i. e. 5 mg kg"). Rats were killed 3,9,12,18,24,48 or 72 hrs 
following this administration of isoprenaline. Additionally the natural 
catecholamines, adrenaline and noradrenaline, were also investigated for closer 
relevance to sporting activities as well as medical conditions. In these experiments 
rats were only killed 18 hrs after equimolar 20 mmol kg" (6.7 mg kg") 
subcutaneous injections. 
ITA 
Control groups of rats (n--5) were run along side the experimental groups, and 
received an equivalent volume (-0.3ml) of the saline vehicle only, without any of 
the synthetic or natural catecholamine. 
Fibre regeneration and the time course of the regenerative process 
Figure 2.1 shows a schematic representation of the experimental design. Animals 
were randomly divided into groups of n=5 for each time point. Each animal was 
administered a single injection of either 20 mmol of isoprenaline kg" or adrenaline 
kg'I at day zero. This dose has been shown in our lab (Ellison et al., 2002) to cause 
significant necrosis and apoptosis in the soleus muscle. 
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The regeneration of skeletal muscle following catecholamine-induced injury was 
monitored by killing animals at specified time points over 28 days (Figure 2.1). 
Continuous infusion of catecholamines 
Chronic delivery of either isoprenaline, adrenaline or saline was facilitated using 
osmotic mini-pumps (i. e. Alzet Model 2002 delivering 0.5gl/hr, or 2004 delivering 
0.25gl/hr; Charles River, UK). These were implanted subcutaneously in the dorsal 
region via a small interscapular incision using sterile surgical technique, while the 
animals were under light isoflurane anaesthesia. Isoprenaline bitartrate or adrenaline 
hydrochloride (Sigma, Poole, UK) was prepared in 0.9% sodium chloride (pII 5.5) 
at a concentration calculated to deliver 20 mmol kg"d" during either a 5,7,14 or 28 
day infusion period (n=20,5 per group). Sham-operated (Placebo) rats received 
pumps filled with 0.9% sodium chloride for 7,14 and 28 days (n=l 5,5 per group). 
All rats were killed by cervical dislocation and the heart, soleus, diaphragm, tibialis 
anterior and plantaris muscles isolated. To establish whether continuous exposure of 
catecholarnines had caused hypertrophic growth in the heart and skeletal muscles, 
the weights of the heart and each skeletal muscle were recorded for each animal. For 
the heart, the atria were dissected from the ventricles and the ventricles mounted on 
cork discs apex uppermost. Cross-sectional samples taken from the mid-belly region 
of each skeletal muscle were mounted on cork discs and supported by a piece of 
liver. Longitudinal samples were also mounted on cork discs for each muscle. 
Tissues were embedded in optimal cutting temperature compound, immediately 
snap frozen in super-cooled isopentane and stored at -80"C. These were 
subsequently cryo-sectioned at 5ýtrn (Leica, CM3050S), mounted on microscope 
slides and stored at -20'C until analysed, as described below. 
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2.1.3 Analytical procedures 
Detection of fibre necrosis and apoptosis 
Necrosis 
Myocyte or fibre specific necrotic damage was detected using a mouse anti-myosin 
monoclonal Ab in vivo (Benjamin et al., 1989; Kajstura et al., 1996; Goldspink et 
al., 2004). All animals received I mg of the anti-myosin Ab kg" intraperitoneally 
(i. p. ) lh prior to either the saline vehicle (control), isoprenaline, adrenaline or 
noradrenaline injection. Significant levels of the Ab have been shown to remain in 
the circulation for up to 72 hours (Benjamin et al., 1989), i. e. well within the time 
frame of these experiments., Once introduced into the circulation, this Ab only 
permeates the disrupted membrane of necrotic myocytes and is too large to pass into 
viable myocytes. Once inside the necrotic myocyte or fibre it binds to myosin heavy 
chain where it can be visualised. It is therefore an excellent, highly sensitive and 
selective method for detecting myocyte necrosis. This Ab is not commercially 
available and was obtained through collaboration with Prof. W. A. Clark (Michael 
Reese Hospital, Chicago, USA). It is therefore an 'in house' method. Due to limited 
availability of the myosin Ab, it was only injected into the 18 hr group. This time 
point has been shown previously within our laboratory to cause significant 
cardiomyocyte and muscle fibre specific necrosis in the soleus muscle (Goldspink et 
al., 2004). 
For the continuous infusion of catecholamines, 12 animals received I mg of the 
anti-myosin Ab kg" intraperitoneally 24 hrs prior to being killed. These animals 
were n=3 for the 7 day adrenaline, isoprenaline or sham-operated group and n=3 
from the 14 day isoprenaline group. 
Cellular apoptosis 
Apoptosis was detected in vitro on 5ýtm serial cryo-sections. A rabbit anti-caspase 3 
I*Ab (1: 200 dilution; R&D systems, Abingdon, UK) was used to detect the 
activated caspase 3 enzyme. Sections were incubated for I hour at 371C. This 
enzyme is only activated in apoptotic cells (Saraste and Pulkki, 2000). A positive 
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control for apoptosis, using sections of lactating mammary glands (Majno and Joris, 
1995) was run along side all experimental sections, in order to ascertain antibody 
specificity, accuracy and reliability of the staining protocol on a day to day basis. 
ImmunqJ7uorescence 
For the time course of catecholamine-induced damage, the anti-myosin I"Ab and 
caspase 3 1"Ab were detected in turn using immunofluorescence on the same 
sections. Sections were incubated for I hour at 37C with fluorescin anti-mouse 
conjugated 2*Ab (1: 200 dilution) and Texas red anti-rabbit conjugated 2"Ab (1: 50 
dilution; Vector Labs, Peterborough, UK) to visualise necrosis (stained green) and 
apoptosis (stained red), respectively. Sections were examined under a fluorescent 
microscope (Nikon 131000) and digitised using a 12-bit cooled digital camera (DVC 
1312C). 
Standard histochemistry 
For the continuous infusion of catecholamines, the anti-myosin Ab was detected 
using a rabbit anti-mouse horseradish peroxidase-conjugated (HRP) 2"Ab (I hour at 
3TIC; 1: 200 dilution; Dako) and caspase 3 Ab was detected using a goat anti-rabbit 
HRP-conjugated 2*Ab (I hour at 37'C; 1: 200 dilution; Vector Labs). The 
chromogen 3,3-diaminobenzidine (DAB) (Sigma) and Nova red (Vector Labs) 
were used to visualise the necrotic and apoptotic cardiomyocytes, respectively. 
Sections were then counterstained with haernatoxylin and permanently mounted 
before being examined by light microscopy. Negative controls were run in parallel 
with the experimental slides, these were exposed to the same procedure, but the 
2*Abs were omitted. 
Quantification 
For the time course of catecholamine-induced damage, the number of fibres in the 
skeletal muscles that were damaged via either necrosis and/or apoptosis were 
counted (-800 fibres in total) in 4 randomly chosen fields of whole cross-sections of 
the muscle belly, using image analysis (Lucia G) (xIOO magnification). Results 
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were expressed as the percentage of damaged fibres relative to the total number 
counted. 
For the heart, percent apoptosis (i. e. percent area of positive staining in field of 
view) was determined using image analysis on 6 randomised fields of view (x 100 
magnification) around the LV lumen of heart, and specifically at 2.2 mm from the 
apex. This method is semi-quantitative and allowed some limited interaction by the 
operator. Work in our laboratory has shown previously that the peak necrotic and 
apoptotic damage is localised 2.2mm from the apex along the longitudinal axis and 
within the sub-endocardium (Goldspink et al., 2004). 
For the continuous infusion of catecholamines, the numbers of fibres damaged via 
either necrosis or/and apoptosis in the skeletal muscles were counted in the entire 
cross-sections of the muscle belly using image analysis (xlOO magnification). 
Results were expressed as the number and percentage of damaged fibres in the 
whole soleus. 
In the heart, percent necrosis or apoptosis was determined for the entire cross 
section of the heart at 2.2 min from the apex, using xlOO magnification (-50 fields). 
Measured fields were selected using a motorized microscope stage which had been 
programmed to move across the entire cross section. The mean value of all fields 
quantified for each animal was calculated. 
Detection of fibre types 
Histochemical staining 
The principle is to identify different isoforms of the enzyme, myosin ATPase, by 
marking the sites of myosin ATPase activity in the muscle fibres. The first stage of 
the procedure consists of pre-incubating the muscle sections at either an acid or 
alkali pH. Generally, fast myosins are inactivated at acid pH (between pH 4.3 to 4.6) 
and slow myosins are inactivated at an alkaline pH, of around pH 9.4. Having 
inactivated the enzyme activity in one set of fibres during the pre-incubation, the 
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remaining ATPase activity can be detected by incubating the section with ATP 
substrate and an excess of calcium at pH 9.4. The inorganic phosphate which is 
liberated from the ATP couples with calcium to produce a colourless precipitate of 
calcium phosphate, which is insoluble at this alkaline pH. The section is then placed 
in a solution of cobalt chloride, and the calcium phosphate precipitate is replaced by 
cobalt phosphate. After adding ammonium sulphide, the phosphate is replaced, 
leaving cobalt sulphide a highly visible black-brownish precipitate and marking the 
sites of myosin ATPase in the muscle fibres. This can then be visualised using light 
microscopy. 
Acid (pH 4.35) and alkaline (pH 10.4) pre-incubation conditions were used to detect 
3 fibre types, and the staining methods were based on that described previously by 
Guth and Samaha (1970). Following pre-incubation for either 30 min or 15 min for 
acid or alkaline, respectively, the sections were rinsed in solution consisting of 18 
mM CaC12 in 100 mM Tris buffer at pH 7.8 for 2x1 min. Sections were then 
incubated for 15 min at 37C in a medium containing 2.7 mM ATP, 50 mM KCI, 18 
mM CaC12 in 100 mM 2-amino-2-methyl-l-propanol (AMP) buffer, at pH 9.4. 
Following incubation with the substrate, slides were washed 3-times in 1% CaC12, 
and then placed in a 2% solution of cobalt chloride (COC12) for 3 min. Sections were 
then washed 4-times in an alkaline solution (lOOmM AMP buffer, pH 9.4) before 
being placed in a 1% solution of ammonium sulphide (NH4S) to develop the colour. 
Sections were finally washed under running tap water, dehydrated, cleared and 
mounted. ' 
Acid pre-incubation results in the identification of 3 fibre types: type I stain as 
positive, dark staining fibres, type Ha stain as pale (negative) fibres and type Ilb as 
intermediate staining fibres (Figure 2.2). According to Ranatunga et al. (1990), the 
contraction characteristics of a muscle, i. e. the shortening-velocity and force- 
velocity relationships closely correlate with the muscle's histochemically- 
determined fibre type composition. The contraction speed is either faster or slower 
if more type II or type I fibres predominate within the muscle, respectively. 
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Figure 2.2 Myosin ATPase stain. 
Serial cross-sections of the myosin ATPase stain followim, acid (pli 435) (A and 
C) or alkali (pH 10.4) (B and D) pre-incubation for the plantaris (A and B) and 
soleus (C and D) muscles. Acid pre-incubation (pH 4.35) results in tile identification 
of 3 fibre types. Type I (dark), type Ila (pale) and type lib (light brown) for tile 
plantaris muscle (A). The soleus muscle (C) does not contain type llb fibres but it 
does contain an intermediate fibre (In) which stains a colour intermediate between 
type Ila and type 1. Alkali pre-incubation (pH 10.4) (B and D) results in the 
identification of 2 fibre types. Type I (pale) and type 11 (dark). No discrimination 
can be made between type Ila and I lb with this stain. 
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The soleus muscle contains predominantly type I fibres and a minor component of 
type Ha fibres (Schiaffino et al., 1989). Also found in the soleus are some lighter 
brown staining fibres that have been classified as intermediate or type Ilc fibres 
(Figure 2.2). The latter possess myosin ATPase activity that is intermediate between 
type I (positive) and type Ila (negative) (Brooke and Kaiser, 1974). 
Alkaline pre-incubation to inactivate slow myosin ATPase activities is the reverse 
of acid pre-incubation. However, there is no differentiation between the two fast 
fibre types, IIa and Ub. Therefore, type I fibres appear negatively stained (very pale) 
and type II fibres positively dark stained (Figure 2.2). 
Immunohistochemical staining 
To complement the histochernical procedures, more sensitive identification of slow 
or fast fibres was achieved using selective antibodies against either slow or fast 
MHC. More specifically, monoclonal anti-slow-twitch and anti-fast-twitch 
antibodies (Sigma), which are highly specific for the slow or fast MHC of adult 
skeletal muscle, were used. 
Initially, a titration assay was performed in order to determine the optimal working 
dilution for each Ab against rat skeletal muscles. Table 2.1 shows the dilutions that 
were assayed and the semi-quantitative staining intensities observed in the muscle 
fibres. The soleus and tibialis anterior muscles were used specifically in the assay 
due to their slow and fast contractile properties, respectively. 
A working dilution of 1: 500 was chosen for both the anti-slow and anti-fast MHC 
antibodies in relation to quality and intensity of staining and cost. Thereafter, 
muscle sections were incubated overnight at 4"C with 1: 500 dilution of IAb in 5% 
normal serum and PBS, in a Sequenza staining/histology unit (Thermo Shandon, 
Basingstoke, UK). The secondary Ab (2"Ab) used was a rabbit anti-mouse 
conjugated with HRP (1: 100 dilution) (Dako, Glostrup, Denmark). The chromogen, 
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Nova Red (Vector Labs), was used to visualise the slow or fast fibres. The sections 
were examined under a light microscope. 
Table 2.1 Immunohistochemical staining of skeletal muscle. 
Titration Assay to determine optimal working dilution for anti-slow and anti-fast 
MHC antibodies. + denotes poor reactivity, +++ denotes strong reactivity. 
Soleus Tibialis anterior 
Ab Dilution Anti-slow Anti-fast Anti-slow Anti-fast 
1: 1000 + + + + 
1: 500 ... ... ... ... 
1: 200 ... ... ... ... 
1: 100 +++ +++ +++ 
Succinate dehydrogenase (SDH) 
Succinate dehydrogenase is an enzymatic component of the inner mitochondrial 
membrane and is involved in the transfer of hydrogen ions along the oxidative 
pathway (electron transport chain) of the Krebs cycle. 
Succinate dehydrogenase serves as a marker enzyme of aerobic end-oxidation and 
can be used to classify a fibre's metabolic characteristics (Nemeth and Pette, 198 1). 
By measuring the activity of SDH within a muscle, an idea of the number of 
mitochondria present and the muscle's oxidative capacity can be obtained. 
The staining procedure works by using sodium succinate as a substrate, which is 
oxidised by SDH. Upon adding an artificial hydrogen ion (H) acceptor, e. g. 
nitroblue tetrazolium (nitro-BT), nitro-BT is reduced producing a blue precipitate. 
The method used was a modification of those described by Nachlas et al. (195 7) and 
Nemeth and Pette (198 1). The intensity of the reaction, characterises the metabolism 
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of the fibre; the higher the oxidative capacity and hence SDH activity, the greater 
the staining intensity. 
The slides were incubated in a solution consisting of 0.67 M Sodium Dihydrogen 
Orthophosphate, 0.67 M DiSodium. Hydrogen Orthophosphate and 0.2M Sodium 
Succinate at pH 7.0. Nitro-BT (O. ImM) was added and slides were incubated for I 
hr at 371C. After incubation, slides were fixed in 10% formal saline, washed in 
phosphate buffered saline (PBS), before being dehydrated, cleared and mounted. 
The amount of SDH enzyme activity is different in different fibre types, and this 
determines staining intensity. Type I and IIa fibres stain positive (blue), whereas 
type Ilb fibres usually stain negative (Figure 2.3). However, it has been found 
previously that some type Ilb fibres can stain positively, such that a poor correlation 
can exist between the myosin type Il identified subgroups (as obtained from the 
myosin ATPase stain) and the metabolic subgroups (Nemeth and Pette, 1981). 
These findings suggest that the myosin-based classification system alone may not 
always be a reliable indicator of the metabolic characteristics of type II fibres. 
Hence, in the study by Nemeth and Pette (1981), SDH staining was used in 
conjunction with the myosin ATPase stain for effective fibre typing and 
classification. 
To obtain the proportions of fast and slow fibre types within the soleus muscle, 
using image analysis (x1OO magnification), fibres in the entire cross section at the 
muscle belly were counted and the percentage of each fibre type calculated. 
Newly regenerating fibres 
Regenerating fibres were detected using an anti-mouse MHC (developmental) PAb 
(Novacastra Laboratories, Newcastle, UK). This Ab recognises a MHC present 
during embryonic and neonatal stages of development in skeletal muscle. The same 
MHC is re-expressed during regeneration of new muscle fibres (Ecob-Prince et al., 
1989; Williams ct al., 2001). 
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Figure 2.3 Myosin ATPase and SDH stain. 
Serial cross sections of the myosin ATPase stain (acid pre-incubation) (A and C) 
and the SDH stain (B and D) for the plantaris (A and B) and soleus (C and D) 
muscles. The SDH stain results in the identification of type I and Ila fibres staining 
as dark blue, exhibiting high levels of SDH enzyme activity. and type Ilb fibres 
staining as light blue. exhibiting low levels of SDH activity and thus low oxidative 
capacity (B and D). 
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To detect these newly regenerating fibres, muscle sections were incubated with the 
I'Ab (1: 20 dilution) either for I hr at 37"C, or overnight at 40C in a Sequenza 
staining/histology unit. The 2"Ab used was a rabbit anti-mouse, conjugated with 
HRP (1: 200 dilution; Dako). The chromogen DAB (Sigma) was used to visualise 
the regenerating fibres. Positive control tissue, obtained from 7 day-old rat limb 
muscles, was stained along side these experimental muscles in order to test antibody 
specificity, and the accuracy and reliability of this staining protocol. Negative 
controls were also processed alongside the experimental slides, these were not 
exposed to the 2"Ab. Stained sections were examined under the light microscope 
(xlOO magnification). Image analysis was used to count both the total number of 
regenerating fibres (i. e. positive for embryonic/neonatal myosin) and viable adult 
fibres in whole cross sections derived from the muscle belly. The number of animals 
for these determinations were n=9 for saline control and n=5 for 2,3,5,7,10,14 
and 28 days. 
Satellite cells 
In order to identify satellite cells throughout the stages of skeletal muscle 
regeneration (I to 14 days), sections were stained for protein markers of quiescent 
(c-met) or activated, proliferating and differentiating (the myogenic transcription 
factor - MyoD) satellite cells (Cornelison and Wold, 1997). ' 
Double immunofluorescence was performed on sections. Sections were exposed 
overnight at 4*C to a I"Ab against c-met (1: 50 dilution; rabbit polyclonal, Santa 
Cruz, Autogen Bioclear, UK). Anti-rabbit Texas Red (1: 100 dilution; Vector Labs) 
conjugated 2"Ab was used to detect the I"Ab, after incubation for I hr at 37"C. 
Sections were then exposed to MyoD (1: 50 dilution; mouse monoclonal, Dako) 
1 "Ab for 2 hr at 37"C. This I "Ab was detected using Fluorescein (FITC)-conjugated 
donkey anti-mouse IgG (1: 100 dilution; Jackson Immunochemicals, Strathtec, UK). 
Nuclei were counterstained with the DNA binding dye, 4,6-diamidino-2- 
phenylindole (DAPI, Sigma) at Igg/ml and sections mounted in Vectashield and 
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viewed under a fluorescence microscope. BrdU incorporated satellite cells were also 
labelled to identify proliferating satellite cells - see description of technique later. 
Mechano-growth factor (MGF) 
It has recently been documented that the expression of mRNA for MGF, a splice 
variant of the IGF-I gene, is associated with the activation of satellite cells 
following injury to skeletal muscle (Hill et al., 2003; Hill and Goldspink, 2003). To 
examine the role of MGF, if any, in the catecholamine-induced damage and repair, 
the protein expression of MGF in the heart and skeletal muscle was detected using a 
rabbit polyclonal anti-MGF Ab, kindly gifted by Prof. Geoffrey Goldspink 
(University College, London). Using immunofluorescence, sections were exposed to 
the MGF I*Ab (1: 400 dilution) overnight at 4"C. In turn, the MGF l*Ab was 
detected using an anti-rabbit fluorescein 2"Ab (1: 200 dilution; Vector Labs) after 
incubation for I hour at 37"C. Nuclei were counterstained with DAPI (I[Lg/ml). 
Sections were mounted in Vectashield and viewed under a fluorescence microscope 
(x200 magnification). The number of MGF positive nuclei in 4 randomised fields 
across the entire cross section of each skeletal muscle were quantified using image 
analysis. Results were expressed as the percentage of MGF positive nuclei relative 
to the total number of nuclei (DAPI positive). For the heart, percent MGF 
expression (percent area of positive staining) was determined using image analysis 
on 6 randomised fields of view (x 200 magnification) taken from around the LV 
lumen of heart, at 2.2 mm from the apex. The number of animals for these 
determinations were n--5 for 3,9,12,18,24,48,72 hours and saline control. 
Growth and hypertrophy 
To determine whether continuous infusion of catecholamines for 28 days caused 
significant growth and hypertrophy, the cross sectional areas of 100 muscle fibres at 
the belly of each soleus muscle were measured on an image analyser at xlOO 
magnification. The number of animals for these determinations were n=5 for 28 
days after isoprenaline, adrenaline and placebo saline infusion. 
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Fibrosis 
To establish whether continuous exposure of catecholamines caused significant 
myocardial fibrosis, sections of the heart and soleus muscle were stained with Sirius 
red, by the method previously described by Sweat et al. (1964). Serial sections were 
fixed in 10% formalin in PBS for 20 min. After washing in distilled water for 5 min, 
sections were incubated at room temperature for 30 min in 0.1% Fast Blue RR in 
Magnesium Borate buffer at pH 9 (Sigma). Then sections were washed in distilled 
water before incubation at room temperature for 10 min in 0.1% Sirius red in 
saturated picric acid (Sigma). Sections were further washed in distilled water before 
they were dehydrated, cleared and mounted. In this protocol, connective tissue 
(mainly collagen) stains red and myocytes yellow/orange. 
Semi-quantitative evaluation of the amount of myocardial connective tissue was 
carried out using image analysis (xlOO magnification). Percent collagen (percent 
area of positive staining) was determined in the entire cross section of the heart at 
2.2 mm from the apex and in the entire cross section at the muscle belly of the 
soleus. The number of animals for these determinations were n=5 at 14 days for 
isoprenaline, adrenaline, saline placebo infusion and zero day control. 
U 
2.2 Cardiomyocyte Death and Regeneration 
2.2.1 Animals and husbandry 
Experiments were performed on 25 Male Wistar rats (Charles River, UK) weighing 
336 ± 18g up to 14 days following a single 5mg injection of isoprenaline kg-1. 
Another group of 5 animals received a single injection of saline and acted as the 
control rats. Animals were housed under controlled conditions of 25"C, 50% 
relative humidity and a 12 hr light (6: 00 - 18: 00) and 12 hr dark cycle, with water 
and food available ad libitum. All animals were injected (i. p. ) with 50 mg of 
bromodeoxyuridine (BrdU) kg" twice daily until they were killed. Experiments 
were approved by the New York Medical College. 
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2.2.2 Cardiac haemodynamics 
For haernodynamics measurements, rats were anaesthetised with 30% chloral 
hydrate (i. e. 400 mg/kg body weight) administered i. p. A Millar microtip pressure 
transducer (Houston, Texas, USA), connected to a chart recorder, was advanced into 
the LV cavity through the right carotid artery. This facilitated evaluation of LV end- 
diastolic and end-systolic pressures, developed pressure and +dP/dt (contraction) and 
-dP/dt (relaxation) in the closed chest preparation (Torella et al., 2004). The number 
of animals for these determinations were n=5 at 1,3,6,14 days and saline vehicle 
controls. 
After completion of the haemodynamic measurements, the abdominal aorta was 
cannulated and the heart arrested in diastole using cadmium chloride (CdC12). Then 
the myocardium was perfused with 10% buffered formalin (Orlic et al., 2001 a; Orlic 
et al., 2001b; Beltrami et al., 2003). 
The isolated hearts were cut into right and left ventricles, and right and left atria. 
After being weighed, the long axis of the LV was measured before it was sectioned 
into 3, i. e. apical, mid and basal regions. Anatomical measurements were taken 
using the mid region of the LV. From these measurements chamber diameter was 
calculated by combining the lateral (LD) and anterior-posterior (A-PD) diameters 
and dividing by 2. LV Chamber volume was determined through the following 
equation, where LVIgaxis denotes the measurement taken of the LV long axis: 
Chamber volume = 4/3*7r*LD/2*A-PD/2*LVIgaxis/2 (Anversa and Olivetti, 2002) 
Free wall thickness was calculated by dividing free wall area by free wall length. 
Septum thickness was calculated by dividing septum wall area by septum wall 
length. After anatomical measurements were taken, samples were embedded in 
paraffin, cut into 5gm sections on a cryotome and mounted on microscope slides. 
The LV was sectioned at 2.2 min from the apex, as this distance has been shown 
previously to exhibit peak necrosis and apoptosis along the longitudinal axis 
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(Goldspink et al., 2004). The soleus muscles in these animals were also isolated and 
fixed in 10% buffered formalin, before being paraffin embedded, cryo-scctioncd 
into 5grn sections and mounted on microscope slides. 
2.2.3 Morphornetric analysis 
The quantitative estimation of the ventricular myocardium requires the application 
of morphometric methods. Using two-dimensional samples, i. e. tissue sections, and 
a superimposed grid of test points and line segments, the three-dimensional volume, 
surface area, number and length of recognizable components through the process of 
counting can be determined (Anversa and Olivetti, 2002). The population of cells of 
any given cell type distributed within a tissue may be considered in general terms to 
be a group of individual compartments existing in a spatial volume (Anversa and 
Olivetti, 2002). Sections of the LV were stained with H&E. The sub-endocardial, 
mid-wall and sub-epicardial layers of the LV wall were analysed. Sections were 
examined at x1000 magnification with a morphometric reticle containing 42 
sampling points to determine the area fraction of viable myocytes, dead myocytes 
and interstitial cells in the myocardium, (Anversa and Olivetti, 2002). Cells were 
classified as dead if they displayed disrupted sarcolemmal membranes and pale 
cytoplasmic staining, implicating focal necrosis. 
The area fraction, AA, is the fraction of all the points that lie over these cell profiles, 
Pp, i. e. if 36 of the sampling points lie over viable myocytes, then 34/42 would give 
an area fraction of 86%: 
AA = Pp 
Conversion of the morphometric area measurements, AA, to their three-dimensional 
counterparts is accomplished by stereologic formulas. For any component its 
volume fraction, Vv, volume per unit volume, is directly equal to its area fraction: 
Vv = AA-2 PP 
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The sampling error was kept below 10% by counting at least 100 of each cell type 
(viable myocytes, dead myocytes, and interstitial cells) for each LV layer (sub- 
endocardium, mid-wall and sub-epicardium). If this number could not be achieved 
then the entire area of each layer was measured (Anversa and Olivetti, 2002). 
The total number of myocytes in the LV, NT, is evaluated through knowledge of the 
absolute volume of myocytes VT. The quantity of VT was obtained by first 
calculating the LV volume (volume of LV muscle mass) which is determined by 
dividing the weight of the LV by the specific gravity of muscle tissue, 1.06g/ml 
(Mendez and Keys, 1960), and then multiplying by the volume fraction of 
myocytes, Vv: 
VT= LV volume*Vv 
The myocyte volume, Vc, was determined through measuring -100 myocyte 
diameters (MD) across the nucleus, in the sub-endocardium with image analysis 
(Olivetti et al., 1997), and assuming a spherical cross-section (7rr2 ) and a length, of 
100pim. The calculation of myocyte volume poses as a potential limitation of the 
present methods as the myocyte length is an assumed variable (10OAm). This is 
limiting in the calculation of myocyte volume, as alterations in myocyte growth 
could occur through changes in both cross-sectional area and length: 
Vc = 7r*((MD/2)2)*100 
Thus, the total number of myocytes, NT (Anversa and Olivetti, 2002), is derived 
from: 
NT -2 VT/VC 
These determinations were n=5 at 1,3,6,14 days and saline vehicle controls. 
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2.2.4 Apoptotic cell death 
Terminal deoxynucleotidyl Transferase (TdT) assay 
Nuclei with all forms of damaged DNA have a high concentration of 3'hydroxyl 
ends that are a substitute for TdT (Gavrieli et al., 1992). TdT can extend the 3' base 
of single stranded DNA and overhanging, blunt and recessed Ybases of double- 
stranded DNA (Didenko, 2003). 
For the reaction of available DNA Yhydroxyls with TdT, myocardial sections were 
incubated with a solution containing 100 units/ml of TdT, 2.5 mM cobalt chloride, 
0.2 M potassium cacodylate, 24 mM TRIS/HCI, pH 7.2 and 0.5 nM biotin-16- 
deoxyuridine triphosphate (dUTP) (Roche, Indianapolis, IN) for 30 minutes at 37"C 
in an humidified chamber. Sections were then incubated in staining buffer 
containing 4x salted sodium citrate (SSQ and non-fat dried milk for 30 minutes at 
room temperature. Then sections were exposed to staining buffer containing, 5gg/ml 
of fluorescein isothiocyanate-Extravidin (Sigma). Nuclei were counterstained with 
DAPI and sections were mounted in Vectashield and viewed under a fluorescence 
microscope. Positive and negative controls were included in the protocol to confirm 
the specificity of the methods. As a positive control, myocardial sections were 
treated with DNase I to induce enzymatically the formation of DNA strand breaks. 
This tissue was treated with this enzyme for 15 minutes at 37"C and after washing 
in PBS, the TdT assay was performed. Negative controls consisted of incubating 
tissue sections in which the DNA strand breaks had been enzymatically formed, as 
described above, but omitting biotin-16-dUTP or TdT from the procedure. This was 
also carried out on experimental heart sections, where DNA strand breaks had been 
identified. 
In order to determine the fraction of myocyte nuclei labelled by dUTP, the number 
of dUTP positive myocyte nuclei in each layer of the LV wall (sub-endocardium 
mid-wall and sub-epicardium) were counted in each 5gm section (xlOOO 
magnification). The number of myocyte nuclei per unit area of tissue was 
determined by counting the number of myocyte nuclei in an average of 60 fields, 
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0.6mm 2, so the numerical density of myocyte nuclei in each myocardial area was 
obtained. By combining these data with the preceding estimations of dUTP labelled 
myocyte nuclei per unit area of myocardium, the percentage of apoptotic myocyte 
nuclei was determined (Olivetti et al., 1996). These determinations were n=5 at 1,3, 
14 days and saline vehicle controls. 
2.2.5 Immunohistochemistry 
Myocyte cytoplasm 
Myocyte cytoplasm was labelled by an antibody against ci-sarcomeric actin (1: 50 
dilution; clone 5C5, Sigma) for 2hrs at 37T and this was detected with Rhodamine 
(TRITC)-conjugated donkey anti-mouse IgM 2"Ab (1: 100 dilution; Jackson 
Immunochemicals, West Grove, PA). Sections were incubated with 2*Ab for I hr at 
37C. Nuclei were counterstained with DAPI. Sections were mounted in 
Vectashield and viewed under a fluorescence microscope. 
Cardiac stem cells 
Cardiac stem cells (CSCs) were identified by employing an antibody against the 
stem cell marker c-kit (Beltrami et al., 2003). Sections were incubated for 2 hr at 
37'C with mouse anti-human cýkit (1: 50 dilution; DAKO, Carpinteria, CA). The c- 
kit Ab was detected using a Rhodamine (TRITC)-conjugated donkey anti-mouse 
2"Ab (1: 100 dilution; Jackson Immunochemicals). Nuclei were counterstained with 
DAPI. Sections were mounted in Vectashield and viewed under a fluorescence 
microscope. 
Cardiac stem cells were quantified using image analysis. The number of c-kit 
positive cells was counted for a total of 3 sections of the LV at xlOOO magnification. 
The areas of these 5gm cross sections were then measured using image analysis and 
the number of c-kit positive cells present was expressed per unit area (Torella et al., 
2004). These determinations were n=5 at 1,3,6,14 days and saline vehicle controls. 
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Cardiac stem cell progeny 
To recognize the committed progeny of CSCs, an antibody against a transcription 
factor expressed early in the myocyte lineage, i. e. GATA4, was used in conjunction 
with c-kit staining (as described above) on the same section. Sections were stained 
with an anti-rabbit GATA4 Ab (1: 100 dilution; Santa Cruz Biotechnology, Santa 
Cruz, CA) overnight at 41C (Urbanek et al., 2003). This PAb was then detected 
with donkey anti-rabbit FITC (1: 200 dilution; Jackson Immunochemicals). Nuclei 
were counterstained with DAPI. Sections were mounted in Vectashield and viewed 
under a fluorescence microscope. 
Proliferating cardiac stem cells 
An antibody against Ki67, a nuclear antigen expressed on all proliferating cells 
during late GI, S, M and G2 phases of the cell cycle (Novocastra, Newcastle, UK) 
was employed to identify proliferating CSCs. Sections were incubated overnight at 
4"C with Ki67 Ab (1: 30 dilution). This in turn was detected using an anti-rabbit 
FITC (1: 100 dilution; Jackson Immunochemicals). Sections were then stained for c- 
kit (as previously described). Nuclei were counterstained with DAPI. Sections were 
mounted in Vectashield and viewed under a fluorescence microscope. 
Macrophages 
To determine the presence and extent of the inflammatory reaction following 
catecholamine-induced cardiomyocyte damage, tissue sections were incubated with 
a monoclonal antibody against myeloid cells (CD68; clone EDI; Serotec, Oxford, 
UK). The antigen is expressed by the majority of tissue macrophages and weakly by 
blood granulocytes. Sections were incubated overnight at 41'C with mouse anti-rat 
CD68 (1: 50 dilution) and this was recognized with FITC (1: 100 dilution). Myocyte 
cytoplasm was labelled as previously described, using the anti-a-sarcomeric actin 
antibody. Nuclei were stained with DAPI, before sections were mounted in 
Vectashield and viewed under a fluorescent microscope. 
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Myocyte proliferation 
Tissue sections were incubated with an antibody against BrdU (1: 50 dilution; 
Roche) for 45 minutes at 370C. This antibody was detected with an anti-mouse IgG 
FITC (1: 100 dilution; Jackson Immunochemicals). Myocyte cytoplasm was labelled 
with anti-a-sarcomeric actin (as previously described), after the BrdU detection 
procedure and nuclei stained by DAPI. The samples were viewed under a 
fluorescent microscope. 
The fraction of myocytes labelled by BrdU was measured (xlOOO magnification) by 
counting a total of 1500 cardiomyocytes for each layer of the LV wall (sub- 
endocardium, mid-wall and sub-epicardium), across a total of 4 cross sections from 
each animal. The number of newly formed cardiornyocytes (i. e. BrdU positive) per 
1500 cardiomyocytes was expressed as a percent fraction. To determine any 
changes in the size of the newly formed myocytes with time, the myocyte diameter 
of the first 10 newly formed myocytes were measured in the sub-endocardium, 
using image analysis. These determinations were n--5 at 3,6,14 days and saline 
vehicle control. 
To complement the identification of a newly formed cardiomyocyte with BrdU 
labelling, the antibody against Ki67 (Novocastra) was also employed to identify 
cycling myocytes. Sections were incubated overnight at 41C with Ki67 Ab (1: 30 
dilution), and this was detected using an anti-rabbit FITC (Jackson 
Immunochemicals). Myocyte cytoplasm was labelled using the anti-ct-sarcomeric 
actin antibody, as previously described and nuclei counterstained with DAPI. 
Sections were mounted in Vectashield and viewed under a fluorescence microscope. 
2.3 Statistical Analysis 
Results are presented as either Mean ± SD or Mean ± SEM. Significance between 2 
groups was determined by Student's t test and in multiple comparisons by the 
analysis of variance (ANOVA). Tukey's Honestly Significant Difference (HSD) 
post hoc analysis was used to locate the differences. However, if any of the data 
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violated the homogeneity of variance, an assumption of ANOVA, the non- 
parametric equivalent, Kruskal-Wallis test, was employed and 2-Sample Mann- 
Whitney tests used as follow tests to identify where the differences lay (Altman, 
199 1). Significance was set at P<0.05. 
, at 
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3.0 RESULTS 
3.1 Histochemical and immunohistochemical staining procedures 
to establish flbre type profiles. 
Sections of soleus, plantaris and tibialis anterior muscles were pre-treated with an 
acid incubation prior to staining for myosin ATPase (Figure 3.1 A-C, respectively). 
This procedure demonstrated 3 fibre types: - dark brown (type I fibres), light brown 
(type Ilb fibres) and pale/clear (type Ila fibres). These criteria apply to the tibialis 
anterior and the plantaris muscles. However, the soleus muscle contains 
predominantly type I fibres and a minority of type Ila components (Schiaffino et al., 
1989). The lighter brown staining fibres found in the soleus have been classified as 
intermediate fibres or type IIc, their myosin ATPase activity being placed in 
between that of type I (dark brown) and type Ila (pale/clear) (Brooke and Kaiser, 
1974). 
This standard myosin ATPase staining procedure was confirmed by the use of 
monoclonal antibodies. The slow anti-myosin antibody was specific for the slow 
MHC of skeletal muscle (type I fibres). In contrast, the anti-myosin (fast) antibody 
was specific towards the fast isomyosin molecules in skeletal muscle but could not 
distinguish between types Ha and type Ilb fibres. Figures 3.2 (A-C), 3.3 (A-C) and 
3.4 (A-C) show serial sections for the myosin ATPase (acid pre-incubation) stain 
(A), slow MHC antibody stain (B) and fast MHC antibody stain (C) for the soleus, 
plantaris and tibialis anterior muscles, respectively. 
These procedures allow fibre types to be identified with confidence within adult 
skeletal muscles. Furthermore, any fibre type transition which may occur during the 
regenerative process in skeletal muscle can be identified. 
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Figure 3.1 Fibre type profiles. 
Transverse sections of the soleus (A), plantaris (B) and tibialis anterior (C) muscle 
were stained for myosin ATPase (acid pH 4.35) to identify the different 1-ibre types: 
Type I-slow (1). Intermediate (in), Type Ila-fast oxidative (Ila) and Type llb-l'. Ist 
glycolytic (Ilb) (x200 magnification. except B which is x 100). 
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Figure 3.2 Specificity of the histochernical and immunohistochernical 
staining procedures showing the fibre type profile of the soleus muscle. 
Myosin ATPase (acid pH 4.35) stain (A), the slow invosin heavy chain antibody (13) 
clearly interacts with slow (1) and partially with interniediate (in) tibres. but not fast 
(Ila). Conversely. the fast inyosin heavy chain antibody (C) reacts NNIth type Ila and 
In, but not type I (all x200 magnification). 
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Figure 3.3 Specificity of the histochernical and immunohistochemical 
staining procedures showing the fibre type profile of the plantaris muscle. 
Myosin ATPase (acid pH 4-335) stain (A), the slow myosin heavy chain antibody (13) 
clearly interacts with slow (1) fibres. but not fast (Ila or Ilb). Conversely. tile 1'. 1st 
myosin heavy chain antibody (C) reacts with both type Ila and Ilb. but not type I (all 
x 100 magnification). 
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Figure 3.4 Specificity of the histochemical and immunohistochemical staining 
procedures showing the fibre type profile of the tibialis anterior muscle. 
Myosin ATPase (acid pH 4.35) stain (A). the slow myosin heavy chain antibody (13) 
clearly interacts with slow (1) fibres. but not fast (Ila or Ilb). Converseiv, tile fast 
myosin heavy chain antibody (C) reacts with both type Ila and Ilb. but not type I (all 
x200 magnification). 
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3.2 Catecholamine-induced damage 
The soleus, plantaris, tibialis anterior and diaphragm muscles from the saline control 
group showed no signs of fibre necrosis or apoptosis, i. e. a baseline of zero damage. 
Throughout all the experiments using 20 mmol of isoprenaline, adrenaline or 
noradrenaline kg-1, no damage was ever found in the plantaris, tibialis anterior or 
diaphragm muscles at any time point. In marked contrast, the heart and soleus 
muscles, of the same animals, showed severe damage and cell death, via both 
necrosis and apoptosis, in response to a single injection of either 20 mmol of 
isoprenaline, adrenaline or noradrenaline (Figures 3.5; 3.6; 3.7; 3.8). 
Cardiomyocyte apoptosis was evident between 3 and 72 hours, peaking at 3 hours 
and decreasing thereafter (Figure 3.7) following the isoprenaline administration. 
This peak at 3 hours (2.5 + 1%), was significantly different (P<0.001) from the 
amounts of apoptosis found in saline controls and all other time points (Figure 3.7). 
In contrast to the heart, catecholamine-induced apoptosis and necrosis in the soleus 
muscle has only recently been described by our laboratory and warrants more 
intensive study. In the soleus mTcle, fibre apoptosis was also evident from 3 to 24 
hours, and this increased with time (Figure 3.8). The peak amount of apoptosis 
occurred at 24 hours (4 ± 1%), some 21 hours later than that seen in the heart, and 
this was significantly greater (P<0.05) than that found in saline control samples, and 
at 3,9,12,48 and 72 hours. By 48 and 72 hours the amount of apoptosis had fallen 
to zero, i. e. equivalent to saline control tissue (Figure 3.8). 
A single injection of either 20 mmol kg" of the natural catecholarnines adrenaline or 
noradrenaline, similarly caused severe fibre necrosis and apoptosis in the soleus 
muscle (Figure 3.9). Examples of this type of damage are shown in Figure 3.5 (C 
and D). 
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Figure 3.5 Catecholamine-induced necrosis and apoptosis in the heart and 
soleus muscle. 
Necrotic (containing myosin Ab) and apoptotic (caspase-3 labelled) n1yocytes were 
identified in transverse sections of the heart (A and B) and SOICUS (C and D). For 
necrosis (A and C) the myosin Ab was detected using a rabbit anti-inouse HRII- 
con 
. jugated 
2'Ab. Necrotic myocytes were visualised using DAB (broxvil: 
arrowheads). For apoptosis (B and D; arrowheads) sections were exposed to 
caspase-3 VAK before incubation with a goat anti-rabbit UIRII-conjugated 2'Ab. 
Apoptotic rnyocytes were visuallsed using Nova red (red, arrowheads). All sections 
were counterstained with haernatoxylin (all x200 magnification). 
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Figure 3.6 Immungifluorescence staining of necrosis and aipoplo%i% in flic 
heart. 
II ralISN'cl-se Sections of' the 11cart %%cl-c CXposcd to a caspasc- " Ah. 
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Figure 3.7 Time course of catecholamine-induced apoptosis In the heart. 
Cardiomyocyte apoptosis (caspase-3 labelled) in response to a single injection (s. c. ) 
of 20 mmol of isoprenaline kg". No apoptosis was found in the control muscles 
(CTRL) receiving saline vehicle only. However, caspase-3 labelled myocytes, 
quantified as the percentage area, were evident after 3 hours. Results are Mean ± 
SEM for n=5 and *denotes significant difference (P<0.001) from CTRL and all 
other time points. 
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Figure 3.8 Time course of catecholamine-induced apoptosis in the soleus 
muscle. 
Fibre apoptosis (caspase-3 labýhed) in response to a single injection (s. c. ) of 20 
mmol of isoprenaline kg". No apoptosis was found in the control muscles (CTRL) 
receiving saline vehicle only. However, caspase-3 labelled fibres, quantified as 
percent number of fibres counted in the soleus, were evident after 3 hours. Results 
are Mean ± SEM for n=5, with *denoting significant differences (P<0.05) from 
CTRL, 48 and 72 hours. 
tdenotes 
significant difference (P<0.05) from 3,9 and 12 
hours. 
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Figure 3.9 Catecholamine-induced fibre necrosis and apoptosis. 
Myocyte necrosis (anti-myosin, labelled) and apoptosis (caspase-3 labelled) in the 
soleus muscle l8hr following either a single injection (s. c. ) of 20 mmol of 
isoprenaline, adrenaline or noradrenaline kg". Fibre specific necrosis (m) and 
apoptosis (o) were quantified as percent number of fibres counted in the soleus. No 
necrosis or apoptosis was found in the control muscles receiving saline vehicle only. 
Results are Mean ± SEM for n=5-9 and *denotes significant difference (P<0.01) 
between isoprenaline vs. saline, adrenaline or noradrenaline treatments. 
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While each natural catecholamine induced similar amounts of necrosis and 
apoptosis (Figure 3.9), the total number of necrotic and apoptotic fibres was 
significantly greater (P<0.01) in response to isoprenaline, than in the saline controls, 
adrenaline or noradrenaline treated soleus muscles (Figure 3.9). 
Other recent studies in our laboratory have suggested substantial similarities in the 
time of onset, threshold dose and optimal amounts of necrosis and apoptosis in the 
soleus in response to a single 20 mmol injection of isoprenaline kg"(Goldspink et 
al., 2004). This raises the question as to whether necrosis and apoptosis are two 
distinct processes. To investigate this in greater depth, both necrotic (myosin 
antibody labelled) and apoptotic (caspase-3 labelled) fibres can be identified on the 
same section using double immunofluorescence. Hence, using this approach the 
possibility of cellular co-localisation could be investigated. 
The percent of damaged fibres in the soleus muscle that were either apoptotic, 
necrotic or exhibited co-localisation for both processes were counted from 4 random 
fields of view (-800 fibres). After exposure to the isoprenaline 521 injured fibres 
were counted. None (0%) of the fibres were purely apoptotic, while 377 (72%) 
fibres exhibited co-localisation (i. e. both apoptotic and necrotic) and 144 (28%) 
fibres were found to be purely necrotic. Figure 3.10 shows double 
immunofluorescent stained fibres in the soleus muscle. Hence, many fibres exhibit 
co-localisation for both necrosis and apoptosis, following a 20 mmol injection of 
isoprenaline. 
After adrenaline-induced damage, 76 injured fibres were counted. Similarly, none 
(0%) of these fibres were purely apoptotic, 58 (76%) exhibited co-localisation of 
both death pathways, and 18 (24%) of the fibres were necrotic only. After 
noradrenaline administration, 66 injured fibres were counted. None (0%) were 
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Figu re 3.10 Co-localisation of catecholainiiie-indticed fibrc necro%i% and 
apoptosis. 
Irans\erse sections \\ci*c stained mth lltl()[. Cscclll and lc\. Is red Io ý, Ilo\\ licclillic- 
111\, ()Slll antillo(k labelled (green. A) and apoplotic-caspasc-I lahcllckl (red. H) 
11hres. 18 hours A, tel- 20 111111ol of, citlicl. Isopl-cliallile. adrellaIllic or iloraduclial I lie 
kg- l. Whell the 'Images are merged (C). allý co-lahcHing millill III,: 
I)CCOIIICS apparent. 
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purely apoptotic, 57 (86%) exhibited co-localisation being labelled for both 
apoptosis and necrosis, and 9 (14%) fibres were found to be purely necrotic. 
Therefore, all apoptotic fibres found in the soleus muscle following an injection of 
either isoprenaline, adrenaline or noradrenaline were also found to be labelled as 
necrotic. 
Key points: 
1. Acute catecholamine exposure causes significant fibre apoptosis and necrosis to 
the predominantly slow-twitch soleus muscle, but not the other predominantly fast 
muscles. 
2. Apoptotic fibre death is co-localised with necrotic fibre death, in the same muscle 
fibres in the soleus. 
3.3 Fibre regeneration and the time course of the regenerative 
process 
3.3.1 Time course of the regenerative process 
The normal soleus muscles from 250 ± 7g rats contains on average 2653 ± 111 
fibres. Because of the necrotic and apoptotic cell death, the total number of fibres in 
the entire soleus muscle initially decreased following a single injection of 
isoprenaline. A significant (P<0.05) loss of -500 fibres (23%) occurred between day 
0 (2653 ± 111) and day 5 (2196 ± 145) after the isoprenaline administration. By day 
7, the total number of fibres begun to increase, and by day 28 the number was 
almost the same as at day 0 (Figure 3.11). The effects of equimolar amounts of 
adrenaline were less severe (see Figure 3.9). Hence, the trend of changes in fibre 
numbers after adrenaline (Figure 3.12) was less dramatic than for isoprenaline. 
Consequently, the number of normal fibres in the soleus muscle following a single 
injection of adrenaline was not statistically different at any point over the 28 days 
(Figure 3.12). 
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Figure 3.11 Time course of fibre regeneration In the soleus muscle after 
synthetic catecholamine administration. 
Number of nonnal fibres (o) and newly-formed regenerating fibres (0) following a 
single injection (s. c. ) of 20 mmol of isoprenaline kg-1. Results are Mean -4- SEM for 
n--5-9. *denotes significant difference (P<0.05) from 0 day control. 
tdenotes 
significant differences (P<0.05) from 0 (control), 2,3 and 28 days. 
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Figure 3.12 Time course of ribre regeneration In the soleus muscle after 
natural catecholamine administration. 
Number of normal fibres (o) and newly-formed regenerating fibres (N) following a 
single injection (s. c. ) of 20 mmol of adrenaline kg". Results are Mean d: SEM for 
n=5-9. *denotes significant differences (P<0.05) from 0 (control), 2 and 28 days. 
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Following catecholamine-induced injury, there was an increase in the number of 
mononucleated cells within the extracellular space and connective tissue (Figure 
3.13 B). These cells probably consisted of both inflammatory and myogenic cells, 
involved in the removal of necrotic debris and repair and regeneration of new 
muscle fibres, respectively. Phagocytosis of necrotic fibres appeared to be almost 
complete by 3 days. Cells that are thought to be immature myotubes could be seen 
after 3 days (Figure 3.13 Q. At this stage the adrenaline group exhibited 16 ±2 
regenerating fibres within the population of normal fibres in the soleus muscle. 
These fibres were small, angulated and stained positively for embryonic/neonatal 
myosin and as a consequence were classified as regenerating fibres (Figure 3.13 D). 
The isoprenaline-treated muscles started to exhibit regenerating fibres later than the 
adrenaline group, these becoming evident by day 5. These regenerating fibres 
represented 6% (P<0.05) and 1% (157 ± 66 fibres, compared with 20 ±8 fibres) of 
the total number of fibres in the whole soleus 5 days (Figures 3.11; 3.12) after 
isoprenaline and adrenaline administration, respectively. Seven days after 
catecholamine-induced injury more regenerating fibres were evident within the 
soleus muscle. These now accounted for 8% and 2% (176 ± 45 fibres; 42 ± 16 
fibres) of the total number of fibres in the entire soleus following isoprenaline and 
adrenaline administration, respectively and were significantly different (P<0.05) 
from days 0 (control), 2 and 28 (Figures 3.11; 3.12). 
The soleus muscles obtained 10 days post-isoprenaline showed evidence of fibre 
splitting within a few individual muscle fibres (Figure 3.13 F). Despite this, by day 
10 the number of regenerating fibres had decreased to 4% (105 ± 30) and 0.4% (11 
± 2) in the isoprenaline and adrenaline groups, respectively. This trend continued 
and by 14 days there was only 38 ± 12 regenerating fibres, representing only 1.4% ± 
0.7 of the total number for the isoprenaline group (Figure 3.11). By this stage there 
was also an increase in the number of centralised nuclei within muscle fibres 
(Figure 3.13 G). This is a characteristic common to newly regenerated fibres prior to 
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Figure 3.13 Degenerative and regenerative changes in the soleus muscle after 
catecholamine-induced injury. 
85 
Results 
- I. 
. _/ 
.. 
. 6_. " 
.- 
-" 
'1 - 
. 41 
"44 
- -" 
$ 
4èi 
-s,. " 
Transverse sections were stained with embryonic/neonatal I'Ab during 
regeneration, following catechol amine- induced fibre damage. A, zero time control-, 
B, 2 days; C, 3 days; D, 5 days; E. 7 days; F. 10 days; G, 14 days and 11.28 days 
after catecholamine injection (all x200 magnification, except F which is x400). The 
arrowheads (B) indicate an increase in the number of mononucleated cells withirl 
the extracellular space after 2 days. Arrowheads (C) indicate the emergence of 
immature myotubes after 3 days. Arrowheads (D) indicate small, angulated 
regenerating (embryonic/neonatal MHC positive) fibres at 5 days. Arrowheads (F) 
indicate fibres growing within basement membranes of another fibre attcr 10 days. 
The arrowheads (G and H) indicate newly regenerated fibres with characteristic 
centralized nuclei after 14 and 28 days. 
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their re-innervation (Palmer and Rudnicki, 2002). In the adrenaline group, by 14 
days the number of regenerating fibres was minimal (8 ± 1), suggesting that 
regeneration was almost complete (Figure 3.12). Total regeneration of the soleus 
muscle in the isoprenaline group was almost complete after 28 days, with only 0.2% 
(5 ±2 fibres in the entire soleus) of the fibres staining for embryonic/neonatal 
myosin (Figure 3.11). Indeed, by day 28 after either the injection of isoprenaline or 
adrenaline the soleus muscle looked normal. At this time there were very few 
regenerating fibres or those with centralized nuclei (Figure 3.13 H), with the 
complete restoration of the muscle's total fibre number (Figure 3.11: Figure 3.12). 
Although the total number of fibres was fully restored by 28 days, this itself says 
nothing about the properties of the newly regenerated fibres, i. e. whether slow- or 
fast-twitch, and whether the fibre type profile of the soleus had changed as a 
consequence. To investigate whether there was any transitional changes in the fibre 
type proportions during regeneration, a myosin ATPase stain was carried out and 
the different fibre types quantified at 14 
_and 
28 days. There was a significant 
decrease (P<0.05) in the number of type Ila (0.04%) and intermediate (0.3%) fibres 
14 days after the isoprenaline injection, compared to zero time (7% type Ila; 3% 
intermediate). At day 14 all fibres in the soleus were type 1 (99.7%) (Figure 3.14). 
By 28 days the fibre type proportion had returned to the normal complement of 91% 
type 1,7% type Ila and 2% intermediate (Figure 3.14). 
3.3.2 Data from control muscles 
Fibre type proportions of the rat soleus muscle change during development and with 
age (Caccia et al., 1979). Since these experiments were conducted over a period of 
28 days, it was necessary to ascertain whether any developmental changes had 
occurred in the soleus muscle of growing (250g) rats. This was a safeguard to check 
that any such normal developmental changes did not affect the accuracy of the 
experimental results. The total number of fibres and proportion of fibre types in 
these normal control soleus muscles at 28 days (Figure 3.15) were almost identical 
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Figure 3.14 Fibre type proportions in the recovering soleus muscle. 
Soleus muscle sections were stained for myosin ATPase 14 and 28 days after a 
single injection (s. c) of 20 mmol of isoprenaline kg-'. Results are Mean ± SEM flor 
n=5-9. Fibre types are indicated by Type 1 (0), Type Ila (M) and Intermediate (E] ). 
*denotes significant decreases (P<0.05) in the number of type Ila and intermcdiate 
fibres, compared to both 0 day control and 28 days. 
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Figure 3.15 Total number, and fibre type proportions, In the normal soleus 
muscle. 
Type 1, Ha and intennediate fibres are shown for the soleus muscle during non-nal 
development in growing 250g male rats at zero time (m) and 28 days later (o). 
Results are Mean ± SEM, with n--5. 
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to those at day 0 and 28 in the experimental groups (Figure 3.14), with no 
significant differences. These precautionary findings indicate that no significant 
developmental changes had occurred in the soleus muscle during this stage of life. 
These findings also indicate that no additional control muscles were necessary for 
any of the time points throughout the time course of regeneration. 
3.3.3 Satellite cells 
Satellite cells, or dormant myoblasts, reside within skeletal muscle. These stem cells 
are involved in the regeneration of fibres following injury, and can be identified 
using specific antibodies. This was done on 5gm sections of the soleus muscle. The 
tyrosine kinase receptor, c-met is known to be expressed on satellite cells 
(Cornelison and Wold, 1997). Such c-met positive cells were found in the sections 
of soleus muscle (Figure 3.16 A and B) within the areas of inflammatory response 
(Figure 3.1613), and specifically 2 and 3 days after catecholamine-induced injury. 
Using double immunofluorescent staining, it was possible to demonstrate that some 
of these c-met positive cells had incorporated BrdU, which is indicative of satellite 
cell activation and re-entry into the cell cycle (Figure 3.16 Q. Subsequently, some 
c-met positive cells co-expressed the myogenic transcription factor, Myol) in their 
nuclei (Figure 3.16 D). This is indicative of satellite cell proliferation and 
differentiation into the skeletal muscle lineage, thereby ensuring regeneration of lost 
fibres. 
3.3.4 Mechano-growth factor (MGF) expression 
This splice variant of IGF-1 is thought to be involved in stimulating satellite cell 
activation, proliferation and fusion (Hill and Goldspink, 2003; Hill et al., 2003). 
Catecholamine-induced damage to the soleus muscle was shown to have a marked 
effect on MGF expression (Figures 3.17; 3.18). Examples of MGF stained nuclei in 
the soleus muscle are shown in Figure 3.17. MGF expression increased throughout 
the 72 hour experimental period following isoprenaline injection. At 3 hours, 26% 
of the nuclei in the soleus muscle were MGF positive (Figure 3.18). Thereafter, 
90 
Results 
Figure 3.16 Satellite cells during regeneration of the soleus muscle. 
Transverse sections were stained with c-met I 'Ab, and then with Texas red to sllo\N, 
satellite cells (c-met labelled, A and B; arrowhead). Nuclei were identilled using 
DAPI (blue). Double immunofluorescence staining showed that c-nIet positive cells 
had incorporated BrdU (green fluorescein stained, C; arrowheads), indicatilig their 
entry into the cell cycle. Also, some c-met labelled cells were positive for Myol) 
(green fluorescein stained. D. arrowheads) the myogenic transcription tactor, 
indicating satellite cell proliferation and differentiation into the skeletal muscle 
lineage (all x 1000 magnification). 
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3.17 Mechano-growth factor (MGF) expression in the soleus muscle. 
Longitudinal sections were stained with MGF I'Ab and this was detected with 
fluorescein 2'Ab to show MGF positive nuclei. No MGF positive nuclei were lourid 
in the control muscle (A). In contrast. nuclei positive for MGF were detected after 
isoprenaline injection (green. B: arrowheads). Nuclei were identified using DAN 
(blue, C; arrowheads). The localisation of MGF in the nuclei becomes apparent 
when the two images are merged (1), arrowheads) (all x200 magnification). 
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Figure 3.18 Time course of mechano-growth factor (MGF) expression In the 
soleus muscle. 
Percent of MGF positive nuclei after a single injection (s. c. ) of 20 mmol of 
isoprenaline kg-1. While no MGF was found in the control muscles (CTRL) 
receiving saline vehicle only, detectable levels were observed between 3 and 72 
hours after the isoprenaline. Results are Mean +- SEM for n=5 with *denoting 
significant differences (P<0.01) from CTRL. 
tdenotes significant differences 
(P<0.0 1) compared with 12,18,4 8 and 72 hours. 
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MGF expression decreased with time and by 72 hours the amount of MGF positive 
nuclei was only 1%. 
It was of interest that the hearts from the same isoprenaline-treated rats also had 
higher than normal expression levels of MGF (Figures 3.19; 3.20). MGF increased 
over time. At 24 hours MGF represented 1.6% of the field of view and it remained 
elevated up to 72 hours, following isoprenaline injection (Figure 3.20). The time 
course in the heart was a little different from that found in the soleus. It is however 
indicative of this growth factor's potential role in regeneration of the heart. 
Key points: 
1. Despite catecholamine-induced fibre death and loss, the soleus muscle repaired 
and replaced its full fibre complement by 28 days. 
2. Muscle stem cells, satellite cells (c-met positive), were identified in the soleus 
muscle at the initiation of the fibre regeneration process. 
3. Mechano-growth factor (MGF) expression in the soleus muscle and heart was 
significantly elevated up to 72 hours-, following catecholamine-induced damage. 
This is in accordance with satellite cell activation and proliferation. 
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3.19 Mechano-growth factor (MGF) expression in the heart. 
Transverse sections were stained with fluorescein to identify MGF positive staining 
in the heart. No MGF expression was detected in control hearts (A), but \%, as 
apparent in the heart (B, arrowheads) after isoprenaline administration. Nuclei wci-c 
identified using DAM (blue, C, arrowheads). The localisation ofMGF in the nuclei 
becomes apparent when the two images are merged (D; arrowheads) (x200 
magnification). 
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Figure 3.20 Time course of mechano-growth factor (MGF) expression In the 
heart. 
Percent of MGF expression in response to a single injection (s. c. ) of 20 mmol of 
isoprenaline kg". No MGF was found in the control muscles (CTRL) receiving 
saline vehicle only. Results are Mean ± SEM for n=5 and *denotes significant 
differences (P<0.01) from CTRL. 
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3.4 Cardiomyocyte Death and Regeneration 
3.4.1 Cardiac function 
Evaluations of ventricular function showed that a single injection of isoprenaline 
(20 mmol kg-1) caused marked changes in LV performance (Figure 3.21). When 
compared to control animals, at 1 day after injection, isoprenaline-treated animals 
exhibited a significantly (P<0.05) decreased LV developed pressure (LVDevP; 
CTRL, 88.5 ± 8.2; ISO, 64.3 ± 12.7 mmHg), +dP/dt (CTRL, 8124 ± 1027; ISO, 
6546 ± 888 mmHg/s) and -dP/dt (CTRL, 7889 + 1240; ISO 5730 ± 625 mmHg/s) 
and increased LV end-diastolic pressure (LVEDP; CTRL, 3.8:: h 1.5; ISO, 21.0 ± 4.2 
mmHg), uncovering acute LV failure. Interestingly, these parameters started to 
improve after 3 days and all returned to control values by 14 days, indicating 
restored LV function. 
3.4.2 Myocyte death, size and number 
Gross characteristics of the heart are shown in Table 3.1. Briefly, isoprenaline 
injection caused significant (P<0.05) decreases in body weight, compared to control 
animals. Catecholamine exposure at the concentrations used here, caused both 
necrotic and apoptotic cardiomyocyte death in the rat heart in the presence of a 
patent coronary circulation, resulting in remodelling of the ventricular wall. 
Morphometric analysis revealed considerable myocardial injury and focal necrosis 
to the LV, resulting in an increased area fraction of dead myocytes and interstitial 
cells and a decreased percentage area of viable myocytes, following bolus 
isoprenaline administration (Table 3.2). This cell damage occurred shortly after 
isoprenaline administration. The effect was most pronounced I day after injection, 
but for all time points (1,3,6 and 14 days), the myocardium showed significantly 
(P<0.05) less area occupied by viable myocytes, and a greater area occupied by 
dead and interstitial cells, compared to control animals. By 14 days, the area fraction 
of viable myocytes had increased slightly, so that it was now significantly (P<0.05) 
greater than at 1,3 and 6 days. In parallel, the percentage of dead myocytes had 
significantly decreased (P<0.05) from I and 3 days. 
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Figure 3.21 Left ventricular (LV) function. 
Time course of changes in LV function in response to a single injection (s. c. ) of 20 
mmol of isoprenaline kg". One group of animals (CTRL) received the saline 
vehicle. Haemodynamic measurements were taken by advancing a microtip pressure 
transducer into the LV cavity through the right carotid artery. Results are Mean ± 
SD for n=5. *denotes significant differences (P<0.05) from CTRL. 
tdenotes 
significant differences (P<0.05) from I day. ISO indicates isoprenaline-treated 
animals; LVEDP, LV end-diastolic pressure; LVDevP, LV developed pressure; 
+dP/dt, LV contraction; -dP/dt, LV relaxation. ISO indicates isoprenaline-treated 
animals. 
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Table 3.2 Catecholamine-induced myocardial injury. 
Percent number of viable myocytes, dead myocytes and interstitial cells were 
measured in the LV wall after a single injection (s. c. ) of 20 mmol of isoprenaline 
kg-1. One group of animals (CTRL) received the saline vehicle only. The percent 
area of myocytes, dead myocytes and interstitial cells was determincd by using a 42 
point morphometric reticle and counting the fraction of all points that lie over these 
cell profiles. At least 100 of each cell type were counted for each layer of the LV 
wall (sub-endocardium, mid-wall, sub-epicardium). But, if these numbers could not 
be achieved, then the entire region was measured (Anversa and Olivetti, 2002). 
Results are Mean ± SD for n=5. *denotes significant differences (P<0.05) from 1,3, 
6 and 14 days. +denotes significant differences (P<0.05) from 1,3 and 6 days and 
tdenotes significant differences (p<0.05) from I and 3 days. 
Total Wall 
Myocytes Dead Cells (%) Interstitium 
CTRL 90 ± 0* O: h 0* 
'I@L 
10±0* 
ld 69 ±3 17 ±4 15 ±2 
3d 67 ±3 15 ±2 19 ±I 
6d 70 ±3 11 ±3 19 ±5 
Ad 76 ± 37- 7± It 
1 
18 ±2 
11 
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Left ventricular weight was found to be significantly increased (P<0.05) at I and 3 
days, when compared to controls. Notably, it had returned to normal values by 14 
days after the isoprenaline injection (Figure 3.22). Comparable with the latter 
finding, myocyte volume was markedly increased (P<0.05) after 3 days, transiently 
decreased at 6 and 14 days, but consistently remained higher (P<0.05) than control 
values (Figure 3.22). Analysis of LV myocyte number revealed a significant and 
linear loss of myocytes from I to 3 days, (21 to 49 % decrease, P<0.05). Then, 
myocyte number increased slightly at 6 days becoming significantly (P<0.05) higher 
by 14 days compared to 3 days after isoprenaline injection. However, this value still 
remained lower than control animals (Figure 3.22). 
Catecholamine-induced cardiomyocyte apoptosis, identified by labelling for 
caspase-3 (Figures 3.6; 3.7), was confirmed using the TdT (TUNEL) assay with 
dUTP (Figure 3.23). Table 3.3 describes the analytical process for assessing the 
effects of isoprenaline on dUTP labelled myocyte nuclei in the LV. The 
myocardium. of control animals exhibited a low rate of myocyte apoptosis (0.01 ± 
0.01%). In contrast, the amount of apoptotic myocyte nuclei was significantly 
(P<0.05) increased at 1,3 and 14 days, compared to controls (Table 3.3). 
1%. 
The fraction of dUTP labelled myocyte nuclei in the LV was similar to the amount 
of caspase-3 labelled cardiomyocytes at I and 3 days (Figure 3.7), further 
confirming the specific identification of catecholamine-induced apoptosis in the 
heart. There were also clear distinctions between LV layers, in terms of myocyte 
death. The sub-endocardium. was much more affected by isoprenaline than the mid- 
wall and sub-epicardium. The sub-endocardiurn exhibited a significantly (P<0.05) 
greater loss of myocytes, paralleled with more pronounced (P<0.05) areas of dead 
myocytes and interstitial cells, when compared to the mid-wall and sub-epicardium 
(Table 3.4). Similarly, the sub-endocardium and mid-wall displayed significantly 
(P<0.05) greater apoptotic myocyte nuclei I day after isoprenaline injection, when 
compared to sub-epicardiurn. By 3 days the number of apoptotic cells detected had 
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Figure 3.22 LV weight, myocyte volume and total myocyte number. 
Time course of LV weight (top panel), myocyte cell volume (middle panel) and 
number (bottom panel), in response to a single injection (s. c. ) of 20 mmol of 
isoprenaline kg-1. One group of animals (CTRL) received the saline vehicle. 
Myocyte cell volume was calculated from the product of myocyte CSA and length. 
Myocyte number was determined from the total volume of myocytes and individual 
myocyte cell volume. Total volume of myocytes is the product of LV volume and 
percent area of viable myocytes (see methods). Results are Mean :h SD for n=5. 
*denotes significant differences (P<0.05) from CTRL. 
tdenotes 
significant 
difference (P<0.05) from 3 days. ISO indicates isoprenaline-treated animals. 
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Figure 3.23 lsoprenaline-induced apoptosis in the LV. 
Animals were injected (s. c. ) with 20 mmol of isoprenaline kg-', killed at various 
time points up to 14 days, and 5ýtm cryo-sections of the heart cut transversely. DNA 
strand breaks in myocyte nuclei were immunohistochernically detected using the 
Ten-ninal deoxynucleotidyl Transferase (TdT) assay with dUTP. dUTI, positivc 
nuclei (green, A; arrowhead) were detected in the myocardium. Myocyte cytoplasm 
was identified using an antibody against a-sarcomeric actin (red, 13), and nuclei 
were counterstained with DAPI (blue, Q. The dUTP labelled nuclei were confirnied 
as myocyte nuclei by merging the three images (D) (all x 1000 magni fication). 
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Table 3.3 Effects of isoprenaline on dUTP labelled myocyte nuclei in the LV. 
The fraction of apoptotic myocytes (dUTP positive) was determined by first 
obtaining the numerical density of myocyte nuclei in the myocardial area. This was 
done by counting the number of myocyte nuclei per unit area and multiplying by the 
total area of the myocardial tissue section. As the entire cross-section of 
myocardium was examined for apoptosis, the number of dUTP labelled myocytes 
divided by the numerical density of myocyte nuclei yields the percent apoptotic 
myocyte nuclei. Results are Mean ± SD for n=5. *denotes significant differences 
(P<0.001) from control animals. 
tdenotes significant differences (P<0.05) from I 
day. 
CTRL 1 DAY 3 DAYS 14 DAYS 
Myocardial area examined for 
apoptosis (mm2) 
3 5.8 3.7 27.5 2.1 34.5 ± 1.7 32.2 ±1.7 
Tdt labelled myocyte nuclei 31 71 11 33 ±4 31 d: 10 
Myocardial area examined for 
myocyte nuclear density (MM2) 
0.6 0.01 0.6 0.01 0.6-4-0.01 0.6 ± 0.01 
Myocyte nuclei 444 89 376 ± 36 332 ± 37 380 ± 47 
My cyte nuclei/ MM2 755 151 639 ± 61 564± 62 646 ± 80 
% Tdt labelled myocyte nuclei 0.01 0.01 0.42 ± 0.09* 0.19±0.04*t 0.15±0.06*t 
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decreased so that there were no differences between myocardial layers (Figure 
3.24). 
As isoprenaline-treated animals exhibited a larger myocyte volume than their 
control counterparts (Figure 3.22), it was interesting to determine the distribution of 
myocyte sizes in the isoprenaline-treated animals. The frequency distribution of 
myocyte sizes showed that in control animals 85% were distributed between, 5000 
to 22000 gm 3. In contrast, in isoprenaline-treated animals, only 66% of the 
myocytes were in this range. The remaining myocytes were both larger (range of 
23000 to 39000: ISO 18%; CTRL, 12%), revealing myocyte hypertrophy and 
smaller (range of 1000 to 4000: ISO, 14%; CTRL, 0%), suggesting myocyte 
hyperplasia (Figure 3.25). 
3.4.3 Myocyte regeneration 
These interesting findings of smaller myocytes after isoprenaline injection pointed 
to the occurrence of cellular hyperplasia in the rat hearts following isoprenaline- 
induced acute and diffuse myocardial damage. To test this hypothesis, BrdU and 
Ki67 staining were used to assess myocyte-specific proliferation. Remarkably, 
BrdU-positive small myocytes (Figure'r3.26) were detected as soon as 3 days after 
isoprenaline-injection. 
This BrdU incorporation could reflect either new myocyte formation or reactive 
DNA synthesis in LV cardiomyocytes after catecholamine-induced myocardial 
damage. Ki-67 is somewhat preferable to BrdU for labelling proliferating cells 
because it is not involved in DNA repair. In fact, Ki-67 is a nuclear antigen 
expressed in all phases of the cell cycle, except Go. All types of proliferating cells 
express Ki-67. On this basis, Ki67 labelling was used in conjunction with BrdU to 
confirm that these myocytes were 'true' replicating cells and not myocytes 
undergoing DNA repair. 
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Figure 3.24 Apoptosis in the 3 layers of the LV wall. 
Time course of percent apoptotic myocytes (dUTP positive) in the sub- 
endocardium, mid-wall and sub-epicardium, layers of the LV wall, in response to a 
single injection (s. c. ) of 20 mmol of isoprenaline kg-1. One group of animals 
(CTRL) received the saline vehicle. The number of dUTP labelled myocyte nuclei 
per unit area of tissue were counted and by obtaining the numerical density of 
myocyte nuclei in each myocardial layer, the percentage of apoptotic myocyte 
nuclei was determined. Results are Mean ± SD for n=5 and *denotes significant 
differences (P<0.05) from sub-epicardium. ISO indicates isoprenaline-treated 
animals. 
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Figure 3.25 Distribution of myocyte sizes in the sub-endocardium. 
Myocyte volume distribution in saline control animals (CTRL, top panel) and 14 
days (bottom panel) after a single injection (s. c. ) of 20 mmol of isoprenaline kg". 
Myocyte cell volume was calculated from the product of myocyte cross-sectional 
area and length. ISO indicates isoprenaline-treated animals. 
108 
Results 
Figure 3.26 NeA I-, formed m,. oq. te in the ms ocardium (Brdt' positive). 
NeýýI\ 1"Ormed ni\oc-, tc,, Nwre identified on trans,. erse sections using antibodies 
against BrdU and a-sarcomeric actin. following isoprenaline-induced iqiurN'. A 
BrdU positive (green. A: arrox%head) myocyte (red. B) nuclei (blue. C) becornes 
clearly apparent %%hen the three images are merged (D) (all x 1000 magnification). 
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Accordingly, Ki67-positive myocyte nuclei were present in the LV myocardium 
following isoprenaline-injury, verifying the cycling nature of these cells (Figure 
3.27). Consistent with myocyte death, regenerating myocytes were most evident in 
the sub-endocardium. At 6 days, there were 2± 1% BrdU positive myocytes 
(P<0.05) in the sub-endocardium, compared to only 0.3 ± 0.2% in the sub- 
epicardium. By 14 days, 4± 2% BrdU-positive myocyte nuclei (P<0.05) were 
present in the sub-endocardium, whereas only 2± 1% and I± 1% were present in 
the mid-wall and sub-epicardium, respectively (Figure 3.28). In turn, the percentage 
of newly formed myocytes in the total LV wall increased in a linear time dependent 
manner, and by 6 days the number of BrdU positive myocytes were significantly 
(P<0.05) greater than 3 days and control animals. The peak amount of BrdU- 
positive myocytes (2%) was observed at 14 days (Figure 3.29). As described above, 
it should be noted that myocyte apoptosis decreased over time from I to 14 days 
after isoprenaline administration. This time dependent decrease in cardiac cell death 
was then simultaneously met by an increase in myocyte renewal over time (Figure 
3.29). These findings suggest that myocyte regeneration is injury triggered, i. e. 
occurring as a response of the myocardiurn to replace the lost myocytes in a self- 
mediated attempt to repair the damage. 
A subpopulation of small sized myocytes was identified in the hearts of 
isoprenaline-treated rats (Figure 3.25). To verify that this subset of cells 
corresponded to small developing myocytes, BrdU labelled myocyte sizes were 
measured at each time point after isoprenaline injection. Interestingly, the smallest 
myocytes were mainly BrdU-positive. 
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Figure 3.27 NeA 1, formed m, * oc, * tes in the myocardium, (Ki67 positive). 
Ne%%I% fOrmed ni\oc\tes \\ere continued hý staining for K167 and cc-sarcomeric 
actin. K167 positive nuclei (green. A. arrowhead) were identified in the myocardium 
as soon as 33 da\s after isoprenaline itliection. The asterisk indicates a Ki67 positive 
nucleus of a small developing. myocyte. \I\oc\-te cytoplasm was detected by 
staining for a-sarcomeric actin (red. B). Nuclei were counterstained With DAPI 
(blue. C). The identification ofa newly formed mvocyte can be seen clearly when 
the three images are merged (D) (all x 1000 magnification). 
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Figure 3.28 Newly formed myocytes in the 3 layers of the LV wall. 
Time course of percent newly formed myocytes (BrdU positive) in the sub- 
endocardial, mid-wall and sub-epicardial layers of the LV wall, in response to a 
single injection (s. c. ) of 20 mmol of isoprenaline kg". One group of animals 
(CTRL) received the saline vehicle. All animals were injected (i. p. ) with 50 mg of 
BrdU kg" twice daily until they were killed. The number of BrdU positive myocyte 
nuclei per 1500 myocytes were counted for each layer of the LV wall, across a total 
of 4 tissue sections, and expressed as a percent fraction. Results are Mean ± SD for 
n--5. *denotes significant difference (P<0.05) from mid-wall and sub-epicardium. 
tdenotes significant difference (P<0.05) from sub-epicardium. ISO indicates 
isoprenaline-treated animals. 
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Figure 3.29 Cardiac cell death and regeneration. 
Percent apoptotic (dUTP positive, top panel) and newly formed (BrdU positive, 
bottom panel) myocytes in the entire LV wall, in response to a single injection (s. c. ) 
of 20 mmol of isoprenaline kg". One group of animals (CTRL) received the saline 
vehicle. Results are Mean ± SD for n--5. *denotes significant differences (P<0.001) 
from CTRL. "denotes significant differences (P<0.05) from I day. tdenotes 
significant differences (P<0.05) from 3 days. ISO indicates isoprenaline-treated 
animals. 
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Moreover, there were significant differences (P<0.001) in the sizes of the BrdU- 
positive cells over time, suggesting progressive maturation of these newly formed 
myocytes (Figures 3.30; 3.31). Indeed, beginning at 3 days, the average diameter of 
BrdU-positive myocytes was 3.5 ± 0.4gm. This had increased to 7.7 ± 0.8pm by 14 
days (Figures 3.30; 3.31). More specifically, at 3 and 6 days after isoprenaline 
administration the sizes of BrdU-positive myocytes were significantly (P<0.001) 
smaller than BrdU-positive cells from control hearts. However, this difference was 
no longer apparent by 14 days (Figure 3.3 1). However, the BrdU-positive myocyte 
diameters of control and isoprenaline-treated animals were all significantly 
(P<0.001) smaller than BrdU-negative myocytes, indicating the immature 
phenotype of these cells. 
3.4.4 Cardiac stem progenitor cells 
In view of the recent identification of primitive and early-committed cells in the 
heart and their role in myocyte regeneration, the number of c-kit positive (c-ki? os) 
cells in the myocardium. was measured. Clusters of primitive and early committed 
cells expressing the stem cell antigen c-kit were found in the myocardium of control 
and isoprenaline-treated hearts (Figure 3.32). Interestingly, the number of cardiac c- 
kitpos cells was found to be significantl')"(P<0.01) increased in isoprenaline-treated y 
rats, when compared to controls. In fact, this value was 4-, 5-, 6- and 4-fold higher 
than controls at 1,3,6 and 14 days, respectively (Figure 3.33). Accordingly, the 
number of c-ki? os cells increased I day after isoprenaline injection, compared to 
the control. Then, it peaked at 3 days remaining constant up to 6 days, being 
significantly (P<0.05) higher than at I day (Figure 3.33). By 14 days, c-kitpos cell 
numbers started to decrease, but remained above control values (Figure 3.33). Many 
of these c-kitpos cells were found to express ki67 in their nuclei, indicating 
activation and proliferation of these cells following the isoprenaline-injury (Figure 
3.34). Consequently, some of the c-ki? os cells expressed the transcription factor 
GATA4, which implicated cardiomyocyte differentiation (Figure 3.35). The 
recognition of cells positive for c-kit and GATA4 provided evidence of a link 
between primitive cells and early differentiating myocyte progenitors. 
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Figure 3.31) N e" h -formed nu. oc% te sizes. 
The nc%% Iý fOrmed in) ocý teý, iarrox\ [leads) increased in size from 3 davs to 14 days, 
after isoprenaline bolus administration. BrdU positive (green) myocyte (red) nuclei 
(blue) in saline CTRL animals (A): and 33 (B). 6 (C) and 14 (D) days after 
isoprenaline injection. A difierentiated nlýocyte (red: ct-sarcomeric actin. blue, 
DAPI. arro\-. ) (F) is larger than the all the Brdt' Positive myocytes (all xJ000 
magnification). 
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Figure 3.31 The size of newly formed myocytes 
Time course of BrdU-positive myocyte diameter, in response to a single injection 
(s. c. ) of 20 mmol of isoprenaline kg". One group of animals (CTRL) received the 
saline vehicle. All animals were injected (i. p. ) with 50 mg of BrdU kg"I twice daily 
until they were killed. The myocyte diameters of BrdU-positive and BrdU-negative 
myocytes were measured across the cell nucleus in each sub-endocardium of the 
LV. Results are Mean ± SD for n--5. *denotes significant differences (P<0.001) 
from BrdU-negative myocytes in control animals. tdenotes significant differences 
(P<0.001) from BrdU-positive myocytes in control animals. ISO indicates 
isoprenaline-treated animals. 
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Figure 3.32 Cardiac stem progenitor cells in the rat myocardium. 
Trans\ erse sections \\ere stained \% Ith C-kIt I -Ab and this \Nas detected with TRITC 
2'Ab to show c-kit positive cells (red. A. arro\Nheads) in the myocardium. Nuclei 
vvere stained with DAM (blue. B). The localisation of the c-kit receptor on the 
surface of the nuclei is apparent when the mo images are merged (C) (all x1000 
magnification). 
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Figure 3.33 Cardiac stem progenitor cells. 
Time course of c-kitms cardiac cells, in response to a single injection (s. c. ) of 20 
mmol of isoprenaline kg-'. One group of animals (CTRL) received the saline 
vehicle. The number of c-kitpos cells in a total of 3 myocardial cross-sections was 
counted and by measuring the area of each myocardial cross section, the number of 
c-kit+ cells per unit area of myocardial tissue determined. Results are Mean + SD 
for n=5. *denotes significant differences (P<0.0 1) from CTRL. "denotes significant 
differences (P<0.05) from I day. ISO indicates isoprenaline-treated animals. 
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Figure 3.34 Proliferating cardiac stem progenitor cells in the rat 
myocardium. 
Transverse sections were double stained for c-kit and Ki67 to identifv cyclino stem 
cells. following isoprenaline-induced myocardial damage. Two c-kit positive cells 
(red. A. arrowheads) are also positive for Ki67 (green, B. arrowheads). indicating 
their activated state. Nuclei %vere counterstained with DAPI (blue, C). The cycling 
stem cells can be seen more clearly when the three images are merged (D) (all 
x 1000 magnification). 
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Figure 3.35 Commitment of cardiac stem progenitor cells in the rat 
myocardium. 
Transverse sections were double stained for c-kit and GATA4 to recognize the 
committed progeny of cardiac stem cells during the regeneration process. after 
isoprenaline-irljun-. Two c-kit positive cells (red. A. arrowheads) express GATA4 
(green dots. B. arrowheads) in their nuclei (blue. C). This becomes more apparent 
when the three images are merged (D) (all x 1000 magnification). 
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Notably, these myocyte progenitors (c-kitPos/GATA4Pos) were constantly identified 
between 3 and 14 days after isoprenaline-induced myocardial damage (Figure 3.35). 
Key points: 
1. Cardiac function was depressed at I day after isoprenaline injection, exhibiting 
acute cardiac failure. However, by 6 days it started to improve and this persisted 
through to 14 days. 
2. Acute isoprenaline exposure caused significant cardiomyocyte necrosis and 
apoptosis. This was most prominent in the sub-endocardial layer. 
3. Acute isoprenaline exposure caused increases in LV weight, which returned to 
control values by 14 days. 
4. Acute isoprenaline exposure resulted in a decreased LV myocyte number and an 
increased myocyte volume. 
5. Isoprenaline-treated animals exhibited a change in the frequency distribution of 
cardiomyocyte size, with a greater number of larger and smaller myocytcs when 
compared to control animals. 
6. Isoprenaline-treated hearts respondedto, the extensive cardiomyocyte damage and 
loss caused by isoprenaline, in part through myocyte hyperplasia. This was evident 
through the generation of newly formed myocytes which were positive for BrdU 
and ki67. These myocytes were all smaller than the other myocytes and most 
prominent in the sub-endocardial layer. 
7. Resident cardiac progenitor cells expressing the stem cell antigen, c-kit, were 
identified in the myocardium. Isoprenaline-induced damage caused these cells to 
increase in number up to 6 days and many expressed ki67, exhibiting their cycling 
nature. Also many of these c-kit positive cells expressed GATA4, indicative of early 
differentiating myocyte progenitors. 
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3.5 Continuous Infusion of Catecholamines 
To more faithfully reflect the sustained higher than normal levels of catecholamines 
in heart failure patients, a continuous infusion, rather than a bolus injection, of 
catecholamincs was studied. This was achieved using osmotic mini pumps. 
3.5.1 Growth and hypertrophy 
Continuous infusion of catecholamines over 28 days resulted in marked increases in 
bodyweight and the individual weights of the heart and various skeletal muscles. 
Since rats continue to grow throughout most of their adult life, all groups showed a 
significant increase (P<0.05) in body weight over time (Figure 3.36). However, the 
isoprenaline group showed the greatest increase of 38% over the 28 day period, 
compared with 17% for the adrenaline group and 26% for the sham-operatcd 
controls. The fact that the adrenaline treated rats gained less weight than the placebo 
controls meant that by 28 days the isoprenaline group were significantly (P<0.05) 
16% heavier than the adrenaline group (Figure 3.36). Over 28 days, no differences 
were found for body weight between the experimental groups and the placebo group 
(Figure 3.36). 
RL 
To determine whether continuous infusions of the catecholamines affected the 
animals' appetite and consequently their food and water consumptions, these 
variables were monitored over the course of the 28 day experimental period. Both 
isoprenaline and adrenaline-treated groups showed initial significant decreases 
(P<0.05) in their appetites and total food consumptions at 3 days, when compared to 
the saline placebo group (Figures 3.37; 3.38). However, these returned to values 
above those of the placebo group by 7 days and remained stable up to 28 days 
(Figure 3.37; 3.38). 
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Figure 3.36 Rat body weights during chronic exposure to catecholamines. 
All animals were weighed daily during 28 days of continuous infusion with either 
20 mmol kg"d-1 of isoprenaline, adrenaline or saline (placebo) only, delivered via 
osmotic mini pumps. Results are Mean ± SEM for n--5-20. 'denotes significant 
differences (P<0.05) within the placebo controls, between 28 days and 0,3 and 7 
days. "denotes significant difference (P<0.05) within the isoprenalinc group, 
between 28 days and 0,3 and 7 days. 
tdenotes significant difference (P<0.05) 
within the adrenaline group, between 28 days and 0,3 and 7 days. *denotes 
significant difference (P<0.05) between isoprenaline vs. adrenaline groups. 
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Figure 3.37 Food consumption during chronic exposure to catecholamines. 
The food consumptions were measured daily during the continuous infusion of 
either 20 mmol kg"d"' of isoprenaline, adrenaline or saline (placebo) only and 
delivered via osmotic mini pumps. Results are Mean ± SEM for n=5-20. No 
differences were found over time for the saline placebo controls. *denotes 
significant differences (P<0.05) between isoprenaline and adrenaline groups vs. 
placebo controls. tdenotes significant difference (P<0.05) between isoprenaline 
group vs. placebo controls. 
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Figure 3.38 Changes In appetite during chronic exposure to catecholumines. 
Animals' appetites were measured during continuous infusion with either 20 mmol 11, 
kg"d" of isoprenaline, adrenaline or saline (placebo) only, delivered via osmotic 
mini pumps. Results are Mean + SEM for n=5-20. No differences were found over 
time for the saline placebo controls. tdenotes significant differences (P<0.05) ovcr 
time, specifically 3 day vs. all other time points in the isoprenaline and adrenaline 
groups. *denotes significant difference (P<0.05) between isoprenaline and 
adrenaline groups vs. placebo controls. 
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By 28 days the amount of food consumed by the isoprenaline group was 
significantly greater (P<0.05) than that consumed by the placebo rats (Figure 3.37). 
There were no statistical differences between groups in terms of their water 
consumptions, over the 28 day infusion period (Figure 3.39). However, comparable 
to their appetite and food consumptions, the isoprenaline and adrenal ine-treatcd 
animals did show an initial decrease in their water consumptions at 2 days. 
Thereafter, it remained slightly but consistently higher than in the control animals 
(Figure 3.39). 
In keeping with the growth of the whole animal, the hearts of the placebo group 
increased by 15% over time (Figure 3.40). However, no significant differences were 
seen in heart weight between the zero day control and the placebo groups at any of 
the time points. Both the continuous infusions of isoprenaline and adrenaline caused 
the weight of the heart to increase over time (Figure 3.40). In the isoprcnalinc 
group, the weight of the heart increased by 43% (P<0.05 versus zero day control) by 
28 days of infusion. However, most of this increase over the controls had occurred 
by just 5 days (Figure 3.40). In the adrenaline group, the weight of the heart 
increased, but not as quickly or to the 0 
same extent as the isoprenaline group, this 
being 16% heavier (P<0.05 versus zero day control) after 28 days of infusion 
(Figure 3.40). 
It was found that continuous infusion of 20 mmol isoprenaline kg*ld" caused -35% 
increase (P<0.05) in heart weight, when compared to the placebo group at every 
time point analysed over 28 days infusion (Figure 3.40). Also the increase in heart 
weight over 28 days seen in the isoprenaline group was significantly different 
(P<0.05) from the adrenaline group (26,18,16 and 23% greater at 5,7,14 and 28 
days, respectively). Although the adrenaline animals displayed an increase in heart 
weight over 28 days, these increases were not found to be significant, when 
compared to the saline placebo group (Figure 3.40). 
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Figure 3.39 Water consumption during chronic exposure to catecholamines. 
Water intake was measured daily during the continuous infusion of either 20 mmol 
kg-ld-1 of isoprenaline, adrenaline or 'saline (placebo) only, delivered via osmotic 
mini pumps. Results are Mean ± SEM for n=5-20. No differences were found over 
time for the saline placebo controls. "denotes significant difference (P<0.05) within 
in the isoprenaline group, between 2 days and 0,7 and 28 days. No differences were 
found over time for the adrenaline group. 
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Figure 3.40 Heart weight after chronic exposure to catecholamines. 
The weight of the heart was measured in response to continuous infusion with cithcr 
20mmol kg"d-1 of isoprenalinc, adrenaline or saline (placebo) only, as delivered via 
osmotic mini pumps. Results are Mean ± SEM for n=5. No significant differences 
were found between zero day control and placebo controls at any time points. 
"denotes significant differences (P<0.05) in heart weights within the isoprcnalinc 
group, compared with zero day control. t denotes significant differences (P<0.05) in 
heart weights within the adrenaline group, compared with zero day control. *denotes 
significant differences (P<0.05) between isoprenaline vs. adrenaline groups and 
placebo controls. 
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A similar sequence of events emerged with the soleus muscle. Muscles in the 
placebo group increased gradually over time, even though these increases in weight 
were not significantly different from the zero day control muscles (Figure 3.41). The 
isoprenaline and adrenaline-treated groups, both showed significant increases 
(P<0.05) over time, being 42% and 28% heavier at 28 days respectively, compared 
to zero day control (Figure 3.41). Although not always significantly greater, the 
muscles exposed to the two catecholamines were always larger than those of the 
sham-operated saline placebo group (Figure 3.41). 
To establish whether these increases in muscle mass represented true hypertrophy, 
after 28 days soleus muscles were sectioned and fibre cross-sectional areas 
determined (Figure 3.42). The isoprenaline and adrenaline infused groups exhibited 
significant (P<0.05) increases in the fibre cross-sectional areas of their solcus 
muscles, when compared to the placebo group (Figure 3.42). These findings, 
combined with the increases in muscle weight, indicate that significant muscle 
hypertrophy had occurred in the soleus following 28 days of catecholamine 
infusion. 
Two predominantly fast twitch muscles, the tibialis anterior and the plantaris 
muscles were also studied. These too showed increases in their weights over 28 days 
of either isoprenaline or adrenaline infusion (Figures 3.43; 3.44). Following 28 days 
of isoprenaline infusion, both muscles were significantly heavier (P<0.05) than the 
zero time control and placebo control groups, with the tibialis anterior 68% heavier 
than zero day control and 28% heavier than the placebo group (Figure 3.43). 
Changes in the plantaris were similar, i. e. 72% and 33% heavier than zero time and 
placebo controls, respectively (Figure 3.44). The adrenaline group showed similar 
increases in muscle weight (P<0.05) over time, but generally not as great as in the 
isoprenaline group (Figures 3.43; 3.44). 
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Figure 3.41 Soleus weights after chronic exposure to catecholamines. 
Wet weights of the soleus muscle were measured in response to continuous infusion 
with either 20 mmol kg"d-1 of isoprenaline, adrenaline or saline (placebo) only and 
delivered via osmotic mini pumps. Results are Mean± SEM for n=5. No significant 
differences were found between zero day control and placebo controls at any time 
points. "denotes significant differences (P<0.05) in solcus weights within the 
isoprenaline group, compared with zero day control. 
tdenotes significant 
differences (P<0.05) in soleus weights within the adrenaline group, compared with 
zero day control. *denotes significant difference (P<0.05) between isoprenalinc 
group vs. placebo controls. 
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Figure 3.42 Cross-sectional areas of fibres In the soleus muscle after chronic 
exposure to catecholamines. 
Muscles were isolated 28 days after continuous infusion with either 20 mmol kg"d" 
of isoprenaline, adrenaline or saline (placebo) only, delivered via osmotic mini 
pumps. These were sectioned (5gm) and stained for myosin ATPase. Regardless of 
fibre type the cross-sectional area of at least 100 fibres were measured for each 
muscle. Results are Mean ± SEM for n--5. *denotes significant differences (P<0.05) 
from saline placebo controls. 
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Figure 3.43 Tibialis anterior weights after chronic exposure to 
catecholamines. 
Wet weights of the tibialis anterior muscle were taken in response to continuous 
infusion with either 20 mmol kg"d-1 of isoprenaline, adrenaline or saline (placebo) 
only, delivered via osmotic mini pumps. Results are Mean ± SEM for n=5. +denotes 
significant differences (P<0.05) in tibialis anterior weights within the placebo 
controls, compared with zero day control. "denotes significant differences (P<0.05) 
in tibialis anterior weights within the isoprenaline group, compared with zero day 
control. tdenotes significant differences (P<0.05) in tibialis anterior weights within 
the adrenaline group, compared with zero day control. *denotes significant 
difference (P<0.05) between isoprenaline group vs. placebo controls. 
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Figure 3.44 Plantaris weights after chronic exposure to catecholamines. 
Wet weights of the plantaris muscle were measured in response to continuous 
infusion with either 20 mmol kg"d-1 of isoprenaline, adrenaline or saline (placebo) 
only, delivered via osmotic mini pumps. Results are Mean ± SEM for n=5. +denotes 
significant differences (P<0.05) in plantaris weights within the placebo controls, 
compared with zero day control. "denotes significant differences (P<0.05) in 
plantaris weights within the isoprenaline group, compared with zero day control. 
tdenotes significant differences (P<0.05) in plantaris weights within the adrenaline 
group, compared with zero day control. *denotes significant difference (P<0.05) 
between isoprenaline group vs. placebo controls. 
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Overall, both natural and synthetic catecholamines induced a larger heart and 
skeletal muscles, with isoprenaline being more potent than the adrenaline. The 
effect on the skeletal muscles was greater for fast-twitch muscles, with isoprcnaline 
infusion resulting in higher percent increases in muscle mass of the tibialis anterior 
and plantaris (72% and 68%, respectively), than the soleus muscle (42%). 
3.5.2 Necrotic and apoptotic cell death 
The sham-operated saline placebo rats showed no necrosis or apoptosis in any of the 
muscles analysed, i. e. heart, tibialis anterior, soleus, plantaris, diaphragm, over the 
28 day experimental period. Similarly neither necrotic nor apoptotic fibres were 
found in the plantaris or diaphragm muscles, following 28 days of continuous 
infusion with either 20 mmol of isoprenaline or adrenaline kg"d". Also, only a 
single necrotic fibre was found in one tibialis anterior muscle from the isoprcnalinc- 
treated group (n=5). 
In marked contrast, continuous infusion of catecholamines resulted in both necrotic 
and apoptotic myocyte death in the heart and soleus muscles from the same animals. 
Fourteen days exposure to 20 mmol isoprenaline kg"d"' lead to 0.6% (P<0.05, 
versus placebo sham) cardiornyocyte necrosis (Table 3.5), approximately 15-fold 
higher than the levels of apoptosis. Although small, the amount of apoptosis 
increased in a time-dependent manner (Table 3.5) and by 28 days was almost 0.1%, 
which was significantly greater (P<0.05) than the sham-operated controls, but 
remained approximately 10- 1 5-fold less than the amount of necrosis. 
Seven days exposure to 20 mmol of adrenaline kg"d*l also caused significant 
(P<0.05, versus placebo sham) cardiomyocyte necrosis (Table 3.5). However, the 
amount of necrotic damage seen in the adrenaline group was not as great (-10%) as 
that found in the isoprenaline group. Despite this, the apoptotic death was similar 
between the 2 groups, i. e. adrenaline vs. isoprenaline. 
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Table 3.5 Myocyte death in the heart after chronic exposure to catecholamines. 
Necrotic (anti-myosin labelled) and apoptotic (caspase-3 labelled) cardiomyocytes 
were quantified (% area) after continuous infusion of either 20 mmol kg*ld" of 
isoprenaline, adrenaline or saline (placebo) only, delivered via osmotic mini pumps. 
Results are Mean ± SEM for n=5. *denotes significant differences (P<0.05) from 
placebo controls. ND denotes not detennined. 
% AREA PLACEBO 
7 days 14 days 28 days 
Necrosis 0±0 0±0 ND 
Apoptosis 0±0 0±0 0±0 
Isoprenaline 
Necrosis 0.3 0.09 0.6 ± 0.29* ND 
Apoptosis 0.03 0.01 0.04 ± 0.02 0.07 ± 0.02* 
Adrenaline 
Necrosis 0.03 0.00* ND ND 
Apoptosis 0.02 0.01 0.04 ± 0.01* 0.07 ± 0.01* 
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In the adrenaline group, the amount of apoptosis progressively increased over time 
(Table 3.5) and was significantly greater (P<0.05) than found in the saline placebo 
group (Table 3.5). 
In the soleus muscle, continuous infusion of 20 mmol isoprenaline kg"d-1 caused a 
significant increase (P<0.05) in the number of necrotic fibres at 14 days (6 :hI 
fibres; 0.3%), compared with no necrotic fibres in the soleus muscles of the placebo 
control animals (Table 3.6). Twenty mmol of adrenaline kg"d*l also caused 
significant (P<0.05, versus saline placebo) necrotic fibre damage after 7 days 
(0.1%). 
In a similar manner to the heart, apoptotic fibres increased over time in the soleus 
muscle for both isoprenaline and adrenaline groups; these being significantly 
different (P<0.05) from placebo at 14 and 28 days (Table 3.6). Also, the amounts of 
apoptosis and necrosis were similar within and between these groups, over the 28 
day experimental period (Table 3.6). 
3.5.3 Fibre regeneration in the soleus 
As predicted, from the above results for the placebo muscles, no differences were 
found in the total number of fibres in the soleus muscle between placebo groups at 
7,14 and 28 days. Also, only a total of five regenerating fibres were found in all of 
the 15 soleus muscle samples from placebo controls. Hence, all placebo data were 
pooled to create just one saline sham-operated group. 
In contrast, 7 days of continuous infusion with isoprenaline had a marked effect on 
the number of viable fibres in the soleus muscle (Figure 3.45). The total number of 
fibres decreased by 28% (P<0.05) from 2653 ± Ill to 1923 ± 84. The number of 
viable fibres present at 14 days was still 20% lower than in the controls. 
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Table 3.6 Fibre death in the soleus muscle after chronic exposure to 
catecholamines. 
Necrotic (anti-myosin labelled) and apoptotic (caspase-3 labelled) fibres were 
measured in the soleus muscle after continuous infusion of either 20 mmol kg"d-I of 
isoprenaline, adrenaline or saline (placebo) only, delivered via osmotic mini pumps. 
Results are Mean ± SEM and expressed as total number of necrotic or apoptotic 
fibres in the entire soleus muscle, with percentage cell death shown in parentheses 
for n--5. *denotes significant differences (P<0.05) from placebo controls. ND 
denotes not determined. 
NUMBER OF 
FIBRES (%) 
7 DAYS 14 DAYS 28 DAYS 
Placebo 
Necrosis 0±0(0) 0±0(0) ND 
Apoptosis 0±0 (0) 0±0 (0) 0±0 (0) 
Isoprenaline 
2± 1(0.1) 6±1 (0.3)* ND 
Apoptosis 2± 1(0.1) 5±2 (0.2)* 7±1 (0.2)* 
Adrenaline 
Necrosis 31 (0.1)* ND ND 
Apoptosis 32 (0.2) 5±2 (0.3)* 6±1 (0.2)* 
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Figure 3.45 Fibre loss and regeneration in the soleus muscle after chronic 
exposure to isoprenaline. 
I& 
Number of normal (o) and newly-formed regenerating fibres (m) following 
continuous infusion with 20 mmol of isoprenaline kg"d"', delivered via osmotic 
mini pumps. Results are Mean ± SEM for n=5. *denotes significant differences 
(P<0.05) from zero day control (CTRL) and placebo control animals. 
tdenotes 
significant differences (P<0.05) from zero day control, 5 and 28 days. 
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However, by 28 days the total number (2602 ± 87) had almost returned to normal 
(Figure 3.45). The number of regenerating fibres, as detected by labelling with 
embryonic/neonatal myosin Ab, represented 1,2,2 and 1% of the total number of 
fibres in the entire soleus at 5,7,14 and 28 days, respectively. Although low, these 
numbers of regenerating fibres at all time points were significantly greater (P<0.05) 
than in either the muscles from zero day control or saline placebo animals (Figure 
3.45). 
Continuous infusion of equimolar adrenaline resulted in a similar pattern of fibre 
loss and regeneration in the soleus muscle. That is, seven days of adrenaline 
exposure caused a significant (P<0.01) 23% loss of fibres (Figure 3.46). After 14 
days the total number of fibres increased to 2217, and by 28 days to 2360. 
Comparable with the events after the isoprenaline infusion, the number of 
regenerating fibres was significantly (P<0.05) increased following 5,7,14 and 28 
days of continuous adrenaline (compared to zero day control and saline placebo 
animals). Similarly, the number of regenerating fibres represented 2,1,1 and 1% of 
the total number of fibres present at 5,7,14 and 28 days, respectively (Figure 3.46). 
IL 
To compare the differences, in terms of fibre loss and regeneration, induced by the 
acute bolus injection and continuous infusion of catecholamines data were analysed 
using 2-way ANOVA. With isoprenaline the number of normal fibres 5 days 
following the single injection was significantly lower (P<0.05) than that seen after 5 
days following its daily infusion. In contrast, this was reversed at 7 days, with the 
total number of fibres following continuous infusion significantly lower (P<0.05) 
than compared to that at 7 days after the single injection. These findings suggest a 
shifting of fibre loss to the right of the time spectrum, with continuous infusion. 
However, the number of regenerating fibres following a single injection was 
significantly (P<0.05) greater at 5 and 7 days, compared to the number following 
continuous infusion. 
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Figure 3.46 Fibre loss and regeneration in the soleus muscle after chronic 
exposure to adrenaline. 
"A 
Number of normal (o) and newly-formed regenerating fibres (0) following 
continuous infusion with 20 mmol of adrenaline kg-ld-1, delivered via osmotic mini 
pumps. Results are Mean ± SEM for n=5. *denotes significant differences (P< 0.05) 
from zero day control and placebo control animals. 
tdenotes 
significant difference 
(P<0.01) from zero day control. 
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These findings suggest that a single injection of isoprenaline resulted in a greater 
regenerative response at 5 and 7 days than that solicited when administered as a 
daily infusion. No differences were seen between acute and continuous adrenaline 
exposures concerning the total numbers of viable or regenerating fibres. 
3.5.4 Fibrosis 
The collagen content of control and all catecholamine-treated soleus muscles were 
not different at 2% each. 'Mis could reflect the rapid and extensive regenerative 
capacity of this skeletal muscle, without any fibrosis. However in the heart 
significant changes in fibrosis were observed. Here, in contrast to skeletal muscle, 
continuous infusion of catecholamines caused marked increases in the collagen 
content (Figures 3.47; 3.48). Examples of collagen staining in sections of the soleus 
and heart muscle can be seen in Figure 3.47. By 14 days, the percent collagen in the 
hearts taken from the isoprenaline and adrenaline-treated groups was 12 and 7%, 
respectively (Figure 3.48). This was -9 and -4% higher than that found in zero time 
control and saline placebo control hearts. The increase in cardiac collagen in the 
isoprenaline group was found to be significantly different (P<0.05) from all other 
groups (Figure 3.48). The greater fibrosis in response to the more potent 
isoprenaline is consistent with the higher levels of necrotic cell death that this 
synthetic catecholamine induces. 
Key points: 
1. Continuous infusion of catccholamincs over 28 days caused significant increases 
in body weight and individual weights of the heart and slow and fast skeletal 
muscles. 
2. Continuous infusion of catecholarnines resulted in fibre hypertrophy, as 
exemplified by increases in fibre CSA in the soleus muscle. 
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Figure 3.47 Collagen content in the heart and soleus muscle. 
Transverse sections Nvere stained with Sirius Red to identify connective tissue 
(mostly collagen) in the heart and soleus muscle (collagen, red; rnyocytes, 
vellow/orange). No changes in collagen content were present in the soleus muscle 
(control. A. isoprenaline-treated. B). In contrast. the heart exhibited increased 
collagen content after 14 days of continuous catecholamine infusion (control, C, 
isoprenaline-treated. D) (all x200 magnification). 
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Figure 3.48 Collagen content in the heart after chronic exposure to 
catecholamines. 
Ilk Percent area of collagen was measured in the heart following 14 days of continuous 
infusion with either 20 mmol kg"d-1 of isoprenaline, adrenaline or saline (placebo) 
only, delivered via osmotic mini pumps. Results are Mean ± SEM for n=5. *denotes 
significant difference (P<0.05) from zero day control (CTRL), placebo controls and 
adrenaline groups. 
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3. Continuous infusion of catecholarnines caused necrotic and apoptotic cell death in 
both the heart and soleus muscles. This was met by a continual process of fibre 
regeneration in the soleus muscle. 
4. Continuous infusion of catecholamines resulted in extensive fibrosis (increased 
collagen content) in the heart, but not the soleus muscle. 
ITA 
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4.0 DISCUSSION 
Three main findings emanate from this study. First, whether administered acutely or 
chronically catecholamines induce both necrotic and apoptotic fibre death in the 
soleus muscle. Chronic exposure also caused muscle hypertrophy, against a 
background of continual fibre death and regeneration. The latter could lead to 
detrimental consequences, with a net loss of muscle fibres, due to a compromised 
skeletal muscle regenerative capacity. Second, acute and chronic exposure to 
catecholamines is also detrimental for the heart causing significant cell death, 
hypertrophy and fibrosis. Third, the heart compensated for the acute damage caused 
by excessive catecholamines through both cardiornyocyte hypertrophy and 
hyperplasia. 
4.1 Fibre Death and Skeletal Muscle Regeneration 
4.1.1 Catecholamine-induced damage 
A single injection of the natural catecholamines adrenaline or noradrenaline, or the 
synthetic derivative, isoprenaline, induced fibre necrosis and apoptosis in the soleus 
muscle of the rat. These findings are highly significant as no damage was found in 
any of the control muscles from those animals that received the saline vehicle, but 
no catecholamine. Previous findings from our laboratory have shown that the 
amount of damage depends on the dose administered and the time course defining 
optimal necrotic and apoptotic damage (Ng et al., 2002; Goldspink ct al., 2004). 
Interestingly, significant damage to skeletal muscle in response to excess 
catecholamines is a novel finding. This study shows for the first time that acute 
exposure to adrenaline or noradrenaline, as well as isoprenaline, results in 
significant necrosis and apoptosis in the skeletal myocytes of otherwise normal rats. 
The time course of apoptosis in the soleus muscle in the present study are also 
novel. Previously, Ng et al. (2002) reported the injurious effects of isoprenaline, 
causing severe fibre necrosis, in the rat soleus muscle. Ng et al. (2002) found that 
this toxic damage was initiated at lower doses than that in the myocardium (I Pg vs. 
lOgg kg") and peaked earlier at 12 vs. 18 hr post injection. While the present 
findings of significant necrosis in the soleus muscle following acute catccholamine 
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exposure confirm these earlier observations in our laboratory, apoptosis increased in 
a time dependent manner, being greatest at about 18-24 hours. This provides 
evidence of the similarities in the onset and time course of apoptosis and necrosis in 
the soleus muscle, when comparing with the study by Ng et al. (2002). Interestingly, 
these data could suggest that the two processes may be one and the same, rather than 
2 separate independent pathways. Recently, our laboratory suggested that 
catecholamine-induced apoptosis and necrosis either originate from common initial 
pathways, or that they maybe one and the same process, i. e. a continuum of events. 
This was a result of finding close similarities in the dose-responses, spatial 
distributions and receptor sub-type mediation for apoptosis and necrosis after a 
single injection of isoprenaline (Goldspink et al., 2004). Through the 
immunohistochernical technique of double immunofluorescence, both necrosis and 
apoptosis could be visualised on the same section of the soleus muscle. 
Interestingly, the present findings revealed that apoptosis (caspase-3 labelled) and 
necrosis (myosin antibody incorporated) co-localised within the same muscle fibres 
(Figure 3.10). More specifically, the number of fibres that were apoptotic alone was 
zero. Therefore, all fibres that were initially detected as apoptotic also became 
labelled as necrotic, suggesting at the least a process of secondary necrosis. That is, 
apoptotic fibres initially with intact membranes were not phagocytosed rapidly 
enough, such that their sarcolemmal membranes subsequently became disrupted (i. e. 
secondary necrosis) allowing the large anti-myosin Ab to enter. Caspase-3 positive 
fibres with disrupted sarcolemmal membranes after the isoprenaline administration, 
confirm this secondary necrosis (Figure 3.10). Hence all apoptotic fibres appear to 
undergo this secondary phase before being removed from the muscle. Conceivably, 
this could occur before, or after, the formation of apoptotic bodies (Goldspink et al., 
2003). In contrast, some fibres were necrotic only, with no signs of apoptosis. A 
possible explanation for these findings may be that once a fibre becomes necrotic 
and its membrane becomes disrupted and leaky, its intracellular contents leak out 
and cause inflammatory responses such that neighbouring viable fibres become 
damaged and subsequently necrotic. Alternatively, a completely different 
mechanistic pathway, independent of apoptosis and any inflammation caused by 
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secondary necrosis, may have initiated this small portion of the injured and necrotic 
fibres. 
The current findings could also be explained by taking into account the role of the 
mitochondria in cell death. Permeabilisation of the outer membrane of mitochondria 
is a feature of both apoptosis and necrosis, and this process of simultaneous 
induction of apoptotic and necrotic death has been termed 'necrapoptosis' 
(Lemasters et al., 2002). Following permeabilisation of the outer mitochondrial 
membrane, the availability of ATP could determine which type of cell death 
predominates, in that cells rapidly depleted of ATP undergo necrosis as opposed to 
apoptosis (Leist and Jaattela, 2001). This process of simultaneous induction of both 
types of cell death could also explain the present findings. Regardless, of how 
distinctive the two cell death pathways may actually be, or whether they share 
common initial pathways, the present findings highlight the importance of 
examining both types of cell death following a common insult. This is an area which 
many investigators have previously ignored, examining either one or the other cell 
death phenotype, and in particular the more 'fashionable' apoptosis. 
The present findings of necrotic fibre-death in the soleus muscle after acute 
catecholamine exposure, also agrees with the previous findings of Heap et al. 
(1996). The workers (Heap et al., 1996) reported isoprenaline-induced necrosis in 
the soleus muscle of the rat. Although the same dose of isoprenaline was used (i. e. 
5mg kg") in both studies, the amount of necrosis reported here was significantly 
greater than that found by Heap et al. (1996), i. e. 8.0 ± 1.8% fibres vs. 1.8 :L0.3% 
volume. The reason for this discrepancy could be due to differences in the detection 
of necrotic fibre damage. In the present study, a highly sensitive method (in vivo) 
which is specific for detecting damaged myocytes was used. However, Heap et al. 
(1996) assessed the extent of necrosis by the size of interstitial space and connective 
tissue using standard haematoxylin and eosin (H&E) staining, and did not 
specifically detect necrotic fibres. Another #2-agonist, clenbuterol, has also been 
found to cause a similar amount of necrotic fibre damage to the soleus muscle, 
examined 18 hours after a single 5mg kg" injection (Burniston et al., 2002). 
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Furthermore, the necrotic damage was reduced by 89% by the prior administration 
of the fl2-AR antagonist, ICI 118,551. It was reported by Ng et al. (2002) that 
isoprenaline myotoxicity was mediated via fl2-AR in the soleus and #I-AR in the 
heart (Ng et al., 2002). Also, it has been shown that P2-AR blockade before 
isoprenaline injection, significantly decreased the amount of myocyte death in the 
soleus, whereas fl, -AR blockade was ineffective (Goldspink et al., 2004). These 
findings prove that the damaging effects of catecholamines on the soleus muscle are 
mediated through the 92-AR pathway. These findings agree with the present 
findings demonstrating further the detrimental effects of P-AR stimulation on the 
soleus muscle. 
Interestingly, the present study revealed that only the soleus muscle out of the 4 
skeletal muscles examined was damaged by catecholamine administration. That is 
the tibialis anterior, plantaris and diaphragm muscles showed no necrotic or 
apoptotic fibres following catecholamine injection. All of these muscles were 
isolated from the same animals, clearly demonstrating different sensitivity levels to 
the catecholamines. The soleus muscle is composed of predominantly slow-twitch 
oxidative (Type I) muscle fibres (Figure 3.15), and is highly active due to its 
involvement in the control of posture and gait. It is suggested that slow-twitch 
postural muscles have a higher incidence of fibre degeneration and consequent 
regeneration, and a higher number of satellite cells (Schmalbruch and Hellhammer, 
1977), than fast- twitch muscles. This is due to more frequent and chronic 
recruitment of postural muscles in maintaining stance and gait. Therefore, these 
characteristics make it increasingly more susceptible to injury (Wanek and Snow, 
2000). 
As catecholamines also cause significant damage to the heart, it is thought that 
because the soleus muscle is close to the metabolic pattern (oxidative) and 
characteristics of contractile proteins (i. e. slow MHQ in the cardiac muscle, this 
could explain why it is damaged, when compared to the other faster contracting and 
glycolytic skeletal muscles. They are predominantly oxidative muscles relying on 
their many mitochondria to generate their ATP and due to the role the mitochondria 
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plays in cell death this could partially explain why these myocytes are more 
vulnerable to the injurious effects of catecholamines (Primeau et al., 2002). Another 
explanation is that the soleus muscle has a -3-fold greater number of P-ARs than 
fast glycolytic muscles, e. g. vastus lateralis and gastrocnernius (Martin et al., 1989; 
Jensen et al., 1995). Also, it has been suggested that type I fibres have -4.5-fold 
greater P-AR density than that found in type Ilb fibres and 2-fold greater than type 
Ila. Hence, the overall fl-AR density will be directly proportional to the percentage 
of the different fibre types present in any muscle (Martin et al., 1989). Although 
Martin et al. (1989) did not specify which sub-type of fl-AR was upregulated in 
these different skeletal muscles, it has previously been shown that skeletal muscles 
predominantly express fl2-ARs (Yang and McElligott, 1989; Jensen et al., 1995). As 
it has previously been shown that the damaging effects of isoprenaline on the soleus 
muscle are mediated through the P2-AR pathway (Goldspink et al., 2004), then the 
higher proportion of fl-ARs in this muscle could explain the different effects of 
catecholamines between the different muscle types, with their different fibre type 
compositions, in the present study. In contrast to these logical differences in fl-AR 
density between slow and fast skeletal muscle, the heart contains more fl-ARs than 
the soleus and could explain the extensive cell death and myocyte loss in the heart 
in the present study. qký 
Interestingly, unlike fast fibres, it is noted that both slow skeletal muscle fibres and 
cardiac muscle cells contain phospholamban (PLB), the principal inhibitor of SR 
Ca2+ uptake by SERCA2 (Simmerman and Jones, 1998). In fact, over-expression of 
the fll-ARs in PLB -/- knockout mice have an enhanced survival, decreased cardiac 
hypertrophy, fibrosis and improved cardiac function, due to a faster decay of 
intracellular calcium transients and decreased diastolic calcium levels and loads 
(Engelhardt et al., 2004; Iwanaga et al., 2004). Therefore, these data suggest a 
protective role for deleting PLB in over P-AR stimulation. The mechanism of cell 
death from catecholamines will be discussed later in this section. However, when 
taking all these explanations into account the present findings are still unclear, as it 
cannot be explained why the slow fibres present in the faster glycolytic (tibialis 
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anterior, plantaris) and mixed diaphragm muscles were not damaged by the 
catecholamines and so needs further investigation. 
In the present study, isoprenaline was found to cause greater damage to the soleus 
muscle than did adrenaline or noradrenaline. Noradrenaline is selective for fl, -ARs 
and displays a 10 to 30-fold higher binding affinity to fl, receptors, compared to fl2 
receptors (Bristow, 2000). Therefore, noradrenaline is an exceptionally cardiotoxic 
substance, producing significant myocyte damage in the heart, as cardiac muscle 
predominantly possesses fl, -ARs (Katz, 2001). However, as it is fll-AR selective, its 
effects on skeletal muscle would be expected to be much less (Figure 3.9). In 
contrast, isoprenaline and adrenaline are both fli and fl2-AR agonists with very 
similar affinities for both fl-AR subtypes. Therefore, one might anticipate that on a 
molar equivalent basis they would cause similar significant amounts of damage to 
both the heart and skeletal muscle. However, from the present study is it clear that 
isoprenaline was more potent than both adrenaline and noradrenaline. 
Pharmacologically the 3 catecholamines differ. The half-life of isoprenaline was 
designed to be greater than adrenaline and noradrenaline, so therefore adrenaline 
and noradrenaline are removed from the blood faster than isoprenaline (ti/2 ISO: 5 
minutes; Conolly et al., 1972; t1t2 Ad and NAd: 2 minutes; 
www. anaesthesiauk. com). Furthermore, adrenaline and noradrenaline have 
moderately high affinities for neuronal reuptake, which means that the majority of 
the administered hormone may not reach P-adrenergic receptors (Bristow et al., 
2001). These findings could offer an explanation as to why isoprenaline is more 
potent and induces significantly greater damage to the soleus muscle. However, 
these findings are interesting and warrant further investigation. 
4.1.2 Fibre regeneration and time course of the regenerative process 
Regardless of whether significant fibre degeneration occurred through necrosis 
and/or apoptosis as a consequence of a single injection of catecholamine, the present 
findings confirm the ability of skeletal muscle to regenerate fibres following injury. 
Indeed, the soleus muscle was able to regenerate these fibres with complete 
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restoration of the full fibre complement by 28 days. The process of regeneration and 
sequence of events described in the present study agrees with previous data from 
studies assessing the regenerative capacity of the extensor digitorurn longus (EDL) 
and soleus muscles after very severe toxic damage induced by snake venom (Harris 
et al., 1975; Whalen et al., 1990; Davis et al., 1991). The time course of 
regeneration in the present study was similar to those in previous studies, with 
respect to phagocytotic clearance of damaged fibres, the appearance of immature 
myotubes, their subsequent development into small regenerating fibres and the total 
restoration of functional fibres by 28 days. This rapid process of regeneration 
indicates the existence of an intact nervous system, microcirculation and viable 
satellite cells in this damage model. These variables are crucial for successful 
regeneration to take place (Whalen ct al., 1990; Irintchev et al., 1997; Pavlath et al., 
1998). 
The peak time of detecting regenerating fibres was 7 days following isoprenaline 
administration, with 8±2.6% of the fibres in the whole soleus undergoing 
regeneration (Figure 3.11). These findings correlate exactly with the amount of 
damage (i. e. 8.0 ± 1.8%) found in the soleus muscle within 18 hours of the 
isoprenaline administration. The findings were similar for adrenaline, but with only 
1.7 ± 0.7% of the fibres in the entire soleus regenerating at 7 days, reflecting the low 
level of damage at 1.0 + 0.5%. This confirms that there was complete regeneration 
of the fibres that were initially damaged by the 2 catecholamines. The extent of the 
injury will govern the time course of regeneration (Whalen et al., 1990). It is clear 
that following adrenaline there was less damage, and therefore the time to repair 
these damaged fibres and replace them was quicker, exhibited by complete 
restoration occurring earlier at about 14 days (Figure 3.12). 
Interestingly, the present study found the appearance of some small individual fibres 
regenerating within the basement membrane of another fibre 10 days following 
catecholamine injection (Figure 3.13, F). Fibre splitting or branching is a 
characteristic feature of muscle regeneration, and it is probably due to the 
incomplete fusion of myofibres regenerating within the same basal lamina (Bourke 
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and Ontell, 1984; Blaivas and Carlson, 1991). Furthermore, fibre splitting is 
commonly observed in patients with neuromuscular diseases, hypertrophied muscles 
and aging muscles (Alnaqeeb and Goldspink, 1986), all of which are associated with 
abnormal regenerative capacity. The latter was clearly not the case in the present 
study. The evidence of fibre branching in the present study shows smaller fibrcs that 
appear to have their own individual basement membranes, but are growing within 
another fibre, suggesting the appearance of 3 fibres within 1. This phenomenon is 
not commonly reported and morphologically different from standard described fibre 
branching and splitting. Collectively these findings suggest that there would be full 
restoration of fibres following injury (i. e. one for one), and possibly a few additional 
fibres (e. g. 3 for 1 here: Figure 3.13, F). The present study found that after 28 days 
there was full restoration of muscle fibres in the soleus muscle, i. e. 2653 +III at 
zero time, compared with 2544 ± 69 at 28 days. After 28 days only a very small 
numbers of regenerating fibres were present, suggesting that the 
degeneration/regeneration process was complete. It is possible that the appearance 
of any additional fibres (arising from 3 for 1) was balanced by some fibres that were 
damaged and irreversibly lost, without any regeneration at all. Ilowcvcr, to keep this 
matter in perspective the number of '3 in V fibres seen within the entire solcus 
muscle was very small, and hence the impact of such additional fibres on the overall 
fibre number would be small. 
In order to provide a sufficient source of new myonuclei for muscle repair, 
successful skeletal muscle regeneration relies on a source of myoblast cells (Charge 
and Rudnicki, 2004). In the present study satellite cells were marked using an 
antibody against c-met, the tyrosine kinase receptor. C-met is present on quiescent, 
activated and proliferating satellite cells (Cornelison and Wold, 1997). C-met 
positive cells were identified in sections of the soleus muscle following 
catecholamine-induced damage. Furthermore, the present study also demonstrated 
the existence of proliferating c-met positive cells, shown by the co-expression with 
BrdU. Also, transcription of the myogenic factor, Myol), indicated the muscle tissue 
specific expression of these cells (Figure 3.16). Although not quantified, these cells 
were most abundant 1-3 days after catecholamine injection. The earlier phase of 
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muscle injury was accompanied by the activation of inflammatory cells and 
myogenic cells. In the present study, both inflammatory and myogenic cells 
infiltrated and were most evident in the damaged regions of the muscle at 2 days 
(Figure 3.13, B). As immature myotubes were present at 3 days (Figure 3.13, Q, the 
differentiation of these cells and consequent fusion into myotubes must have 
occurred here. These findings strongly suggest that these c-met, BrdU, Myol) 
positive cells identified after isoprenaline injection could potentially be satellite 
cells or myoblasts, activating the repair process and giving rise to new fibres. 
The splice variant of IGF-1, MGF, has been implicated in the activation of satellite 
cells, following muscle injury (Hill and Goldspink, 2003; Hill ct al., 2003). The 
present findings provide strong evidence of a role played by MGF in the activation 
of satellite cells and consequent regeneration of skeletal muscle. MGF positive 
nuclei were present in the isoprenaline-treated soleus muscles from 3 to 72 hours. In 
contrast, no MGF-labelled nuclei were present in the control muscles (Figures 3.17; 
3.18). MGF mRNA transcripts are elevated before the splice variant IGF-111a, and 
peaked at 24 hours and 4 days after stretch-stimulation and bupivacaine induced. 
injury, respectively. Furthermore, this was before the development of peak damage 
(Hill et al., 2003). In agreement with the present findings, this suggests that there is 
a rapid autocrine 'surge' effect when degeneration begins (3 hours in the present 
study). The levels of MGF remained elevated and surged again 24 hours aftcr 
catecholamine injection (Figure 3.18). MGF mRNA levels increase prior, or at 
similar time points, to M-cadherin and MyoD mRNA and proteins, suggesting a role 
for MGF in initiating the proliferation and differentiation of satellite cells (Hill ct 
al., 2003; Hill and Goldspink, 2003). These findings agree with the present study, in 
that c-met-MyoD positive cells (predicted as activated satellite cells), were 
identified in the soleus muscle 24 hours after treatment. These data are supportcd 
further as the levels of MGF had decreased by 72 hours, once these cells had fused 
to form myotubes and regeneration had begun. These observations were similar to 
the findings of Hill et al. (2003). 
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Certain discrepancies do however exist between the present study and that of Hill et 
al. (2003). Where the present study assessed the protein expression of MGF in 
muscle sections, Hill et al. (2003) reported MGF at the level of mRNA and this 
would be expected to appear before the protein end product. However, 24 hours and 
4 days were the first time points to be analysed by Hill et al. (2003) after stretch 
stimulation and bupivacaine induced-injury, respectively, so it's entirely possible 
that MGF expression could have been apparent sooner had they looked for it. 
Interestingly, the present study found MGF to be present within the nuclei of ccils, 
but due to technical problems the present study failed to exhibit the co-exprcssion of 
MGF with satellite cell markers. However, these findings may provide first 
evidence of MGF's possible status as a transcription factor. 
The present study reveals that 14 days after catecholamine administration, the solcus 
muscle fibres were predominantly composed of the slow MIIC isofonn (Figure 
3.14). These findings confirm those reported by Whalen et al. (1990), who found 
that the slow phenotype was homogeneously expressed in the regenerated fibres of 
the soleus 21 days after snake toxin-induced injury. These findings were also 
supported by Davis et al. (1991), but 56 days after venom injury. The present 
findings could be interpreted as suggesting that the relatively few type Ila fibres 
were targeted specifically and destroyed by the catecholamines. Ilowcvcr, this does 
not seem likely considering no catecholamine-induced damage was present in any 
of the predominantly faster muscles, containing an even greater proportion of Ila 
fibres. Further support for rejecting this view is that by 28 days, the fibre 
proportions were the same as in the control muscle (Figure 3.14). 
The accumulation of the slow MHC isoform is largely dependent upon the activity 
pattern delivered by the motor neuronal innervation restored to regenerating muscle 
fibres. In the absence of innervation such fibres are inactive and accumulate adult 
fast myosin (Whalen ct al., 1990; Davis ct al., 1991). As fibres become re- 
innervated, there is a suppression of the production of the developmental and fast 
MHC, and activation of the neurally-regulated expression of slow M1ICs (Davis ct 
al., 1991). These findings agree with the present study, as it was shown that at 14 
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days after the catecholamine injection there was a suppression of the 
embryonic/neonatal MHC, with an increased proportion of newly regenerated fibres 
with centralised nuclei (a characteristic prior to re-innervation) and expression of 
slow MHCs. 
Alternatively, the accumulation of the slow phenotype in the regenerated fibres 
could arise from either the slow motor neurones being more resistant to the effects 
of the catecholamines or fast neurones transforming to slow ones during the course 
of the regeneration (Whalen et al., 1990). Because the full fibre complement and the 
fibre proportions were the same as controls by 28 days, the latter hypothesis is 
rejected. It may seem plausible in the present study, that the slow ncuroncs arc more 
resistant to the catecholamines. In that, the fast ncuroncs simply require a longer 
period to be put back and re-innervate the muscle fibres once again and therefore the 
production of the type Ila and intermediate phenotype. However, this hypothesis is 
also rejected as no fibre death was found in faster muscles, therefore the present 
findings would perhaps suggest that faster neurones are more resistant to the 
catecholamines, and slow neurones are more susceptible. 
4.1.3 Continuous infusion of catecholarnines 
As CHF patients exhibit sustained high levels of catecholamines and these have 
been implicated in the severe muscle wasting seen in some of these patients (Anker 
et al., 1997a, b), it was important to investigate the effects of chronic, as well as 
acute, exposure to the catecholarnines. 
Continuous infusion of the catecholamines (20 mmol kg"d") caused significant 
increases in body weight, muscle mass and fibre cross-sectional area (CSA), with 
these being most dramatic in the isoprcnaline-treated animals. The increase in body 
weight could be a result of oedema, exemplified by the development of heart failure 
with continuous catecholamine exposure. The present findings confirm the work of 
Ryall et al. (2003), who found that continuous infusion of 1.4 mg kg"d*l of the 92- 
agonist, fenoterol, resulted in a significantly greater body mass, EDL and soleus 
muscle weights. This was accompanied by increased fibre CSA, as well as improved 
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muscle function. The present study found that after 28 days of catecholamine 
exposure, the soleus, tibialis anterior and plantaris muscles had increased their 
masses over time and were all heavier, when compared to the placebo controls. The 
increase in muscle mass was explained directly by the increase in fibre CSA, 
measured in the soleus muscle. In keeping with their greater size, the isoprenaline- 
treated animals consumed a greater amount of food over the 28 day experimental 
period, but their appetites (food/lOOg rat) remained the same. In the first 3 days, 
both experimental groups displayed a decreased appetite, food and water 
consumptions most probably due to the initial acute stress effects of the 
catecholamines. After this brief period, everything returned to placebo control 
values, illustrating the adaptation and desensitisation of these animals, with respect 
to hunger and thirst, to the chronic exposure to the catccholamincs. 
Despite their anabolic effects, the continuous infusions of the catecholamines still 
caused small but significant amounts of fibre necrosis and apoptosis in the solcus 
over the 28 day experimental period (Table 3.6). As in acute exposure, there was 
resultant muscle regeneration in the soleus demonstrated by the prcsence of small 
myofibres positive for neonatal and embryonic MHC. However, the incidence of 
cell death and the resultant regeneration was not as great as that caused by a single, 
bolus injection. These findings could be explained by the fact that a single bolus 
injection would have a much greater immediate impact and higher plasma levels for 
a few minutes, than a daily dose infused over 24 hours. Also, although not 
measured, these findings suggest the down-regulation and/or impaired coupling of 
the fl-ARs in the soleus muscle, with chronic P-AR stimulation (Ryall ct al., 2003). 
It is interesting to note that this down regulation and desensitisation of the fl-ARs 
did not affect the physiological response, i. e. muscle hypertrophy. These findings 
would suggest that catecholamines per se may not be responsible for the anabolic 
effects seen in skeletal muscle. Interestingly, in the present study only the anabolic, 
and not myotoxic effects were apparent in the other muscles. These findings could 
suggest that the signalling pathway mediating cell death is different from the 
pathway mediating muscle hypertrophy with exposure to catecholamincs. 
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As stated, - the soleus muscle showed small regenerating fibres positive for 
embryonic/neonatal MHC, and these were present from 5 days. These were constant 
in number up to 28 days. These findings could be interpreted as a retardation of the 
development of the regenerating fibres by the sustained presence of the circulating 
catecholamines. However, the total number of fibres continued to increase over 28 
days, suggesting that these fibres did mature into the adult phenotype (Figure 3.45; 
Figure 3.46). Alternatively, the present findings could indicate that, although small, 
there is a continuous process of fibre death and regeneration occurring in the solcus 
muscle, throughout the continuous infusion of the catecholamincs. If continued for 
long enough, several cycles of degeneration-regeneration could compromise the 
ability of the resident muscle satellite cells to proliferate and replace the damaged 
fibres, due to a decreased telomeric length with consequent satellite cell senescence 
(Reimann et al., 2000; Decary et al., 2000). Furthermore, in muscular dystrophies 
the failure to regenerate fibres has been attributed to exhaustion of the proliferative 
potential of the satellite cell pool because of the continual need for satellite cell 
proliferation and fibre repair. This results in massive muscle atrophy, infiltration of 
collagen and fat and muscle weakness (Reimann et al., 2000). In the present 
investigation, the effects of chronic catecholamine exposure were not studied 
beyond 28 days. However, it would be interesting to investigate whether similar 
muscle wasting through fibre loss would occur if the muscles were exposed for a 
greater period, i. e. creating further cycles of degeneration and regeneration. This 
could be the case in CHF, with the sustained high levels of catecholamines 
compromising satellite cells and a progressive loss of fibres resulting in the dramatic 
fall in muscle mass and weakness. Reduced activity levels would exacerbate the 
situation as well as causing physiological atrophy of the remaining viable fibres. 
In light of recent advances with cellular therapy (Torrente et al., 2001), it is 
questionable whether the pool of muscle stem cells is limiting and can be reasonably 
attributed to the progression of muscle wasting. This is because of the ability of 
other cells e. g. BMDCs to give rise to satellite cells and consequently muscle fibres 
(Ferrari et al., 1998; LeBarge and Blau, 2002), as well as the existence of a side 
population of muscle stem cells possibly originating in the vasculature (Asakura et 
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al., 2001). Furthermore, it would be interesting to investigate whether there could be 
an optimal dose of catecholamines, which induces muscle hypertrophy but does not 
cause cell death. 
Insulin-like growth factor-1 and MGF increases the rate of protein synthesis, 
thereby increasing muscle hypertrophy and mass (Musaro et al., 2001; Goldspink, 
2001), as well as promoting the activation and subsequent proliferation and 
differentiation of muscle satellite (stem) cells (Allen and Boxhorn, 1989; 
Chakravarthy et al., 2000; Rabinovsky et al., 2003; Hill et al., 2003). Therefore, 
muscle repair and hypertrophy appear to involve at kast some of the same 
signalling pathways. Accordingly, it has been questioned whether local muscle 
damage is a pre-requisite for muscle hypertrophy (Hill and Goldspink, 2003). In the 
present study catecholamine-induced damage to the soleus muscle caused an 
uprcgulation of MGF expression, in order to activate the satellite cell pool to ensure 
the regeneration of muscle fibres (Figure 3.18). Due to its role in muscle 
regeneration it is conceivable, yet speculative, that local IGF-1 is also elevated 
following catecholamine damage. Therefore, the anabolic effects of catecholamincs 
could be attributed to an autocrine/paracrine elevation in IGF-1 and its splice variant 
MGF. These factors would serve to activate the satellite cell pool and ensure the 
regenerative process, while simultaneously causing muscle hypcrtrophy by 
mediating part of their effects directly through the differentiated muscle fibres. 
Hence, the muscle adaptation -iLseen following catecholamine exposure is a 
manifestation of repeated injury and repair resulting in over-expression of the two 
growth factors. Furthermore, it has been reported that satellite cells play a critical 
role in the hypertrophic response, giving rise to new myonuclci (Barton-Davis ct al., 
1999). It has been reported that in trained human subjects with fibre hypcrtrophy 
there is a significant increase in the number of fibres which are stained for 
embryonic and fetal MHCs (Kadi and Thornell, 2000). Therefore, the muscle may 
adapt to training through hypertrophy and hyperplasia (Kadi and Thomell, 2000). In 
the present study, at 28 days there was a slight elevation for fibre number above 
control in the soleus, possibly suggesting an adaptive response involving both 
hypertrophy and hyperplasia, caused by IGF-1 and MGF expression. 
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These mechanisms could possibly explain the hypertrophic response in the soleus 
muscle. However, it may not be as straightforward for the other muscles, as they 
were not damaged as a result of the catecholamines, but still exhibited a 
considerable increase in muscle mass. A possible explanation is that due to 
signalling of damage from the soleus muscle there is a paracrine (systemic effect) 
effect of IGF-I, resulting in significant hypertrophy to the other muscles in the 
body. This concept seems particularly warranted due to the findings that chronic 02- 
AR stimulation by clenbuterol caused increased soleus muscle mass (16%) mediated 
by the local production of IGF- I by myocytcs, which subsequently had an autocrinc 
or paracrine effect in eliciting muscle hypertrophy (Awede ct al., 2002). 
Alternatively, another mechanism not involving IGF-I or its splice variants, could 
explain the anabolic effects of catecholamines. Therefore, the possible direct and 
indirect mechanisms of the anabolic effects of catecholamines warrant further 
investigation. Like their #2-AR counterpart, clenbuterol, catccholamincs could 
potentially be considered for clinical application in ameliorating muscle wasting, 
e. g. as seen with ageing and disease states such as heart failure and cancer. 
However, the potential beneficial effects of exposure to catecholamincs are 
counteracted by the severe damaging effects to the heart. 
4.2 Cardiomyocyte Death and Regeneration 
The accepted paradigm considers the adult mammalian heart as a post-mitotic 
organ, which possesses a relatively constant number of myocytcs from shortly after 
birth to adulthood and senescence, dismissing the occurrence of new myocyte 
formation. On this basis, pathologic remodelling of the cardiac left ventricle has 
been so far described as the product of different on-going processes which include: 
myocyte slippage and chamber dilation; fibrosis and scar formation; excessive 
accumulation of interstitial matrix; increased wall stress; myocyte hypertrophy; 
neurohormonal activation; cytokine release; progressive myocyte hypertrophy; cell 
apoptosis and necrosis. The results of the present study shed new light on the 
pathophysiology of ventricular remodelling. Indeed, it has demonstrated that 
myocyte cellular hyperplasia through activation and differentiation of cardiac stem 
cells is a significant phenomenon that participates in the wall repair after diffuse 
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myocardial injury in the presence of a patent coronary circulation. This reinforces a 
new view that considers the heart as a self-renewing organ, able to heal itself 
(Nadal-Ginard et al., 2003). 
4.2.1 Cardiomyocyte death and loss 
Cardiovascular disease in both the human myocardium and animal models have 
demonstrated that a variety of pathological states of the heart are associated with 
myocyte apoptosis, including myocarditis (Blankenberg et al., 1999), transplant 
rejection (Koglin et al., 1999), myocardial ischemic injury (Olivetti et al., 1996) and 
heart failure (Olivetti et al., 1997). Late in heart disease myocyte death exceeds 
regeneration resulting in the reduction in the total number of LV myocytes (Kajstura 
et al., 1995). The imbalance between cell death and cell multiplication in favour of 
the former might be critical in the development of cardiac failure. Since it is known 
that heart failure patients exhibit an elevated circulating level of catecholamines, 
and as the use of fl-AR antagonists have a dramatic impact on both clinical 
outcomes and the progression of the underlying myocardial failure (Bristow, 2000), 
it has been suggested that increased sympathetic activity may play an important role 
in the pathophysiology of myocardial failure, via the stimulation of fl-ARs. 
It is well documented that catecholamines are cardiotoxic (Rona et al., 1959; Todd 
et al., 1980; Teerlink et al., 1994; Heap et al., 1996), causing myocyte necrosis 
(Benjamin et al., 1989) and apoptosis in vitro (Communal et al., 1998) and in vivo 
(Shizukuda et al., 1998; Xi et al., 2000). Catecholamine-induced cardiomyocyte 
apoptosis is mediated through fl-ARs, specifically through the fli-AR subtype 
(Zaugg et al., 2000; Goldspink et al., 2004). This involves increases in cAMP and 
PKA-mediated increase in Ca2+ influx (Communal et al., 1998). Increased cytosolic 
Ca? + affects mitochondrial membrane permeability and triggers the release of 
apoptogenic factors, including the initiator caspase-9 from the damaged 
mitochondria (Zaugg et al., 2000). This in turn activates the effector caspases -3, -6 
and -7 which act downstream in the common pathway to carry out the final 
biochemical changes seen in apoptosis (Kang and Izumo, 2003). Additionally, 
myocardial apoptosis mediated through fl-AR signalling appears to involve both the 
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activation of the MAPKs (i. e. JNK, c-Jun, N-terminal kinase and p38) and increased 
production of reactive oxygen species (Sugden and Clerk, 1998; Siwik et al., 1999). 
In the present study, extensive focal cell death was found in the LV after 
isoprenaline injection, occupying 17 ± 4% of the myocardial area after I day. 
Furthermore, the present findings describe caspase-3 positive cardiomyocytes in the 
hearts of isoprenaline-treated rats. These were most evident just 3 hours following 
the single 20 mmol kg-1 injection (Figure 3.7), and decreased thereafter. These 
findings were similar for dUTP labelled myocytes, showing only 0.4% at 24 hours 
and decreasing to 0.15% by 72 hours (Table 3.3). Therefore, through the certified 
use of both techniques, isoprenaline caused myocardial apoptosis, which was 
evident in a time-dependent manner. The resultant effect of isoprenaline-induced 
necrotic and apoptotic death was the significant loss of myocytes in the LV (Figure 
3.22). 
Continuous infusion of catecholamines in the rat caused significant cardiomyocyte 
necrosis and apoptosis, although this was not as severe as that following a single 
injection. This further supports the notion of desensitisation and/or downregulation 
of P-receptors with chronic sympathetic activation; a protective mechanism that is 
found in heart failure (Vatner et al., 1999). Despite the reduced levels of cell death 
reported in the present study, continuous exposure to the catecholamines resulted in 
a marked hypertrophic response, in the heart. This was apparent as an increase in 
ventricular mass occurring rapidly within 5 days and increasing further with time 
(Figure 3.40). This was more severe in the isoprenaline-treated animals, clearly 
demonstrating the synthetic catecholamines greater potency on hypertrophy as well 
as cell death. This cardiac hypertrophy was coupled with increased myocardial 
collagen content (Figure 3.47; 3.48), possibly due to cardiomyocyte death (necrosis) 
and reparative fibrosis. The effects of chronic sympathetic stimulation on the heart 
are mainly mediated through the P-ARs, as fl-AR blockade significantly prevented 
these deleterious adaptations (Asai et al., 1999; Karoor et al., 2004). The 
mechanisms responsible for these changes have been attributed to abnormal 
cardiomyocyte Ca2+ transients related to decreased expression of the SR protein, 
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junctin (Engelhardt et al., 2001; 2004), the cardiac Na+-H+ exchanger I (NHEI) and 
increased sodium load (Engelhardt et al., 2002), and phospholamban (Iwanaga et al., 
2004). Increased circulating catecholamines have been implicated as a primary 
causative factor in the development of cardiomyopathy and early mortality (Dash et 
al., 2001). Although no measurement of function was obtained here, the present 
findings exhibit the development of a cardiomyopathy with chronic P-AR 
stimulation, confirming the studies of others (Benjamin et al., 1989; Kudej et al., 
1997; Morisco et al., 2001; Engelhardt et al., 1999; 2001; 2002; Geng et al., 1999). 
The SR calcium-release channel is a key component in muscle excitation- 
contraction (EC) coupling (Wehrens and Marks, 2003). The release of calcium from 
the SR through ryanodine receptor (RyR) channels initiates contraction of the 
muscle fibre. After depolarization of the myocyte membrane, voltage-gated L-type 
Ca 2+ channels are activated in the sarcolemmal membrane encompassing the 
transverse T-tubule. The ensuing Ca2+ influx triggers a much greater Ca2+ efflux 
through RyRs on the SR via a process termed Ca 2+_induced Ca 2+ release, inducing 
cell contraction. The increase in cytosolic Ca 2+ concentration during a contraction is 
immediately followed by Ca2+ removal, resulting in deactivation of the contractile 
machinery and muscle relaxation. Cytosolic Ca2+ is pumped back into the SR by SR 
CPýATPase (SERCA2), which is regulated by PLB (Simmerman and Jones, 1998). 
Increased levels of circulating catecholamines activate fl-ARs, elevate intracellular 
cAMP, and activate PKA. PKA phosphorylation modulates RyR and PLB, function 
both in vitro and in vivo (Marx et al., 2000), inducing in the short term, myocyte 
contractility. In contrast, in the long term, mal-adaptation of this classic 
physiological pathway plays an important role in the pathophysiology of heart 
failure, which is a chronic hyper-adrenergic state. Indeed, it has been previously 
found that the RyR is PKA-hyperphosphorylated in end-stage heart failure (Marx et 
al., 2000). Defective Ca2+ handling has been implicated in many pathological 
conditions and the spatial organisation of the RyRs appear to be of key importance 
in determining cell fate. Notably, hyperphosphorylation of RyR induces myocyte 
apoptosis (Jayaraman and Marks, 1997; George et al., 2003). Infusion of 
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isoproterenol results in PKA phosphorylation of RyR in the rat, indicating that 
systemic catecholamines can activate phosphorylation of RyR in vivo (Reiken et al., 
2004). Therefore, it is highly tempting to speculate that the same mechanism has 
been operating to induce cell death in cardiac myocyte and soleus muscle fibres 
following catecholamine administration and exposure, in the present study. 
A universal characteristic of end-stage failing myocardium is depressed SR Ca 2+ 
cycling, caused by decreased expression of the cardiac SR Ca2+ ATPase 
(SERCA2a), and/or a relative overabundance of the SERCA2 inhibitory protein 
PLB. Furthermore, increased PLB expression in slow-twitch skeletal muscle is 
associated with impaired contractile function and muscle remodelling (Song et al., 
2004). More importantly, SERCA2a over-expression and PLB depletion have been 
shown to have beneficial effects on contractility in heart failure (Chaudhri et al., 
2002; Del Monte et al., 2002). Interestingly, in cardiac and slow skeletal muscle SR, 
but not in fast skeletal muscle SF, the Ca 2+-ATPase (SERCA2) is subject to 
regulation by PLB (Simmerman and Jones, 1998). It is widely recognized that 
dephospho-PLB inhibits SERCA2 function through physical interaction with the 
enzyme, and dissociation of the two proteins upon phosphorylation of PLB by PKA 
relieves the inhibition. On this basis, one of the possible mechanisms of 
isoprenaline-induced apoptosis and necrosis selectively in the rat heart and soleus 
muscles could relay on the presence of PLB only in cardiornyocytes and slow twitch 
skeletal fibres (abundant in the soleus), opposed to the absence of this protein in the 
fast fibres (Simmerman and Jones, 1998). Reiken et al. (2004) examined hearts 
from a rat model in which heart failure develops 6-month post-myocardial infarction 
(PMI). Six months PMI, these hearts showed PKA hyperphosphorylation of RyR 
and PKA hypophosphorylation of PLB resulting in Ca2+ myocyte cytoplasmic 
overload (Reiken et al., 2004). This provides evidence that RyR and PLB are 
differentially regulated with respect to PKA-dependent phosphorylation during 
hyper-adrenergic state of heart failure (Reiken et al., 2004). Therefore, the same 
mechanism could partially explain why catecholamines cause significant necrosis 
and apoptosis to cardiornyocytes and the predominantly slow soleus skeletal muscle, 
while not affecting faster muscles. 
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4.2.2 Myocyte regeneration 
Diffuse myocardial injury in the presence of a patent coronary circulation, was 
associated with an increase in the number of myocyte nuclei in the LV synthesizing 
DNA. At 6 and 14 days after injury, this response involved I and 2% of the LV 
myocyte nuclei, respectively. Since the LV possesses 33 x 106 and 34 x 106 
myocytes by 6 and 14 days, then 330 000 and 680 000 nuclei were undergoing DNA 
synthesis, respectively. Importantly, a small fraction of myocyte nuclei (0.01% in 
the LV), showed BrdU labelling in control rats, implying that DNA replication was 
occurring in -5300 myocyte nuclei under control conditions. Therefore, DNA 
synthesis is normally present in a population of differentiated myocytes and this 
process is greatly potentiated by isoprenaline-induced injury. 
The observations arising from this investigation are in contrast with a previous study 
carried out by Soonpaa and Field (1994) who found that in response to isoprenaline- 
induced cardiac hypertrophy, cardiomyocytes isolated from adult mice did not 
synthesise DNA. There are however certain methodological discrepancies between 
the present study and that of Soonpaa and Field (1994). First, in the latter study the 
isolation procedure yielded only big, fully mature cardiomyocytes making it 
impossible to analyse the entire, heterogeneous myocyte population. In the present 
study the majority of BrdU labelled myocytes were of small size. By using 
immunohistochemistry on tissue sections, the analysis of all myocytes could be 
achieved, including those whichwere discarded or missed by Soonpaa and Field 
(1994) during their isolation procedure. Second, Soonpaa and Field (1994) 
intentionally induced hypertrophy through continuous infusion of isoprenaline for 7 
days delivered via osmotic mini pumps. But this occurred in the absence of necrosis, 
which could prove significant for new myocyte formation. Also, chronic 
catecholamine administration could have minimised the detection of DNA 
replicating myocytes by progressively killing these myocytes. It is somewhat 
surprising that Soonpaa and Field (1994) failed to find any 31-1-thymidine labelling 
of myocyte nuclei in an animal model, that under physiologic conditions has a 
mitotic index of 47 myocyte nuclei/million (Oh et al., 2003). If it is assumed that the 
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cell cycle last -24 hours then the percentage of thymidine labelled nuclei should be 
0.1%. Therefore, these data can be questioned. 
These findings are in direct disagreement with the present study and also that 
described by Rumyanstev (1991). Rumyanstev (1991) reported reactive DNA 
synthesis after bolus isoprenaline administration which induced focal necrosis 
within the myocardiurn. These findings, and that from the present study, raise the 
possibility that DNA replication is injury mediated. In fact, it has been shown by 
KaJstura et al. (1998) that human hearts with ischaernic or idiopathic dilated 
cardiomyopathies had a greater number of myocytes undergoing mitosis, than 
control hearts. Also, proliferating human myocytes (ki67-positive) and events 
characteristic of cell division (i. e. the formation of mitotic spindles and contractile 
rings, karyokinesis and cytokinesis) were found in regions adjacent to, and distant 
from, the infarcted area (Beltrami et al., 2001). Together these findings lend support 
for an injury mediated response for new myocyte formation, as these processes exist 
more in the viable myocardiurn after a myocardial infarction, than in control hearts. 
It has recently been postulated that the heart is not a post-mitotic organ, and that 
myocyte death and regeneration are part of the normal homeostasis of the heart. In 
addition to hypertrophy, new myocyte generation predominates over cell death and 
contributes significantly to organ growth during normal cardiac growth to adulthood 
in both animals and humans (Nadal-Ginard et al., 2003). This is supported by the 
detection of myocytes undergoing mitosis in normal, control rat (Overy and Priest, 
1966), mice (Anversa and Kajstura, 1998) and human hearts (Kajstura et al., 1998). 
Subsequently, DNA synthesis persists in the adult heart (Kajstura et al., 1994; 
Anversa and Kajstura, 1998) and even though at a low frequency, this could 
potentially be sufficient to sustain cardiac function in a non-diseased heart during 
adulthood. Also, the increase in myocyte numbers in the adult heart is an under 
estimation due to concurrent cell death seen with maturation (Anversa et al., 1990; 
Kajstura et al., 1996; Anversa and Olivetti, 2002). The finding of myocyte cell death 
in the adult heart again supports the concept of cardiac regeneration, because if 
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myocyte renewal did not take place then the heart would simply disappear within a 
few decades of life (Nadal-Ginard et al., 2003). 
In the present study, BrdU immunofluorescence localisation in nuclei cannot in 
principle discriminate whether the DNA synthetic activity is coupled with nuclear 
hyperplasia or polyploidy formation. It has previously been reported that 3 months 
after coronary constriction myocyte growth was not accompanied by a change in the 
distribution of ploidy, and DNA replication was at most minimally involved in the 
polyploidisation of ventricular muscle cells (Kajstura et al., 1994). In support for 
this, there is no increase in the number of multinucleated myocytes after puberty in 
both animals and man (Alder and Friedburg, 1986; Anversa and Olivetti, 2002). 
Therefore, if the DNA-replicating myocytes underwent karyokinesis without 
cytokinesis, there would be an increase in the number of multi-nucleated myocytes 
with age, which is not the case. However, despite these findings it cannot be 
excluded that this phenomenon may be a significant incident in the present study. 
Furthermore, it could be argued that the finding of BrdU positive myocytes 
represent DNA repair and not actual new myocyte formation. However, the concept 
of BrdU labelled myocytes representing significant DNA repair occurring in these 
myocytes is refuted due to the detection of ki67 in the nuclei of myocytes, following 
isoprenaline injury. Ki67, a nuclear protein expressed in all stages of the cell cycle 
(except G,, ) and not involved in DNA repair, has also been detected in myocytes by 
others investigating the adaptation of the heart in various pathological states 
(Beltrami et al., 2001; Anversa et al., 2002; Quaini et al., 2002; Urbanek et al., 
2003). 
Interestingly, the present study identified that all BrdU and ki67 positive myocytes 
were small. This altered the distribution of myocyte size in the LV, so that a higher 
number of smaller myocytes were present 14 days after injection, when compared to 
control hearts. Previously it has been shown that young adult rats which have been 
subjected to a myocardial infarction possess small replicating myocytes, similar in 
appearance to those identified in the present study, 7 days after infarction (Nadal- 
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Ginard et al., 2003). In the present study, these small BrdU labelled myocytes 
increased in size over time following isoprenaline injection (Figures 3.30; 3.3 1), but 
they never reached the size of a BrdU negative myocyte in 14 days. These findings 
are highly significant. First, importantly they show the generation of new myocytes, 
and secondly they demonstrate the progressive maturation of these myocytes into 
the adult phenotype, with time. 
It should be noted that the presence of a patent coronary circulation could have 
dramatically and positively contributed to the generation and progressive maturation 
of these newly formed myocytes. In contrast, myocardial damage produced by 
coronary occlusion with consequent reduced or absent blood flow could explain the 
little evidence of myocyte regeneration in ischemic cardiac disease. Furthermore, 
the presence of smaller BrdU positive myocytes, strongly demonstrates that this 
DNA synthesis is actual evidence of new myocyte generation after bolus 
administration of isoprenaline. If they were involved in DNA repair or ploidy 
formation, these cells would be expected to be the same size as the adult BrdU 
negative myocytes, not small and increasing in size over time. In parallel, the 
present study found a significant increase in myocyte number after 14 days, 
compared to the loss seen at 3 days (Figure 3.22). These findings support the notion 
that the heart is able to repair itself, replacing a proportion of lost myocytes 
following isoprenaline-induced cell death and loss, and resulting in a compensatory 
increase in myocyte number. This correlates with the restored ventricular function 
14 days after isoprenaline administration, as demonstrated by the normalisation of 
LVEDP (Figure 3.21). 
Isoprenaline-induced injury altered the distribution of myocyte size in the LV, 
shifting the curve to the left (Figure 3.25). These findings add further support for the 
generation of new myocytes which are smaller than existing myocytes, but also 
imply that larger and perhaps older myocytes are more susceptible to the toxic 
effects of isoprenaline. Their loss would also leave less large cells in the 
myocardium. after isoprenaline injection. Cell death has been shown to correlate 
with the size of the cell and the level of cellular senescence (Brenner et al., 1998). It 
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has been shown that large myocytes are older, do not react to growth stimuli and are 
prone to activate the cell death pathway. In contrast, smaller cells are younger, 
possess the ability to undergo hypertrophy, cell division and are less susceptible to 
cell death. 
In the present study the small, newly formed myocytes were most abundant in the 
severely damaged sub-endocardial layer of the LV wall. Due to the transmural 
distribution of myocardial blood flow across the ventricular wall, the 
subendocardium is more vulnerable to reduced coronary perfusion than the rest of 
the myocardium. Isoprenaline injection causes an elevated LVEDP (Figure 3.21) 
and reduced endocardial-to-epicardial flow ratio. These haemodynamic changes 
superimposed on the primary myotoxic effect of isoprenaline creates greater cell 
death and loss in the sub-endocardium, compared to the other layers. These findings 
suggest that cell death could provide the signalling mechanism for initiating new 
myocyte formation. This is supported by a simultaneous decrease in myocyte 
apoptosis and an increase in the number and growth of BrdU labelled myocyte 
nuclei with time. Indeed, Bischoff (1986) showed that skeletal muscle regeneration 
is initiated by the release of an endogenous mitogen from traumatised, crushed adult 
muscle. Furthermore, it is worth noting that tissue-specific micro-environmental 
cues delivered by stromal components influence the fate of both adult stem cells and 
their progeny (Spradling et al., 2003). 
IVL 
The question now is where do these newly formed myocytes come from? There are 
two potential sources; cells which are resident within the heart, i. e. cardiac stem 
cells (Beltrami et al., 2003; Oh et al., 2003; Matsuura et al., 2003), or systemic cells, 
i. e. BMI)Cs which continuously colonise the myocardium and contribute to 
myocyte renewal (Nadal-Ginard et al., 2003). It has previously been shown that 
BMDCs can give rise to new myocytes either when injected into or stimulated to 
'home to' the heart by cytokine administration, following a myocardial infarction 
(Orlic et al., 2001a; 2001b). Supporting these findings, Eisenberg et al. (2003) 
reported the differentiation of hematopoietic progenitor cells into cardiomyocytes in 
vitro. Interestingly, blood cells that are normally recruited to damaged tissue, i. e. 
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macrophages, also demonstrated an ability to integrate into contractile heart tissue 
and underwent cardiac differentiation (Eisenberg et al., 2003). This concept in 
skeletal muscle regeneration is supported by the work of Camargo et al. (2003). In 
the present study, the regeneration of new cardiomyocytes by myeloid cells 
(Eisenberg et al., 2003; Camargo et al., 2003) cannot be neglected. Considering the 
number of interstitiurn cells in the myocardiurn increased with time (Table 3.2), and 
immunostaining showed many cells positive for CD68 in isoprenaline-treated hearts 
(data not shown) this prospect seems conceivable and warrants further investigation. 
'Me present study identified clusters of c-kit positive (c-ki? os) cells in the 
myocardium of both control and isoprenaline-treated rats. These primitive cells have 
been identified by others in the hearts of humans (Quaini et al., 2002; Urbanek et 
al., 2003), rats (Beltrami et al., 2003) and mice (Oh et al., 2003; Matsuura et al., 
2003; Torella et al., 2004) and have been termed cardiac stem cells (CSCs). These 
cells were found to be lineage negative (Beltrami et al., 2003) and represented 
approximately 0.6 per mm 2 myocardium (Torella et al., 2004), agreeing with the 
present findings of 0.7 per min 2 myocardium in control rat hearts (Figure 3.33). As a 
result of the isoprenaline-injury, these cells became activated and proliferated, as 
evidenced through the expression of ki67 in the nuclei of c-kitpos cells (Figure 
3.34). So after 3 and 6 days they were significantly elevated above control values. 
Since the appearance of small BrdU labelled myocytes began at 3 days, and reached 
their peak by 14 days, while themumber of c-kitpos cells decreased from 6 days, 
these findings suggest that these newly formed myocytes were derived from cardiac 
progenitor cells. 
In the present study, many of the cardiac progenitor cells (c-ki? os) expressed the 
transcription factor, GATA4, indicative of early stage cardiac myogenic 
differentiation (Figure 3.35), and small amounts of sarcomeric proteins in the 
cytoplasm (Figure 3.27). This phenotype strongly suggests that these cells represent 
amplifying myogenic precursors and/or progenitors derived from the activation of a 
more primitive stem cell. The expression of transcription factors associated with 
early cardiac development, such as GATA4 and particularly the expression of 
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cardiac specific sarcomeric proteins, by some cells is evidence of their cardiac 
myogenic potential and fate. That cells with similar characteristics have been 
identified in the human (Quaini et al., 2002; Urbanek et al., 2003), rat (Beltrami et 
al., 2003) and mouse (Forella et al., 2004) lends support for the present findings. 
Urbanek et al. (2003) identified myocyte precursors in human cardiac hypertrophy, 
which were very small cells positive for c-kit on the surface membrane, MEF2 in 
the nuclei and a thin cytoplasmic layer positive for cardiac myosin. These were 
confirmed by Torella et al. (2004) in the hearts of 4 month old mice. In the present 
study, the appearance of cells positive for a thin layer of ci-sarcomeric actin and ki67 
in the nuclei were evident (Figure 3.27, asterisk), suggesting an extremely immature 
cardiomyocyte phenotype. Unfortunately, these cells were not stained for c-kit, so 
precise conclusions cannot be made on their exact status and origin. 
Ile present study revealed increased MGF, the splice variant of IGF-1, expression 
in the myocardium. This was most pronounced 24 hours after the isoprenaline 
injection and remained elevated thereafter (Figure 3.20). These findings could have 
implications for the role of MGF in the local control and regulation of both myocyte 
cellular hypertrophy and hyperplasia, perhaps similar to the previous described 
effects of IGF-1 in the heart (Donohue et al., 1994; Ito et al., 1993; Reiss et al., 
1996). Donohue et al. (1994) suggested that IGF-1 may participate in initiating 
ventricular hypertrophy. Similarly but in neonatal myocytes in culture, Ito et al. 
(1993) found IGF-1 increased the mRNA levels of myosin light chain-2 and 
troponin I as early as 60 minutes, with maximum levels after 6 hours. These were 
then maintained for as long as 24 hours. Furthermore, the cell size as evaluated 
morphometrically was almost doubled after 48-hour treatment with IGF- I (Ito et al., 
1993). In contrast to these data, Reiss et al. (1996) reported that transgenic mice in 
which the cDNA for the human insulin-like growth factor 113 (IGF-IB) was placed 
under the control of a rat oWHC promoter, significantly increased myocyte number 
and BrdU labelled myocytes after a period of 45 days. However, myocyte cell 
volume was comparable in both transgenic and control mice at all ages. These 
findings were confirmed by Torella et al. (2004) who showed increased BrdU 
incorporation in cardiomyocytes of IGF-I transgenic mice with increasing age. 
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Therefore, IGF-I over-expression increased the extent of myocyte formation in the 
heart, and this adaptation was consistent with the mitogenic effect of this growth 
factor in several cell types, e. g. skeletal muscle. 
As MGF has been shown to stimulate satellite cell activation and proliferation 
(Yang and Goldspink, 2002; Hill et al., 2003), as well as muscle hypertrophy 
(Goldspink, 2001), it is plausible that given the time course of MGF expression in 
the heart, MGF had a significant mechanistic effect initiating cardiomyocyte 
hypertrophy and formation. Interestingly, Goldspink and Goldspink (2003) reported 
the protective effects of MGF against apoptosis, through Akt phosphorylation in 
cardiac myocytes. In addition, MGF may play a role similar to its effects in skeletal 
muscle (Hill et al., 2003) in the activation of the CSC pool. Indeed, HGF (c-met) 
and IGF-I receptors have been described on the surface of CSCs (Chimenti et al., 
2002). Moreover, local injections of HGF and IGF-1 aid the repair of infarcted 
hearts in mice, with the numbers of viable cardiac stem cells increasing in the 
border zone, the infarcted region and the remote surviving portion of the wall. This 
results in myocyte regeneration two weeks later, with the new myocardium 
containing parenchymal cells and coronary vessels consisting of resistance arterioles 
and capillaries (Chimenti et al., 2002). Notably, MGF and other growth factors, 
elevated after isoprenaline-induced injury could be significant underlying factors 
involved both in CSC proliferation and CSC-mediated myocyte renewal, thereby 
promoting the reparative process in the heart. However, these suggestions are purely 
speculative and further investigations are necessary. 
4.2.3 Myocyte hypertrophy 
Findings in this investigation indicate that myocyte hypertrophy occurred in the LV 
after isoprenaline-induced diffuse myocardial damage. A 58% increase in myocyte 
cell volume in the sub-endocardial layer was observed 3 days after isoprenaline 
injection. Although this decreased after 6 and 14 days (30%), it still remained 
greater than myocyte cell volume in control hearts. When the distribution of 
myocyte size was studied 14 days after isoprenaline injection, the distribution 
pattern changed to indicate an increase in number of both smaller and larger 
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myocytes (Figure 3.25). These findings are supported by Rumyanstev (1991) who 
reported cardiomyocyte hypertrophy following two 85mg injections of isoprenaline 
kg". Chronic fl-AR stimulation results in myocardial hypertrophy (Benjamin et al., 
1989; Engelhardt et al., 1999; 2002) and the present study shows that with chronic 
exposure of catecholamines there is an increase in heart weight. Therefore, the 
hypertrophic myocyte response seen in the present study with bolus isoprenaline 
administration could be mediated through the #-receptor pathway. Karoor et al. 
(2004) found that fl-blockade administration to Gsa over-expressed mice 
significantly reduced the phospho-kinase levels of p38 MAP kinase, p70S6K , ERK, 
Akt and JNK, which were related to the growth and death of cardiomyocytes in 
these mice. Furthermore, Asai et al. (1999) showed that fl-AR blockade with 
propranolol in G,,,, over-expressed mice arrested myocyte hypertrophy, fibrosis and 
apoptosis and decreased mortality rates. 
However, the cellular hypertrophy reported here is most likely to be reactive, being 
a compensatory response for the extensive loss of myocytes. The exact mechanism 
of this isoprenaline-induced myocyte hypertrophy in the present study needs further 
investigation. Particularly as the elevated levels of MGF could exert a hypertrophic 
effect on cardiomyocytes similar to that shown in skeletal muscle (Goldspink, 
2001). Interestingly, it has recently been proposed that clenbuterol, a selective 02- 
AR agonist, causes increased levels of IGF-1 in cardiomyocytes (Yacoub, 2004; 
personal communications) as well as in skeletal muscle (Awede et al., 2002), 
implicating a process of fl-AR stimulation and the local production of these growth 
factors. 
Similar to that observed after discrete myocardial infarction, Teerlink et al. (1994) 
showed myocardial hypertrophy and ventricular dilation that was out of proportion 
to LV mass, when rats were treated with two massive doses of isoprenaline. In the 
present study LV weight was also significantly increased I and 3 days after the 
bolus administration of isoprenaline. It then returned to normal levels after 14 days 
(Figure 3.22). These findings could be explained by oedema being present I and 3 
days after injection. A disproportion existed between the increases in LV weight 
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(7%) and the expansions in myocyte cell volume after the acute exposure to 
isoprenaline. 'Mis apparent inconsistency reflects the impact of myocyte loss, 
myocyte hyperplasia and myocyte cellular hypertrophy on the overall response of 
the myocardium. to this diffuse injury. 
In functional terms the present study showed an increased LVEDP and decreased 
+dP/dt and -dP/dt I day after the isoprenaline injection. These haernodynamic 
responses are indicative of acute overt heart failure. However, interestingly these 
parameters started to improve after 3 days and had almost returned to normal values 
by 14 days (Figure 3.21). This subsequent recovery of cardiac function was due to 
the regenerative capacity of the ventricle, which through myocyte hypertrophy 
(Teerlink et al., 1994) and formation (Urbanek et al., 2003), reconstitutes the 
myocardial mass and restores normal cardiac haemodynamics. However, it could be 
possible that this improved function may not be preserved beyond 14 days. The 
analysis of a later time point, e. g. 28 days, would enable greater insight into whether 
these improvements in cardiac performance persist, or not, due to further myocyte 
hyperplasia and hypertrophy. 
These findings are the first of their kind to report reactive DNA synthesis and new 
myocyte formation following isoprenaline-induced myocardial damage. Most 
importantly, this is the first evidence of successful myocardial repair without the 
need for any treatment. Thus reinforcing the concept of the heart as a self-renewing 
organ. Indeed, previous reports which have examined human hearts (Kajstura et al., 
1998; Beltrami et al., 2001; Urbanek et al., 2003) and animal models (Beltrami et 
al., 2003) injured by myocardial infarction or aortic constriction and in heart failure 
have shown myocyte regeneration in the myocardium, but without maintenance of 
cardiac function. The difference could relate to the presence of a patent normal 
coronary circulation in the present model, which envisions the absolute need of a 
normal blood flow for an effective myocardial repair through CSC activation. 
Therefore, this model could offer further valuable insight into the process and 
control of myocyte cellular renewal. 
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Acute Exposure of Catecholamines 
02 
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RyR hyperphosphorylation lGF 
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mitochondria (ROS? ) 
Stress MAPKs 
increased P-receptors 
Fibre Death Fibre regeneration 
Figure 4.1 Schematic representation of the effects of acute catecholamine 
exposure on skeletal muscle. 
In the skeletal muscle the effects of catecholamine exposure are mediated through 
the #2 receptors. A single 20 mmol injection of either isoprenaline or adrenaline kg" 
induced fibre death, via necrosis and apoptosis, in the soleus muscles of the rat. It is 
speculated that the underlying, % mechanism of fibre death could relate to 
hyperphosphorylation of the RyR. In marked contrast, the faster glycolytic muscles 
(tibialis anterior, plantaris and diaphragm) were not damaged by catecholamines. 
This phenomenon could relate to the absence of PLB, involved in SR Ca 2+ re- 
uptake, less fl-receptors and/or less mitochondria in fast twitch fibres. The soleus 
muscle replaced its lost fibres with new fibres through activation and subsequent 
proliferation of its satellite stem cell pool. These processes are most probably 
governed by paracrine/autocrine regulatory mechanisms of growth factors, IGF and 
its splice variant MGF. 
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Continuous Exposure of Catecholarnines 
1 02 
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Decreased Muscle Function 
Figure 4.2 Schematic representation of the effects of continuous exposure of 
catecholamines on skeletal muscle. 
Continuous exposure of cateqholamines caused a down-regulation and/or 
desensitisation of the fl-receptors. Continuous exposure resulted in fibre death in the 
soleus muscles, but not the faster muscles. There was significant hypertrophy to 
both slow and fast skeletal muscles, and this effect was probably mediated through 
the MAP kinase pathways activated through chronic fl-AR stimulation and/or the 
growth factors IGF and MGF. Continuous exposure of catecholamines caused a 
continual process of fibre death and regeneration in the soleus muscle. In the longer 
term, this could result in muscle wasting due to the limited capacity of the skeletal 
muscle stem cell pool, and therefore a compromised muscle function (blue dotted 
line). 
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Acute Exposur of Catecholamines 
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Figure 4.3 Schematic representation of the effects of acute catecholamine 
exposure on the heart. 
In the heart the effects of catecholamine exposure are mediated through the 
receptors and possibly by the 'non-classical' pathway involving the 02 receptors. A 
single 20 mmol injection of isoprenaline kg" induced extensive cardiomyocyte 
death, via necrosis and apoptosis. It is speculated that the underlying mechanism of 
myocyte death could relate to hyperphosphorylation of the RyR, leading to Ca 2+ 
myocyte cytoplasmic overload and cardiac dysfunction. The heart compensated and 
adapted to the dramatic loss of cardiomyocytes through both myocyte hypertrophy 
and hyperplasia, in order to restore cardiac performance. New myocyte formation 
was produced through the activation and ensuring proliferation and differentiation 
of the cardiac stem cell pool. These processes were most probably governed by the 
growth factors IGF and MGF. 
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Figure 4.4 Schematic representation of the effects of continuous 
catecholamine exposure on the heart. 
In the heart continuous catecho4mine exposure caused a desensitisation and/or 
down-regulation of fl-receptors. Chronic exposure of catecholamines caused 
cardiomyocyte death, reparative fibrosis and hypertrophy, resulting in decreased 
cardiac function and the development of cardiomyopathy. These effects were most 
probably governed by the hyperphosphorylation of the RyR, stress-activated MAP 
kinase pathway and possibly the growth factors IGF and MGF. 
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In summary, the present study shows for the first time the toxic effects of 
catecholamines to the soleus muscle, causing significant fibre apoptosis as well as 
necrosis. Regardless of the nature of the death and loss of fibres, this skeletal muscle 
has the ability to regenerate, with full restoration of fibre number and fibre type 
proportions by 28 days, following acute catecholamine exposure. Chronic 
catecholamine exposure leads to repeated cycles of degeneration-regeneration 
within the soleus muscle of the rat. Over a prolonged period of time, this could lead 
to consequent net loss of muscle fibres and hence muscle wasting, due to the limited 
proliferative potential of the muscle stem cell pool. On the other hand, 
catecholamines could potentially be beneficial in promoting skeletal muscle 
hypertrophy and growth. However, it may not be the effects of the catecholamines 
per se on the adaptive response of the muscle. These mechanisms need to be 
investigated further before any clinical applications are proposed. Furthermore, the 
undesirable effects of chronic P-AR stimulation on the heart render the use of such 
hormones impractical in attempting to ameliorate muscle wasting. The use of IGF-I 
or MGF may offer attractive alternatives considering their roles in regulating the 
satellite cell pool and stimulating protein synthesis, and consequent muscle 
hypertrophy and growth. Therapeutic strategies should focus on promoting the 
expression of these growth factors and rescuing skeletal muscle wasting. 
In the heart, a single bolus injection of isoprenaline produces severe myocardial 
damage, resulting in a loss of imyocytes and an acute impairment of cardiac 
performance. The heart compensates initially by myocyte hypertrophy and 
secondary by myocyte hyperplasia. This myocyte hyperplasia is produced by the 
activation and differentiation of the cardiac stem cell pool. In the presence of a 
patent coronary circulation these processes significantly repair the acute damage, 
restoring normal ventricular function. 
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5.0 CONCLUSIONS 
The chronic hyper-adrenergic state plays an important role in the pathophysiology of 
heart failure. Impaired contractile function and skeletal muscle wasting have been 
observed in CHF patients (Anker et al., 1997a). It is possible that the increased 
sympathetic drive seen in this population is linked to this functional deterioration of the 
skeletal muscles as well as the heart. This thesis has tested the hypothesis that cardiac and 
skeletal muscles respond in a similar manner when exposed to excess catecholamines. 
Acute exposure of catecholamines caused significant necrotic and apoptotic cell death 
and resultant myocyte loss to both the heart and soleus muscles. The catecholamine- 
induced myocyte necrosis and apoptosis in the soleus muscle is a novel finding. The 
damaging effects of catecholarnines on both striated muscles were specific for mature, 
differentiated myocytes. Upon injury, stem-progenitor cells present within cardiac and 
skeletal tissues became activated and through the ensuring proliferation and 
differentiation of these cells, new myocytes were formed and functional capacity was 
restored. 
The present findings raise many questions which remain unanswered. It is postulated that 
the mechanism underlying cell death from catecholamine exposure in both muscles 
relates to the ryanodine receptor (RyR), which is of key importance in determining cell 
fate. Increased protein kinase A (PKA), activated through elevated intracellular cAMP 
from fl-AR stimulation, causes PKA, hyperphosphorylation of RyR. This results in 
defective channel function and excitation coupling, leading to consequent Ca 2+ myocyte 
cytoplasmic overload and cardiac dysfunction (Reiken et al., 2003). In principle, fast- 
twitch muscle fibres could also be exposed to hyperphosphorylation of RyR. Therefore, 
something other this mechanism could account for the damage by catecholamines. As 
phospholamban (PLB) plays a regulatory role in inhibiting Ca2' reuptake by the SR 
through SERCA2, the finding that the faster glycolytic muscles were not damaged by the 
catecholamines, could be related to the absence of PLI3 in these muscle fibre types. 
However, other distinctive characteristics of these faster muscle fibres, e. g. decreased 
number of fl-ARs and fewer mitochondria, when compared to their slower contracting 
counterparts could also explain this phenomenon. But the reason for this discrepancy still 
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remains unclear, considering that the faster muscles examined, even contain slow-twitch 
muscle fibres. 
Sustained high levels of catecholamines caused significant hypertrophy to both the heart 
and skeletal muscles, including the fast-twitch muscles. It may not be the effects of 
catecholamines per se that are responsible for this muscle hypertrophy. As the P2-agonist, 
clenbuterol, has a paracrine and autocrine effect on IGF-l levels (Awede et al., 2002), it 
is speculated that these anabolic effects maybe due to the increased local and systemic 
expression of IGF-I and its splice variant, MGF, after the catecholamine administration. 
However, further investigations are required to clarify the mechanisms involved. Chronic 
exposure to catecholamines leads to repeated cycles of degeneration-regeneration within 
the soleus muscle. In the long term, this could have detrimental consequences through the 
resultant net loss of muscle fibres and wasting, due to the limited proliferative capacity of 
the muscle stem cell pool. Further analysis of the potential of muscle stem cells to 
contribute to this process is warranted, especially in the light of the rapid and dramatic 
loss of muscle mass in HF patients with cachexia. 
Through the continuous infusion of catecholamines the heart was significantly damaged, 
exhibiting reparative fibrosis and undergoing hypertrophy. This could lead to 
considerable deleterious consequences, and further outlines the toxic effects of 
catecholarnines. Following acute damage from isoprenaline, the heart compensated and 
adapted to the dramatic loss of cardiomyocytes through both myocyte hypertrophy and 
hyperplasia. Notably, the present study is the first to report the ability of the heart to 
spontaneously initiate repair mechanisms and bring about new myocyte formation and 
restore cardiac function in the absence of any exogenous treatment. Due to the significant 
amount of myocyte regeneration found in this damage model, when compared to models 
of coronary occlusion or constriction, a patent coronary circulation may be crucial in 
regulating the regenerative process in the heart. Furthermore, by confirming the presence 
of stem progenitor cells in the adult heart, this finding could help to answer the question 
to why these cells do not mobilise and divide in response to an ischemic injury and 
regenerate the damaged myocardium. 
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6.0 FUTURE DIRECTIONS 
* Following acute isoprenaline exposure, does the improved cardiac function 
remain stable after 14 days, and if so, can this be attributed in part due to further 
new myocyte formation? 
9 What is the impervious factor associated with the predominantly fast muscles that 
protects them from the injurious effects of catecholamines? Could it reside in the 
elimination of PLB in fast twitch fibres, fewer fl-receptors, less mitochondria, less 
capillarisation, when compared to their slower counterparts? 
Is the mechanism underlying cell death from catecholamine exposure in both the 
heart and slow soleus muscles due to hyperphosphorylation of the RyR? This 
could be specifically investigated through immunoprecipitation and back- 
phosphorylation of RyRs and immunohistochemistry techniques (Marx et al., 
2000). 
In order to ascertain whether IGF-1 is implicated in the regenerative and 
hypertrophic response of the heart and skeletal muscles, mRNA and protein levels 
should be measured, following catecholamine exposure. 
9 If catecholamines are administered continuously over a longer period (i. e. 56 
days), does the process of continual fibre death and regeneration seen in the 
soleus muscle result in muscle wasting? Is this due a compromised capacity of the 
satellite cell pool? Therefore, can catecholamine exposure be seriously linked to 
the impaired muscle enduranc6-found in some CHF patients? 
Does new cardiomyocyte'formation play a significant role in the remodelling of 
the heart following continuous catecholamine exposure? 
Is a patent coronary circulation crucial in regulating the regenerative process in 
the heart? This could be examined by comparing the effects of isoprenaline 
exposure with a model of coronary occlusion of constriction (TAC). 
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